0001079973-23-000711.txt : 20230515 0001079973-23-000711.hdr.sgml : 20230515 20230515163545 ACCESSION NUMBER: 0001079973-23-000711 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230515 DATE AS OF CHANGE: 20230515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cardio Diagnostics Holdings, Inc. CENTRAL INDEX KEY: 0001870144 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 870925574 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41097 FILM NUMBER: 23923328 BUSINESS ADDRESS: STREET 1: 400 N ABERDEEN ST, SUITE 900 CITY: CHICAGO STATE: IL ZIP: 60642 BUSINESS PHONE: 855-226-9991 MAIL ADDRESS: STREET 1: 400 N ABERDEEN ST, SUITE 900 CITY: CHICAGO STATE: IL ZIP: 60642 FORMER COMPANY: FORMER CONFORMED NAME: Mana Capital Acquisition Corp. DATE OF NAME CHANGE: 20210629 10-Q 1 cdio_10q.htm FORM 10-Q
0001870144 false --12-31 2023 Q1 0001870144 2023-01-01 2023-03-31 0001870144 CDIO:CommonStockParValue0.00001PerShareMember 2023-01-01 2023-03-31 0001870144 CDIO:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember 2023-01-01 2023-03-31 0001870144 2023-05-15 0001870144 2023-03-31 0001870144 2022-12-31 0001870144 2022-01-01 2022-03-31 0001870144 us-gaap:CommonStockMember 2022-12-31 0001870144 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001870144 us-gaap:RetainedEarningsMember 2022-12-31 0001870144 us-gaap:CommonStockMember 2021-12-31 0001870144 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001870144 us-gaap:RetainedEarningsMember 2021-12-31 0001870144 2021-12-31 0001870144 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001870144 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001870144 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001870144 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001870144 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001870144 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001870144 us-gaap:CommonStockMember 2023-03-31 0001870144 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001870144 us-gaap:RetainedEarningsMember 2023-03-31 0001870144 us-gaap:CommonStockMember 2022-03-31 0001870144 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001870144 us-gaap:RetainedEarningsMember 2022-03-31 0001870144 2022-03-31 0001870144 us-gaap:FairValueInputsLevel1Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-03-31 0001870144 us-gaap:FairValueInputsLevel1Member 2023-03-31 0001870144 us-gaap:FairValueInputsLevel2Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-03-31 0001870144 us-gaap:FairValueInputsLevel2Member 2023-03-31 0001870144 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-03-31 0001870144 us-gaap:FairValueInputsLevel3Member 2023-03-31 0001870144 CDIO:KnowHowLicenseMember 2023-03-31 0001870144 CDIO:KnowHowLicenseMember 2023-01-01 2023-03-31 0001870144 2022-10-30 2022-10-31 0001870144 2022-10-31 0001870144 CDIO:StockWarrantsMember 2023-01-01 2023-03-31 0001870144 CDIO:StockWarrantsMember 2022-01-01 2022-03-31 0001870144 CDIO:StockOptionsMember 2023-01-01 2023-03-31 0001870144 CDIO:StockOptionsMember 2022-01-01 2022-03-31 0001870144 us-gaap:IPOMember 2023-01-01 2023-03-31 0001870144 CDIO:LegacyCardioStockholdersMember 2023-01-01 2023-03-31 0001870144 CDIO:LegacyCardioMember 2023-01-01 2023-03-31 0001870144 CDIO:LegacyCardioMember 2023-03-31 0001870144 CDIO:ManasFormerOfficersAndDirectorsMember 2023-01-01 2023-03-31 0001870144 CDIO:Plan2022Member 2023-03-31 0001870144 2021-03-14 2021-03-15 0001870144 2023-03-01 2023-03-02 0001870144 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001870144 2019-10-01 0001870144 us-gaap:StockOptionMember 2022-04-30 0001870144 2022-04-01 2022-04-30 0001870144 2022-05-23 0001870144 us-gaap:StockOptionMember 2022-05-01 2022-05-06 0001870144 us-gaap:StockOptionMember 2022-10-24 2022-10-25 0001870144 2022-05-06 0001870144 us-gaap:WarrantMember 2021-12-31 0001870144 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001870144 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001870144 us-gaap:WarrantMember 2022-03-31 0001870144 us-gaap:WarrantMember 2022-12-31 0001870144 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001870144 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001870144 us-gaap:WarrantMember 2023-03-31 0001870144 2023-03-01 2023-03-08 0001870144 2023-03-07 2023-03-08 0001870144 2023-03-30 2023-03-31 0001870144 2023-03-08 0001870144 us-gaap:ConvertibleCommonStockMember 2023-03-31 0001870144 us-gaap:ConvertibleCommonStockMember 2023-01-01 2023-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2023

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____to _____

 

Commission File Number: 001-41097

 

Cardio Diagnostics Holdings, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   87-0925574

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

 

400 North Aberdeen Street, Suite 900,

Chicago, Illinois

  60642
(Address of principal executive offices)   (Zip Code)

 

(855) 226-9991

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  

Name of each exchange on

which registered

Common Stock, par value $0.00001 per share   CDIO   The NASDAQ Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock   CDIOW   The NASDAQ Stock Market LLC

 

  

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
       
Non-accelerated filer ☒ Smaller reporting company ☒
       
    Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of May 15, 2023 there were 9,977,791 shares of the registrant’s Common Stock, $0.00001 par value, issued and outstanding.

 

 

 
 

 

CARDIO DIAGNOSTICS HOLDINGS, INC.

 

FORM 10-Q

For the Quarter Ended March 31, 2023

 

TABLE OF CONTENTS

 

 

Introductory Note 2
Note About Forward-Looking Statements 2
   
Part I — Financial Information  
Item 1. Financial Statements (unaudited) 3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 15
Item 3. Quantitative and Qualitative Disclosures About Market Risk 23
Item 4. Controls and Procedures 23
     
Part II — Other Information  
Item 1. Legal Proceedings 24
Item 1A. Risk Factors 24
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 26
Item 3. Defaults upon Senior Securities 26
Item 4. Mine Safety Disclosures 26
Item 5. Other Information 26
Item 6. Exhibits 26

 

 

1 
 

INTRODUCTORY NOTE

As used in this Quarterly Report on Form 10-Q, unless the context requires otherwise, references to the “Company,” “Cardio,” “we,” “us,” “our,” and similar terms refer to Cardio Diagnostics Holdings, Inc., a Delaware corporation formerly known as Mana Capital Acquisition Corp. (“Mana”), and its consolidated subsidiary. References to “Legacy Cardio” refer to Cardio Diagnostics, Inc., a privately-held Delaware corporation that is now our wholly-owned subsidiary.

On October 25, 2022, we consummated the previously announced Business Combination (pursuant to the Agreement and Plan of Merger, dated as of May 27, 2022, as amended on September 15, 2022, by and among Mana, Mana Merger Sub, Inc. (“Merger Sub”), Legacy Cardio and Meeshanthini Dogan, Ph.D., as representative of the shareholders of Legacy Cardio, the “Business Combination Agreement”). Pursuant to the terms of the Business Combination Agreement, a business combination (herein referred to as the “Business Combination” or “Reverse Recapitalization” for accounting purposes) between Mana and Legacy Cardio was effected through the merger of Merger Sub with and into Legacy Cardio with Legacy Cardio surviving as Mana’s wholly-owned subsidiary. In connection with the Business Combination, Mana changed its name from Mana Capital Acquisition Corp. to Cardio Diagnostics Holdings, Inc.

SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, changes in laws or regulations, any statements about our business (including the impact of the COVID-19 pandemic on our business), financial condition, operating results, plans, objectives, expectations and intentions, any guidance on, or projections of, earnings, revenue or other financial items, or otherwise, and our future liquidity, including cash flows; any statements of any plans, strategies, and objectives of management for future operations, such as the material opportunities that we believe exist for our Company; any statements concerning proposed products and services, developments, mergers or acquisitions; or strategic transactions; any statements regarding management’s view of future expectations and prospects for us; any statements about prospective adoption of new accounting standards or effects of changes in accounting standards; any statements regarding future economic conditions or performance; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms such as “anticipate,” “could,” “can,” “may,” “might,” “potential,” “predict,” “should,” “estimate,” “expect,” “project,” “believe,” “think,” “plan,” “envision,” “intend,” “continue,” “target,” “seek,” “contemplate,” “budgeted,” “will,” “would,” and the negative of such terms, other variations on such terms or other similar or comparable words, phrases, or terminology. These forward-looking statements present our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q and are subject to change.

Forward-looking statements involve risks and uncertainties and are based on the current beliefs, expectations, and certain assumptions of management. Some or all of such beliefs, expectations, and assumptions may not materialize or may vary significantly from actual results. Such statements are qualified by important economic, competitive, governmental, and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, the risk factors discussed under the heading “Risk Factors” in Part I, Item IA of our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023 (the “2022 Form 10-K”), as supplemented by the risk factors set forth in Part II, Item 1A of this Quarterly Report on Form 10-Q. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change, and significant risks and uncertainties that could cause actual conditions, outcomes, and results to differ materially from those indicated by such statements. Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequence to or effects on the Company or its business or operations. The Company assumes no obligations to update any such forward-looking statements.

 

2 
 

PART I: FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

CARDO DIAGNOSTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 (unaudited)

 

         
   MARCH 31,   DECEMBER 31, 
   2023   2022 
        
ASSETS
         
Current assets          
    Cash  $6,707,770   $4,117,521 
    Prepaid expenses and other current assets   1,430,261    1,768,366 
           
Total current assets   8,138,031    5,885,887 
           
Long-term assets          
    Intangible assets, net   33,333    37,333 
    Deposits   7,050    4,950 
    Patent costs, net   373,197    321,308 
           
Total assets  $8,551,611   $6,249,478 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
           
Current liabilities          
    Accounts payable and accrued expenses  $742,635   $1,098,738 
    Convertible notes payable, net   315,068    —   
    Derivative liability   3,505,771    —   
    Finance agreement payable   566,022    849,032 
Total liabilities   5,129,496    1,947,770 
           
Stockholders' equity          
Preferred stock, $.00001 par value; authorized - 100,000,000 shares;  0 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively   —      —   
Common stock, $.00001 par value; authorized - 300,000,000 shares; 9,615,835 and 9,514,743 shares issued and outstanding   as of March 31, 2023 and December 31, 2022, respectively   96    95 
    Additional paid-in capital   10,446,183    10,293,159 
    Accumulated deficit   (7,024,164)   (5,991,546)
           
Total stockholders' equity   3,422,115    4,301,708 
           
Total liabilities and stockholders' equity  $8,551,611   $6,249,478 

 

The accompanying notes are an integral part of these unaudited financial statements.

 

3 
 

 CARDIO DIAGNOSTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED 

STATEMENTS OF OPERATIONS

(unaudited)

         

         
   For the   For the 
   Three Months Ended   Three Months Ended 
   March 31, 2023   March 31, 2022 
       
         
Revenue  $ —     $ —   
         
Operating expenses        
    Sales and marketing   49,551    22,398 
    Research and development   86,665    1,130 
    General and administrative expenses   1,562,128    205,027 
    Amortization   4,785    4,000 
           
Total operating expenses   1,703,129    232,555 
           
Other income (expenses)          
    Change in fair value of derivative liability   5,686,901    —   
    Interest income   221    —   
    Interest expense   (5,016,611)   —   
    Acquisition related expense   —      (57,500)
           
Total other income (expenses)   670,511    (57,500)
           
Loss from operations before provision for income taxes   (1,032,618)   (290,055)
           
Provision for income taxes   —      —   
           
Net loss  $(1,032,618)  $(290,055)
           
Basic and fully diluted income (loss) per common share:          
Net loss per common share  $(0.11)  $(0.07)
           
Weighted average common shares outstanding - basic and fully diluted   9,547,177    4,223,494 

 

 

The accompanying notes are an integral part of these unaudited financial statements.

 

 

4 
 

 

CARDIO DIAGNOSTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED 

STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

Three Months Ended March 31, 2023 and 2022

(unaudited)

 

                     
           Additional         
   Common stock   Paid-in   Accumulated     
   Shares   Amount   Capital   Deficit   Totals 
                     
Balances, December 31, 2022   9,514,743   $95   $10,293,159   $(5,991,546)  $4,301,708 
                          
    Warrants converted to common stock   100,000    1    389,999    —      390,000 
                          
    Restricted stock awards vested   1,092    —      4,000    —      4,000 
                          
    Placement agent fee   —      —      (315,000)   —      (315,000)
                          
    Adjustment to liabilities assumed in merger with Mana   —      —      74,025    —      74,025 
                          
    Net loss   —      —      —      (1,032,618)   (1,032,618)
                          
Balances, March 31, 2023   9,615,835   $96   $10,446,183   $(7,024,164)  $3,422,115 
                          
Balances, December 31, 2021   4,223,494   $42   $2,398,628   $(1,330,561)  $1,068,109 
                          
    Net loss   —      —      —      (290,055)   (290,055)
                          
Balances, March 31, 2022   4,223,494   $42   $2,398,628   $(1,620,616)  $778,054 

 

  

The accompanying notes are an integral part of these unaudited financial statements.

 

 

5 
 

 

CARDIO DIAGNNOSTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED 

STATEMENTS OF CASH FLOWS

(unaudited)

  

         
   For the   For the 
   Three Months Ended   Three Months Ended 
   March 31, 2023   March 31, 2022 
       
         
CASH FLOWS FROM OPERATING ACTIVITIES:        
    Net loss  $(1,032,618)  $(290,055)
    Adjustments to reconcile net loss to net          
         cash used in operating activities          
            Amortization   4,785    4,000 
            Acquisition related expense   —      57,500 
            Stock-based compensation expense   4,000    —   
            Non-cash interest expense   5,007,740    —   
            Chain in fair value of derivative liability   (5,686,901)   —   
         Changes in operating assets and liabilities:          
            Accounts receivable   —      901 
            Prepaid expenses and other current assets   338,105    20,358 
            Deposits   (2,100)   —   
            Accounts payable and accrued expenses   (282,078)   21,206 
           
            NET CASH USED IN OPERATING ACTIVITIES   (1,649,067)   (186,090)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
    Patent costs incurred   (52,674)   (16,436)
           
            NET CASH USED IN INVESTING ACTIVITIES   (52,674)   (16,436)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
    Proceeds from convertible notes payable, net of original issue discount of $500,000   4,500,000    —   
    Proceeds from exercise of warrants   390,000    —   
    Payments of finance agreement   (283,010)   —   
    Payments of placement agent fee   (315,000)   —   
           
            NET CASH PROVIDED BY FINANCING ACTIVITIES   4,291,990    —   
           
NET INCREASE (DECREASE) IN CASH   2,590,249    (202,526)
           
CASH - BEGINNING OF PERIOD   4,117,521    512,767 
           
CASH - END OF PERIOD  $6,707,770   $310,241 
           
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:          
    Cash paid during the year for:          
      Interest  $8,871   $—   
           
    Non-cash investing and financing activities:          
      Debt discount related to derivative liability  $9,192,672   $—   
      Adjustment to liabilities assumed in acquisition   74,025    —   

 

The accompanying notes are an integral part of these unaudited financial statements.

 

 

6 
 

CARDIO DIAGNOSTICS HOLDINGS, INC.

CONDENSED  CONSOLIDATED

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

Note 1 - Organization and Basis of Presentation

 

The unaudited condensed consolidated financial statements presented are those of Cardio Diagnostics Holdings, Inc., (the “Company”) and its wholly-owned subsidiary, Cardio Diagnostics, Inc. (“Legacy Cardio”). The Company was incorporated as Mana Capital Acquisition Corp. (“Mana”) under the laws of the state of Delaware on May 19, 2021, and Legacy Cardio was formed on January 16, 2017 as an Iowa limited liability company (Cardio Diagnostics, LLC) and was subsequently incorporated as a Delaware C-Corp on September 6, 2019 (Legacy Cardio). The Company was formed to develop and commercialize a patent-pending Artificial Intelligence (“AI”)-driven DNA biomarker testing technology (“Core Technology”) for cardiovascular disease invented at the University of Iowa by the Company’s Founders, with the goal of becoming one of the leading medical technology companies for enabling precision prevention, early detection and treatment of cardiovascular disease. The Company is transforming the approach to cardiovascular disease from reactive to proactive. The Core Technology is being incorporated into a series of products for major types of cardiovascular disease and associated co-morbidities including coronary heart disease (“CHD”), stroke, heart failure and diabetes.

 

Interim Financial Statements

 

The unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of results that may be expected for the year ending December 31, 2023. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023.

 

Business Combination

 

On May 27, 2022, Mana, Mana Merger Sub, Inc. (“Merger Sub”), Meeshanthini Dogan, the Shareholders’ Representative and Legacy Cardio entered into the Business Combination Agreement (the “Merger Agreement”). On October 25, 2022, pursuant to the Merger Agreement, Legacy Cardio merged with and into Merger Sub, with Legacy Cardio surviving as the wholly-owned subsidiary of Mana. Subsequent to the merger, Mana changed its name to Cardio Diagnostics Holdings, Inc

 

Note 2 – Merger Agreement and Reverse Recapitalization

 

As discussed in Note 1, on October 25, 2022, the Company and Mana entered into the Merger Agreement, which has been accounted for as a reverse recapitalization in accordance with US Generally Accepted Accounting Principles (GAAP). Pursuant to the Merger Agreement, the Company acquired cash of $4,021 and assumed liabilities of $928,500 from Mana. The liabilities assumed of $854,775, net of an early payment discount of $74,025 issued by a vendor on March 22, 2023, are payable to two investment bankers and due on October 25, 2023. On March 27, 2023, the Company accepted the early pay discount and paid Ladenburg the net balance due and payable of $419,475. As of March 31, 2023, the remaining assumed liabilities balance was $435,000.

 

Mana’s common stock had a redemption right in connection with the business combination. Mana’s stockholders exercised their right to redeem 6,465,452 shares of common stock, which constituted approximately 99.5% of the shares with redemption rights, for cash at a redemption price of approximately $10.10 per share, for an aggregate redemption amount of $65,310,892. In accounting for the reverse recapitalization, the Company’s legacy issued and outstanding 1,976,749 shares of common stock were reversed,  and the Mana shares of common stock totaling 9,514,743 were recorded, as described in Note 7. Transactions costs incurred in connection with the recapitalization totaled $1,535,035 and were recorded as a reduction to additional paid in capital.

 
7 
 

 

 

Note 3 – Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Cardio Diagnostics, Inc.  All intercompany accounts and transactions have been eliminated.

 

Use of Estimates in the Preparation of Financial Statements

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

 

Fair Value Measurements

 

The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

 

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.

 

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

 

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

 

The estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level 3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the three months ended March 31, 2023 and 2022.

 

         
   2023   2022 
Liabilities:          
Balance of derivative liabilities - beginning of period  $—     $—   
Issued   9,192,672    —   
Converted   —      —   
Change in fair value recognized in operations   (5,686,901)   —   
Balance of derivative liabilities - end of period  $3,505,771   $—   

 

 

8 
 

 

 

 

The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of March 31, 2023, for each fair value hierarchy level:

 

Schedule of fair value hierarchy level      
March 31, 2023  Derivative Liabilities  Total
Level I  $—     $—   
Level II  $—     $—   
Level III  $3,505,771   $3,505,771 

 

Convertible Instruments

 

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

 

Revenue Recognition

 

The Company will host its product, Epi+Gen CHD on InTeleLab’s Elicity platform (the “Lab”). The Lab will collect payments from patients upon completion of eligibility screening. Patients then send their samples to MOgene, a high complexity CLIA lab, which perform the biomarker assessments. Upon receipt of the raw biomarker data from MOgene, the Company performs all quality control, analytical assessments and report generation and shares test reports with the Elicity healthcare provider via the Elicity platform. Revenue is recognized upon receipt of payments from the Lab for each test at the end of each month.

 

The Company will account for revenue under (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606)”, using the modified retrospective method. The modified retrospective adoption used by the Company did not result in a material cumulative effect adjustment to the opening balance of accumulated deficit.

 

The Company determines the measurement of revenue and the timing of revenue recognition utilizing the following core principles:

 

1. Identifying the contract with a customer;

2. Identifying the performance obligations in the contract;

3. Determining the transaction price;

4. Allocating the transaction price to the performance obligations in the contract; and

5. Recognizing revenue when (or as) the Company satisfies its performance obligations.

 

Research and Development

 

Research and development costs are expensed as incurred. Research and development costs charged to operations for the three months ended March 31, 2023 and 2022 were $86,665 and $1,130, respectively.

 

Advertising Costs

 

The Company expenses advertising costs as incurred. Advertising costs of $49,551 and $22,398 were charged to operations for the three months ended March 31, 2023 and 2022, respectively.

 

Cash and Cash Equivalents

 

Cash and cash equivalents are comprised of cash and highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does not have any cash equivalents as of March 31, 2023 and December 31, 2022. Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. The Company is exposed to credit risk in the event of default by the financial institutions or the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured.

 

Patent Costs

 

The Company accounts for patents in accordance with ASC 350-30, General Intangibles Other than Goodwill. The Company capitalizes patent costs representing legal fees associated with filing patent applications and amortize them on a straight-line basis. The Company is in the process of evaluating its patents' estimated useful life and will begin amortizing the patents when they are brought to the market or otherwise commercialized.

 
9 
 

 

Long-Lived Assets

 

The Company assesses the valuation of components of long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.

 

Stock-Based Compensation

 

The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest.  The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants.  Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.

 

Income Taxes

 

The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.

 

The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position.

 

Recent Accounting Pronouncements

 

We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

 

Note 4 – Intangible Assets

 

The following tables provide detail associated with the Company’s acquired identifiable intangible assets:

                 
   As of March 31, 2023 
    Gross Carrying
Amount		    Accumulated Amortization    Net Carrying Amount    Weighted Average Useful life (in years) 
Amortized intangible assets:                    
Know-how license  $80,000   $(46,667)  $33,333    5 
Total  $80,000   $(46,667)  $33,333      

 

Amortization expense charged to operations was $4,000 for the three months ended March 31, 2023 and 2022, respectively.

 

Note 5 – Patent Costs

 

As of March 31, 2023, the Company has three pending patent applications. The initial patent applications consist of a US patent and international patents filed in six countries. The US patent was granted on August 16, 2022. The EU patent was granted on March 31, 2021. The validation of the EU patent in each of the six countries is pending. Legal fees associated with the patents totaled $373,197, net of accumulated amortization of $785 and $321,308 as of March 31, 2023 and December 31, 2022, respectively and are presented in the balance sheet as patent costs. Amortization expense charged to operations was $785 for the three months ended March 31, 2023.

 

 

10 
 

 

Note 6 – Finance Agreement Payable

 

On October 31, 2022, the Company entered into an agreement with a premium financing company to finance its Directors and Officers insurance premiums for 12-month policies effective October 25, 2022. The amount financed of $1,037,706 is payable in 11 monthly installments plus interest at a rate of 6.216% through September 28, 2023. Finance agreement payable was $566,022 and $849,032 at March 31, 2023 and December 31, 2022, respectively. $646,795 has been recorded in prepaid expenses and is being amortized over the life of the policy.

 

Note 7 - Earnings (Loss) Per Common Share

 

The Company calculates net income (loss) per common share in accordance with ASC 260 “Earnings Per Share” (“ASC 260”). Basic and diluted net earnings (loss) per common share was determined by dividing net earnings (loss) applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, common stock warrants, and convertible debt have not been included in the computation of diluted net loss per share for the three months ended March 31, 2023 and 2022 as the result would be anti-dilutive.

 Schedule of anti dilutive earning per share        
   Three Months Ended 
   March 31, 
   2023   2022 
         
Stock warrants   7,854,620    215,654 
Stock options   1,759,599    —   
Total shares excluded from calculation   9,614,219    215,654 

  

Note 8 – Stockholders’ Equity

 

Stock Transactions

 

Pursuant to the Business Combination Agreement on October 25, 2022, the Company issued the following securities:

 

Holders of conversion rights issued as a component of units in Mana’s initial public offering (the “Public Rights”) were issued an aggregate of 928,571 shares of the Company’s common stock;

 

Holders of existing shares of common stock of Legacy Cardio and the holder of equity rights of Legacy Cardio (together, the “Legacy Cardio Stockholders”) received an aggregate of 6,883,306 shares of the Company’s Common Stock, calculated based on the exchange ratio of 3.427259 pursuant to the Merger Agreement (the “Exchange Ratio”) for each share of Legacy Cardio Common Stock held or, in the case of the equity rights holder, that number of shares of the Company’s Common Stock equal to 1% of the Aggregate Closing Merger Consideration, as defined in the Merger Agreement;

 

The Legacy Cardio Stockholders received, in addition, an aggregate of 43,334 shares of the Company’s Common Stock (“Conversion Shares”) upon conversion of an aggregate of $433,334 in principal amount of promissory notes issued by Mana to Legacy Cardio in connection with its loan of such amount in order to extend Mana’s duration through October 26, 2022 (the “Extension Notes”), which Conversion Shares were distributed to the Legacy Cardio Stockholders in proportion to their respective interest in Legacy Cardio.

 

Mana public stockholders (excluding Mana Capital, LLC, the SPAC sponsor (the “Sponsor”), and Mana’s former officers and directors) own 34,548 shares of the Company’s Common Stock and the Sponsor, Mana’s former officers and directors and certain permitted transferees own 1,625,000 shares of the Company’s Common Stock.

 

Immediately after giving effect to the Business Combination, there were 9,514,743 issued and outstanding shares of the Company’s Common Stock.

 

On October 25, 2022, in connection with the approval of the Business Combination, the Company’s stockholders approved the Cardio Diagnostics Holdings, Inc. 2022 Equity Incentive Plan (the “2022 Plan”). The purpose of the 2022 Plan is to promote the interests of the Company and its stockholders by providing eligible employees, officers, directors and consultants with additional incentives to remain with the Company and its subsidiaries, to increase their efforts to make the Company more successful, to reward such persons by providing an opportunity to acquire shares of Common Stock on favorable terms and to attract and retain the best available personnel to participate in the ongoing business operations of the Company. The 2022 Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Performance Units and Performance Shares.

 

 

11 
 

The 2022 Plan, as approved, permits the issuance of up to 3,256,383 shares of Common Stock (the “Share Reserve”) upon exercise or conversion of grants and awards made from time to time to officers, directors, employees and consultants, however that the Share Reserve will increase on January 1st of each calendar year and ending on and including January 1, 2027 (each, an “Evergreen Date”), in an amount equal to the lesser of (i) 7% of the total number of shares of Common Stock outstanding on the December 31st immediately preceding the applicable Evergreen Date and (ii) such lesser number of shares of Common Stock as determined to be appropriate by the Compensation Committee, which administers the 2022 Plan, in its sole discretion. There was no increase in the Share Reserve on January 1, 2023.

 

Common Stock Issued

 

On March 2, 2023, a stockholder exercised warrants in exchange for 100,000 common shares for proceeds of $390,000.

 

During the three months ended March 31, 2023, the Company issued 1,092 common shares to a consultant for services pursuant to vesting of Restricted Stock Units granted, valued at $4,000.

 

Warrants

 

On October 1, 2019, the Company issued warrants to a seed funding firm equivalent to 2% of the fully-diluted equity of the Company, or 22,500 common shares at the time of issuance. The warrant is exercisable on the earlier of the closing date of the next Qualified Equity Financing occurring after the issuance of the warrant, and immediately before a Change of Control. The exercise price is the price per share of the shares sold to investors in the next Qualified Equity Financing, or if the warrant becomes exercisable in connection with a Change in Control before the next Qualified Equity Financing, the greater of the quotient obtained by dividing $150,000 by the Pre-financing Capitalization, and the price per share paid by investors in the then-most recent Qualified Equity Financing, if any. The warrant will expire upon the earlier of the consummation of any Change of Control, or 15 years after the issuance of the warrant.

 

In April 2022, the Company issued fully vested warrants to investors as part of private placement subscription agreements pursuant to which the Company issued common stock. Each stockholder received warrants to purchase 50% of the common stock issued at an exercise price of $3.90 per share with an expiration date of June 30, 2027.

 

As of May 23, 2022, the Company issued fully vested warrants to investors as part of an additional private placement subscription agreements pursuant to which the Company issued common stock. Each stockholder received warrants to purchase 50% of the common stock issued at an exercise price of $6.21 per share with an expiration date of five years from the date of issue.

 

All of the warrants issued by Legacy Cardio were exchanged in the Business Combination for warrants of the Company based on the merger exchange ratio.

 

Warrant activity during the three months ended March 31, 2023 and 2022 follows:

             
       Weighted   Average Remaining 
  

Warrants

Outstanding

   Average Exercise Price   Contractual Life (Years) 
Warrants outstanding at December 31, 2021   215,654   $13.35    5.90 
No warrant activity   —      —        
Warrants outstanding at March 31, 2022   215,654   $13.35    5.07 
Warrants outstanding at December 31, 2022   7,954,620    9.63    4.46 
Warrants exercised   (100,000)   13.35      
Warrants outstanding at March 31, 2023   7,854,620   $9.70    4.22 

 

Options

 

In May 6, 2022, the Company granted 513,413 stock options to the board of directors pursuant to the Cardio Diagnostics, Inc. 2022 Equity Incentive Plan. All of the options granted under this legacy plan were exchanged for options under the Plan adopted by the Company’s stockholders on October 25, 2022, and based on the exchange ratio for the merger, resulted in a total of 1,759,599 options issued upon closing. Each exchanged option has an exercise price of $3.90 per share with an expiration date of May 6, 2032. The exchanged options fully vested upon the merger with Mana.

 

Note 9 – Convertible Notes Payable

 

On March 8, 2023, the Company entered into a securities purchase agreement (“Securities Purchase Agreement”) with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”) under which the Company agreed to sell and issue to Yorkville convertible debentures (“Convertible Debentures”) in a gross aggregate principal amount of up to $11.2 million (“Subscription Amount”). The Convertible Debentures are convertible into shares of common stock of the Company and are subject to various contingencies being satisfied as set forth in the Securities Purchase Agreement. The notes are convertible at any time through the maturity date, which, in each case, is one year from the date of issuance. The conversion price shall be determined on the basis of 92% of the two lowest VWAP (Volume Weighted Average Prices) of the Common Stock during the prior seven (7) trading day period. On March 8, 2023, the Company issued and sold to Yorkville a Convertible Debenture in the principal amount of $5.0 million, for which it received $4.5 million, with a $500,000 original issue discount (“OID”). Interest on the outstanding principal balance accrues at a rate of 0% and will increase to 15% upon an Event of Default for so long as it remains uncured

 

The Company recorded a debt discount related to identified embedded derivatives relating to the conversion features (see Note 10) based on fair values as of the inception date of the Note. The calculated debt discount, including the OID equaled the face of the Note and is being amortized over the term of the note.

 

Convertible notes payable of $315,068 at March 31, 2023 is presented net of debt discount of $4,684,932.

 

Note 10 – Derivative Liability

 

The Company has determined that the conversion feature embedded in the convertible notes described in Note 9 contain a potential variable conversion amount which constitutes a derivative which has been bifurcated from the note and recorded as a derivative liability at fair value, with a corresponding discount recorded to the associated debt. The excess of the derivative value over the face amount of the note is recorded immediately to interest expense at inception which aggregated $4,692,672. The Company used the Binomial Black-Scholes Option Pricing model to value the conversion features. The Company used the Binomial Option Pricing model to value the conversion features.

 

 

12 
 

 

The Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using a Black-Scholes option-pricing model with the following assumption inputs:

 Schedule of option liability      
   March 8,  March 31,
   2023  2023
Annual dividend yield   —      —   
Expected life (years)   1.0    1.0 
Risk-free interest rate   5.28%   4.89%
Expected volatility   164%   169%
Exercise price  $2.20   $3.53 
Stock price  $5.32   $3.91 

  

Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.

 

Note 11 – Commitments and Contingencies

 

Prior Relationship of Cardio with Boustead Securities, LLC

At the commencement of efforts to pursue what ultimately ended in the terminated business acquisition, Legacy Cardio entered into a Placement Agent and Advisory Services Agreement (the “Placement Agent Agreement”), dated April 12, 2021, with Boustead Securities, LLC ("Boustead Securities”). This agreement was terminated in April 2022, when Legacy Cardio terminated the underlying agreement and plan of merger and the accompanying escrow agreement relating to that proposed business acquisition after efforts to complete the transaction failed, despite several extensions of the closing deadline.

Under the terminated Placement Agent Agreement, Legacy Cardio agreed to certain future rights in favor of Boustead Securities, including (i) a two-year tail period during which Boustead Securities would be entitled to compensation if Cardio were to close on a transaction (as defined in the Placement Agent Agreement) with any party that was introduced to Legacy Cardio by Boustead Securities; and (ii) a right of first refusal to act as the Company’s exclusive placement agent for 24-months from the end of the term of the Placement Agent Agreement (the “right of first refusal”). Cardio has taken the position that due to Boustead Securities’ failure to perform as contemplated by the Placement Agent Agreement, these provisions purporting to provide future rights are null and void.

Boustead Securities responded to the termination of the Placement Agent Agreement by disputing Legacy Cardio’s contention that it had not performed under the Placement Agent Agreement because, among other things, Boustead Securities had never sought out prospective investors. In its response, Boustead Securities included a list of funds that they had supposedly contacted on Legacy Cardio’s behalf. While Boustead Securities’ contention appears to contradict earlier communications from Boustead Securities in which they indicated that they had not made any such contacts or introductions, Boustead Securities is currently contending that they are due success fees for two years following the termination of the Placement Agent Agreement on any transaction with any person on the list of supposed contacts or introductions. Legacy Cardio strongly disputes this position. Notwithstanding the foregoing, the Company has not consummated any transaction, as defined, with any potential party that purportedly was a contact of Boustead Securities in connection with the Placement Agent Agreement and has no plans to do so at any time during the tail period. No legal proceedings have been instigated by either party, and Cardio believes that the final outcome will not have a material adverse impact on its financial condition.

The Benchmark Company, LLC Right of First Refusal

As noted in Note 1, the Company completed a business combination with Mana on October 25, 2022. In connection with the proposed business combination, by agreement dated May 13, 2022, Mana engaged The Benchmark Company, LLC (“Benchmark”) as its M&A advisor. Upon closing of the business combination, Cardio assumed the contractual engagement entered into by Mana. On November 14, 2022, Cardio and Benchmark entered into Amendment No. 1 Engagement Letter (the “Amendment Engagement”). Pursuant to the Amendment Engagement, Benchmark has been granted a right of first refusal to act as lead or joint-lead investment banker, lead or joint-lead book-runner and/or lead or joint-lead placement agent for all future public and private equity and debt offerings through October 25, 2023. In this regard, the Company and Benchmark are in discussions regarding the convertible debenture financing the Company entered into in March 2023 whether Benchmark might be entitled to compensation arising from the Company having entered into the convertible debenture financing in March 2023 without first consulting Benchmark. No legal proceedings have been instigated, and the parties are continuing to discuss a resolution to this matter.

13 
 

Demand Letter and Potential Mootness Fee Claim

On June 25, 2022, a plaintiffs’ securities law firm sent a demand letter to the Company alleging that the Company’s Registration Statement on Form S-4 filed (the “S-4 Registration Statement”) with the Securities and Exchange Commission (“SEC”) on May 31, 2022 omitted material information with respect to the Business Combination and demanding that the Company and its Board of Directors immediately provide corrective disclosures in an amendment or supplement to the Registration Statement. Subsequent thereto, the Company filed amendments to the S-4 Registration Statement on July 27, 2022, August 23, 2022, September 15, 2022, October 4, 2022 and October 5, 2022 in which it responded to various comments of the SEC staff and otherwise updated its disclosure. In October 2023, the SEC completed its review and declared the S-4 registration statement on October 6, 2022. On February 23, 2023 and February 27, 2023, plaintiffs’ securities law firm contacted the Company’s counsel asking who will be negotiating a mootness fee relating to the purported claims set forth in the June 25, 2022 demand letter. The Company vigorously denies that the S-4 Registration Statement, as amended and declared effective, is deficient in any respect and that no additional supplemental disclosures are material or required. The Company believes that the claims asserted in the Demand Letter are without merit and that no further disclosure is required to supplement the S-4 Registration Statement under applicable laws. As of the date of filing of this Quarterly Report on Form 10-Q, no lawsuit has been filed against the Company by that firm. The firm has indicated its willingness to litigate the matter if a mutually satisfactory resolution cannot be agreed upon; however, Cardio believes that the final outcome will not have a material adverse impact on its financial condition. The Company cannot preclude the possibility that claims or lawsuits brought relating to any alleged securities law violations or breaches of fiduciary duty could potentially require significant time and resources to defend and/or settle and distract its management and board of directors from focusing on its business.

Note 12 – Subsequent Events

 

The Company evaluated its March 31, 2023 consolidated financial statements for subsequent events through the date the consolidated financial statements were issued.

 

Common Stock Issued

 

Subsequent to the end of the period through the date of this report, Yorkville converted $700,000 of principal to 361,094 shares of the Company’s common stock.

 

 

14 
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

As a result of the closing of the Business Combination, which was accounted for as a reverse recapitalization in accordance with U.S. GAAP as discussed in Note 2 – Merger Agreement and Reverse Recapitalization, the consolidated financial statements of Cardio Diagnostics, Inc., a Delaware corporation and our wholly owned subsidiary, are now the financial statements of the Company.

The following discussion and analysis provide information that Cardio’s management believes is relevant to an assessment and understanding of Cardio’s results of operations and financial condition. You should read the following discussion and analysis of Cardio’s results of operations and financial condition together with its unaudited consolidated financial statements and related notes to those statements included elsewhere in this Quarterly Report on Form 10-Q, and its audited consolidated financial statements and related notes to those statements included in the Company’s 2022 Form 10-K. In addition to historical financial information, this discussion contains forward-looking statements based upon Cardio’s current expectations that involve risks and uncertainties, including those described in the section titled, “Special Note Regarding Forward-Looking Statements.” Cardio’s actual results could differ materially from such forward-looking statements as a result of various factors, including those set forth under “Risk Factors” in this Quarterly Report on Form 10-Q and in the 2022 10-K. Our historical results are not necessarily indicative of the results that may be expected for any period in the future.

Unless the context requires otherwise, references to “Cardio,” the “Company,” “we,” “us” and “our” refer to Cardio Diagnostics Holdings, Inc., a Delaware corporation, together with its consolidated subsidiary.

Overview

Cardio was formed to further develop and commercialize a series of products for major types of cardiovascular disease and associated co-morbidities, including coronary heart disease (“CHD”), stroke, heart failure and diabetes, by leveraging our Artificial Intelligence (“AI”)-driven Integrated Genetic-Epigenetic Engine™. As a company, we aspire to give every American adult insight into their unique risk for various cardiovascular diseases. Cardio aims to become one of the leading medical technology companies for enabling improved prevention, early detection and treatment of cardiovascular disease. Cardio is transforming the approach to cardiovascular disease from reactive to proactive and hope to accelerate the adoption of Precision Medicine for all. We believe that incorporating Cardio’s solutions into routine practice in primary care and prevention efforts can help alter the trajectory that nearly one in two Americans is expected to develop some form of cardiovascular disease by 2035.

Cardio believes it is the first company to develop and commercialize epigenetics-based clinical tests for cardiovascular disease that have clear value propositions for multiple stakeholders including (1) patients, (2) clinicians, (3) hospitals/health systems, (4) employers and (5) payors. According to the CDC, epigenetics is the study of how a person’s behaviors and environment can cause changes that affect the way a person’s genes work. Unlike genetic changes, epigenetic changes are reversible and do not change one’s DNA sequence, but they can change how a person’s body reads a DNA sequence.

Cardio’s ongoing strategy for expanding its business operations includes the following:

  • Develop blood-based and saliva-based products for stroke, congestive heart failure and diabetes;
  • Build out clinical and health economics evidence in order to obtain payer reimbursement for Cardio’s tests;
  • Expand its testing process outside of a single high complexity CLIA laboratory to multiple laboratories, including hospital laboratories;
  • Introduce the test across several additional key channels, including health systems and self-insured employers; and
  • Pursue the potential acquisition of one or more laboratories and/or synergistic companies in the telemedicine, AI or remote patient monitoring space.

 

15 
 

Recent Developments

The Business Combination

On October 25, 2022, we consummated the Business Combination. Pursuant to the Business Combination Agreement, Merger Sub merged with and into Legacy Cardio, with Legacy Cardio surviving the merger and becoming a wholly-owned direct subsidiary of Mana. Thereafter, Merger Sub ceased to exist, and Mana was renamed Cardio Diagnostics Holdings, Inc.

The Business Combination was accounted for as a reverse recapitalization, in accordance with GAAP. Under the guidance in ASC 805, Mana was treated as the “acquired” company for financial reporting purposes. Legacy Cardio was deemed the accounting predecessor of the combined business, and Cardio Diagnostics Holdings, Inc., as the parent company of the combined business, was the successor SEC registrant, meaning that our financial statements for previous periods will be disclosed in the registrant’s periodic reports filed with the SEC.

The Business Combination had a significant impact on the Company’s reported financial position and results as a consequence of the reverse recapitalization. As noted in Note 1 to the Company’s consolidated financial statements, the Company’s financial position reflects current liabilities that include existing, deferred liabilities originally incurred by Mana that are payable by the Company to Ladenburg Thalmann & Co., Inc. (“Ladenburg”) and I-Bankers Securities, Inc. (“I-Bankers”), the underwriters of Mana’s initial public offering, and The Benchmark Company, LLC (“Benchmark”), the M&A advisor Mana retained in connection with the Business Combination. The aggregate amount of the liabilities owed to these investment bankers, as assumed by the Company in connection with the Business Combination, totals $928,500. This sum reflects a decrease in the amount of the original liabilities incurred by Mana, including a 30% decrease in the liability owed to Ladenburg and I-Bankers and a 46% decrease in the original liability incurred by Mana to Benchmark. The $928,500 is due and payable to the investment bankers on October 25, 2023. On March 25, 2023, Ladenburg offered the Company a 15% early pay discount on the balance due. On March 27, 2023, the Company accepted the early pay discount and paid Ladenburg the net balance due and payable of $419,475. As of March 31, 2023, the remaining assumed liabilities balance was $435,000.

In addition, the Company acquired only $4,021 in cash after the payment of transaction costs and outstanding accounts payable, primarily as a result of a redemption rate of over 99% by the holders of Mana’s publicly-traded Common Stock, which shares had a redemption right in connection with the Business Combination. Specifically, Mana’s public stockholders exercised their right to redeem 6,465,452 shares of Common Stock, which constituted approximately 99.5% of the shares with redemption rights, for cash at a redemption price of approximately $10.10 per share, for an aggregate redemption amount of $65,310,892. In accounting for the reverse recapitalization, Legacy Cardio’s 1,976,749 issued and outstanding shares of common stock were reversed, and the Mana shares of common stock, totaling 9,514,743, were recorded, as described in Note 2.

As a result of the Business Combination, Cardio became an SEC-registered and Nasdaq-listed company, which will require the Company to hire additional personnel and implement procedures and processes to address public company regulatory requirements and customary practices. The Company expects to incur additional annual expenses as a public company for, among other things, directors’ and officers’ liability insurance, director fees, and additional internal and external accounting, legal and administrative resources.

COVID-19 Impact

The global COVID-19 pandemic continues to evolve. The extent of the impact of the COVID-19 pandemic on Cardio’s business, operations and development timelines and plans remains uncertain and will depend on certain developments, including the duration and spread of the outbreak and its impact on Cardio’s development activities, third-party manufacturers, and other third parties with whom Cardio does business, as well as its impact on regulatory authorities and Cardio’s key scientific and management personnel.

The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. To the extent possible, Cardio is conducting business as usual, with necessary or advisable modifications to employee travel and with certain of its employees working remotely all or part of the time. Cardio will continue to actively monitor the evolving situation related to COVID-19 and may take further actions that alter our operations, including those that federal, state or local authorities may require, or that we determine in the best interests of our employees and other third parties with whom we do business. At this point, the extent to which the COVID-19pandemic may affect our future business, operations and development timelines and plans, including the resulting impact on Cardio’s expenditures and capital needs, remains uncertain.

16 
 

Results of Operations

The results of operations presented below should be reviewed in conjunction with the consolidated financial statements and notes included elsewhere in this Quarterly Report on Form 10-Q. The following table sets forth Cardio’s results of operations data for the periods presented:

Comparisons for the three months ended March 31, 2023 and 2022:

   Three Months Ended March 31, 
   2023   2022 
Revenue        
Revenue  $ —   $ — 
         
Operating Expenses          
Sales and marketing   49,551    22,398 
Research and development   86,665    1,130 
General and administrative expenses   1,562,128    205,027 
Amortization   4,785    4,000 
Total operating expenses   (1,703,129)   (232,555)
Other (expense) income   670,511    (57,500)
 Net (loss)  $(1,032,618)  $(290,055)

Net Loss Attributable to Legacy Cardio

Cardio’s net loss for the three months ended March 31, 2023, was $1,032,618 as compared to $290,055 for the three months ended March 31, 2022, an increase of $1,921,721, primarily as a result of an increase in General and Administrative expenses.

Revenue

Cardio had no revenue three months ended March 31, 2023 and 2022, respectively.

Sales and Marketing

Expenses related to sales and marketing for three months ended March 31, 2023 were $49,551 as compared to $22,398 three months ended March 31, 2022, an increase of $27,153. The overall increase was due to an increase in sales and marketing efforts after the Business Combination.

Research and Development

Research and development expense three months ended March 31, 2023 was $86,665 as compared to $1,130 for three months ended March 31, 2022, an increase of $85,535. The increase was attributable to laboratory runs performed in the 2023 period on new product offerings in the pipeline.

General and Administrative Expenses

General and administrative expenses for the three months ended March 31, 2023 were $1,562,128 as compared to $205,027 for the three months ended March 31, 2022, an increase of $1,357,101. The overall increase is primarily due to an increase in personnel and legal and accounting expenses related to financing and merger transactional activity, increased expenses associated with being a publicly traded company and some increase in personnel.

Amortization

Amortization expense for the three months ended March 31, 2023 was $4,785 as compared to $4,000 for the three months ended March 31, 2022. The total amortization expense includes the amortization of intangible assets.

Other Income (expenses)

Total other income for the three months ended March 31, 2023, was $670,511 as compared to total other expenses of $57,500 for the three months ended March 31, 2022. The total other income for the three months ended March 31, 2023, is due to a gain on the change in fair value of derivative liability of $5,686,901 and interest income of $221 offset by interest expense of $5,016,611. Interest expense includes the amortization of $31,506 of the original issuance discount, $283,561 amortization of the debt discount related to the derivative liability, and $4,692.672 related to the excess fair value of the derivative liability in excess of the book value of the convertible note at inception.

 

17 
 

Liquidity and Capital Resources

Liquidity describes the ability of a company to generate sufficient cash flows in the short- and long-term to meet the cash requirements of its business operations, including working capital needs, debt service, acquisitions and investments, and other commitments and contractual obligations. We consider liquidity in terms of cash flows from operations and other sources, and their sufficiency to fund our operating and investing activities.

Our principal sources of liquidity have been proceeds from the issuance of equity and warrant exercises. More recently, upon signing the YA Securities Purchase Agreement on March 8, 2023, we issued and sold to YA II PN, Ltd. (“Yorkville”) a Convertible Debenture in the principal amount of $5.0 million for a purchase price of $4.5 million (the “First Convertible Debenture”) to provide additional liquidity. Pursuant to the YA Securities Purchase Agreement, the parties further agreed that we will issue and sell to Yorkville, and Yorkville will purchase from us, a second Convertible Debenture in the principal amount of $6.2 million for a purchase price of $5.58 million, subject to the satisfaction or waiver of the conditions set forth in the YA Securities Purchase Agreement. The conditions include, but are not limited to: (i) the SEC shall have declared effective a resale registration statement covering shares of Common Stock issuable upon conversion of the First Convertible Debenture; and (ii) we shall have obtained stockholder approval for the issuance of the shares of Common Stock issuable upon conversion of the Debentures that would be in excess of the “Exchange Cap” (as defined in the YA Securities Purchase Agreement). The SEC declared effective the resale registration statement on April 11, 2023. We have noticed a special meeting of stockholders to be held on May 26, 2023 where we will seek to satisfy the stockholder approval condition needed to issue and sell the second Convertible Debenture to Yorkville.

Our primary cash needs are for day-to-day operations, to fund working capital requirements, to fund our growth strategy, including investments and acquisitions, and to pay $928,500 of deferred contractual obligations originally incurred by Mana to its investment bankers, which is payable on October 25, 2023, as well as other accounts payable. On March 25, 2023, Ladenburg offered the Company a 15% early pay discount on the balance due. On March 27, 2023, the Company accepted the early pay discount and paid Ladenburg the net balance due and payable of $419,475. As of March 31, 2023, the remaining assumed liabilities balance was $435,000.

Our principal uses of cash in recent periods have been funding operations and paying expenses associated with the Business Combination. Our long-term future capital requirements will depend on many factors, including revenue growth rate, the timing and the amount of cash received from customers, the expansion of sales and marketing activities, the timing and extent of spending to support investments, including research and development efforts, and the continuing market adoption of our products.

In each fiscal year since our inception, we have incurred losses from operations and generated negative cash flows from operating activities. Our total current liabilities as of March 31, 2023 are $5,129,496. As noted above, on March 8, 2023, we issued and sold the First Convertible Debenture, thereby increasing our current liabilities by $5.0 million, with the expectation that we will issue and sell the Second Convertible Debenture in the principal amount of $6.2 million in the second quarter of 2023.

We received less proceeds from the Business Combination than we initially expected. The projections that we prepared in June 2022 in connection with the Business Combination assumed that we would receive at least an aggregate of $15 million in capital from the Business Combination and the Legacy Cardio private placements conducted in 2022 prior to the Business Combination. This base amount anticipated at least $5.0 million in proceeds remaining in the Trust Account following payment of the requested redemptions. At Closing, we received only $4,021 in cash from the Trust Account due to higher than expected redemptions by Mana public stockholders and higher than expected expenses in connection with the Business Combination and residual Mana expenses. Accordingly, we have less cash available to pursue our anticipated growth strategies and new initiatives than we projected. This has caused, and may continue to cause, significant delays in, or limit the scope of, our planned acquisition strategy and our planned product expansion timeline. Our failure to achieve our projected results could harm the trading price of our securities and our financial position, and adversely affect our future profitability and cash flows.

Because of the extremely high rate of redemptions by Mana public stockholders in connection with the Business Combination and higher than anticipated transaction costs, we have almost no Trust fund proceeds available to pursue our anticipated growth strategies and new initiatives, including our acquisition strategy. This has had a material impact on our projected estimates and assumptions and actual results of operations and financial condition. We recorded nominal revenue in 2022 of $950. We expect that revenue in 2023 will also fall short of the projections. Nevertheless, we believe that the fundamental elements of our business strategy remain unchanged, although the scale and timing of specific initiatives have been temporarily negatively impacted as a result of having significantly less than anticipated capital on hand following the Business Combination.

We have had, and expect that we will continue to have, an ongoing need to raise additional cash from outside sources to fund our operations and expand our business. If we are unable to raise additional capital when desired, our business, financial condition and results of operations would be harmed. Successful transition to attaining profitable operations depends upon achieving a level of revenue adequate to support the post-merger company.

18 
 

We expect that working capital requirements will continue to be funded through a combination of existing funds and further issuances of securities. Working capital requirements are expected to increase in line with the growth of the business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund operations over the next 12 months. We have no lines of credit or other bank financing arrangements. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. Cardio intends to finance these expenses with further issuances of securities and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. If we raise additional funds through the issuance of equity or convertible debt securities, the percentage ownership of our equity holders could be significantly diluted, and these newly-issued securities may have rights, preferences or privileges senior to those of existing equity holders. If we raise additional funds by obtaining loans from third parties, the terms of those financing arrangements may include negative covenants or other restrictions on our business that could impair our operating flexibility and also require us to incur interest expense.

The exercise prices of our currently outstanding warrants range from a high of $11.50 to a low of $3.90 per share of Common Stock. We believe the likelihood that warrant holders will exercise their Warrants and therefore the amount of cash proceeds that we might receive, is dependent upon the trading price of our Common Stock, the last reported sales price for which was $1.72 on May 11, 2023. If the trading price of our Common Stock is less than the respective exercise prices of our outstanding Warrants, we believe holders of our Public Warrants, Sponsor Warrants and Private Placement Warrants will be unlikely to exercise their Warrants. There is no guarantee that the Warrants will be in the money prior to their respective expiration dates, and as such, the Warrants may Expire worthless, and we may receive no proceeds from the exercise of Warrants. Given the current differential between the trading price of our Common Stock and the Warrant exercise prices and the volatility of our stock price, we are not making strategic business decisions based on an expectation that we will receive any cash from the exercise of Warrants. However, we will use any cash proceeds received from the exercise of Warrants for general corporate and working capital purposes, which would increase our liquidity. We will continue to evaluate the probability of Warrant exercises and the merit of including potential cash proceeds from the exercise of the Warrants in our future liquidity projections.

Cash at March 31, 2023 totaled $6,707,770 as compared to $4,117,521 at December 31, 2022, an increase of $2,590,249. The following table shows Cardio’s cash flows from operating activities, investing activities and financing activities for the stated periods:

   Three Months Ended March 31, 
   2023   2022 
Net cash used in operating activities  $1,649,067   $186,090 
Net cash used in investing activities   52,674    16,436 
Net cash provided by financing activities   4,291,990    —   

Cash Used in Operating Activities

Cash used in operating activities for the three months ended March 31, 2023 was $1,649,067, as compared to $186,090 for the three months ended March 31, 2022. The cash used in operations during the three months ended March 31, 2023, is a function of net loss of $1,032,618 adjusted for the following non-cash operating items: amortization of $4,785, $4,000 in stock based compensation, $5,007,740 in non-cash interest expense offset by $5,686,901 in change in fair value of derivative liability, , a decrease of $338,105 in prepaid expenses and other current assets, an increase in deposits of $2,100 and a decrease of $282,078 in accounts payable and accrued expenses.

Cash Used in Investing Activities

Cash used in investing activities for the three months ended March 31, 2023, was $52,674 compared to $16,436 for the three months ended March 31, 2022. The cash used in investing activities for the three months ended March 31, 2023 was due to patent costs incurred.

Cash Provided by Financing Activities

Cash provided by financing activities for the three months ended March 31, 2023, was $4,291,990 as compared to $0 for the three months ended March 31, 2023. This change was due to $4,500,000 in proceeds from convertible notes payable, net of original issue discount (“OID”) of $500,000, $390,000 in proceeds from exercise of warrants, offset by $283,000 in payments of finance agreement and $315,000 in placement agent fees, during the three months ended March 31, 2023.

Off-Balance Sheet Financing Arrangements

We did not have any off-balance sheet arrangements as of March 31, 2023.

19 
 

Contractual Obligations

The following summarizes Cardio’s contractual obligations as of March 31, 2023 and the effects that such obligations are expected to have on its liquidity and cash flows in future periods:

Prior Mana Obligations to its Investment Bankers

See “Recent Developments – Business Combination” above for a discussion of the contractual obligations due and payable on October 25, 2023 to Ladenburg/I-Bankers and Benchmark in the aggregate amount of $928,500 for deferred investment banking fees originally entered into by Mana prior to the Business Combination, as reduced at and after the closing of the Business Combination.

 

On March 25, 2023, Ladenburg offered the Company a 15% early pay discount on the balance due. On March 27, 2023, the Company accepted the early pay discount and paid Ladenburg the net balance due and payable of $419,475. As of March 31, 2023, the remaining assumed liabilities balance was $435,000.

Prior Relationships of Cardio with Boustead Securities, LLC

At the commencement of efforts to pursue what ultimately ended in the terminated business acquisition referred to above under “Deposit for Acquisition,” Legacy Cardio entered into a Placement Agent and Advisory Services Agreement (the “Placement Agent Agreement”), dated April 12, 2021, with Boustead Securities, LLC (“Boustead Securities”). This agreement was terminated in April 2022, when Legacy Cardio terminated the underlying agreement and plan of merger and the accompanying escrow agreement relating to that proposed business acquisition after efforts to complete the transaction failed, despite several extensions of the closing deadline.

Under the terminated Placement Agent Agreement, Legacy Cardio agreed to certain future rights in favor of Boustead Securities, including (i) a two-year tail period during which Boustead Securities would be entitled to compensation if Cardio were to close on a transaction (as defined in the Placement Agent Agreement) with any party that was introduced to Legacy Cardio by Boustead Securities; and (ii) a right of first refusal to act as the Company’s exclusive placement agent for 24-months from the end of the term of the Placement Agent Agreement (the “right of first refusal”). Cardio has taken the position that due to Boustead Securities’ failure to perform as contemplated by the Placement Agent Agreement, these provisions purporting to provide future rights are null and void.

Boustead Securities responded to the termination of the Placement Agent Agreement by disputing Legacy Cardio’s contention that it had not performed under the Placement Agent Agreement because, among other things, Boustead Securities had never sought out prospective investors. In its response, Boustead Securities included a list of funds that they had supposedly contacted on Legacy Cardio’s behalf. While Boustead Securities’ contention appears to contradict earlier communications from Boustead Securities in which they indicated that they had not made any such contacts or introductions, Boustead Securities is currently contending that they are due success fees for two years following the termination of the Placement Agent Agreement on any transaction with any person on the list of supposed contacts or introductions. Legacy Cardio strongly disputes this position. Notwithstanding the foregoing, the Company has not consummated any transaction, as defined, with any potential party that purportedly was a contact of Boustead Securities in connection with the Placement Agent Agreement and has no plans to do so at any time during the tail period. No legal proceedings have been instigated by either party, and Cardio believes that the final outcome will not have a material adverse impact on its financial condition.

The Benchmark Company, LLC Right of First Refusal

As noted in Note 1, the Company completed a business combination with Mana on October 25, 2022. In connection with the proposed business combination, by agreement dated May 13, 2022, Mana engaged The Benchmark Company, LLC (“Benchmark”) as its M&A advisor. Upon closing of the business combination, Cardio assumed the contractual engagement entered into by Mana. On November 14, 2022, Cardio and Benchmark entered into Amendment No. 1 Engagement Letter (the “Amendment Engagement”). Pursuant to the Amendment Engagement, Benchmark has been granted a right of first refusal to act as lead or joint-lead investment banker, lead or joint-lead book-runner and/or lead or joint-lead placement agent for all future public and private equity and debt offerings through October 25, 2023. In this regard, the Company and Benchmark are in discussions regarding whether Benchmark might be entitled to compensation arising from the Company having entered into the convertible debenture financing in March 2023 without first consulting Benchmark. No legal proceedings have been instigated, and the parties are continuing to discuss a resolution to this matter.

20 
 

 

Demand Letter and Potential Mootness Fee Claim

On June 25, 2022, a plaintiffs’ securities law firm sent a demand letter to the Company alleging that the Company’s Registration Statement on Form S-4 filed (the “S-4 Registration Statement”) with the Securities and Exchange Commission (“SEC”) on May 31, 2022 omitted material information with respect to the Business Combination and demanding that the Company and its Board of Directors immediately provide corrective disclosures in an amendment or supplement to the Registration Statement. Subsequent thereto, the Company filed amendments to the S-4 Registration Statement on July 27, 2022, August 23, 2022, September 15, 2022, October 4, 2022 and October 5, 2022 in which it responded to various comments of the SEC staff and otherwise updated its disclosure. In October 2023, the SEC completed its review and declared the S-4 registration statement effective on October 6, 2022. On February 23, 2023 and February 27, 2023, plaintiffs’ securities law firm contacted the Company’s counsel asking who will be negotiating a mootness fee relating to the purported claims set forth in the June 25, 2022 demand letter. The Company vigorously denies that the S-4 Registration Statement, as amended and declared effective, is deficient in any respect and that no additional supplemental disclosures are material or required. The Company believes that the claims asserted in the Demand Letter are without merit and that no further disclosure is required to supplement the S-4 Registration Statement under applicable laws. As of the date of filing of this Quarterly Report on Form 10-Q, no lawsuit has been filed against the Company by that firm. The firm has indicated its willingness to litigate the matter if a mutually satisfactory resolution cannot be agreed upon; however, Cardio believes that the final outcome will not have a material adverse impact on its financial condition.

The Company cannot preclude the possibility that claims or lawsuits brought relating to any alleged securities law violations or breaches of fiduciary duty could potentially require significant time and resources to defend and/or settle and distract its management and board of directors from focusing on its business.

Critical Accounting Policies and Significant Judgments and Estimates

Cardio’s consolidated financial statements are prepared in accordance with GAAP in the United States. The preparation of its consolidated financial statements and related disclosures requires it to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in Cardio’s financial statements. Cardio bases its estimates on historical experience, known trends and events and various other factors that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Cardio evaluates its estimates and assumptions on an ongoing basis. Cardio’s actual results may differ from these estimates under different assumptions or conditions.

While Cardio’s significant accounting policies are described in more detail in Note 2 to its consolidated financial statements, Cardio believes that the following accounting policies are those most critical to the judgments and estimates used in the preparation of its consolidated financial statements.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly owned-subsidiary, Cardio Diagnostics, LLC. All intercompany accounts and transactions have been eliminated.

Use of Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

Fair Value Measurements

The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.

21 
 

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

Revenue Recognition

The Company hosts its product, Epi+Gen CHD™ on InTeleLab’s Elicity platform (the “Lab”). The Lab collects payments from patients upon completion of eligibility screening. Patients then send their samples to Mogene, a high complexity CLIA lab, which perform the biomarker assessments. Upon receipt of the raw biomarker data from Mogene, the Company performs all quality control, analytical assessments and report generation and shares test reports with the Elicity healthcare provider via the Elicity platform. Revenue is recognized upon receipt of payments from the Lab for each test at the end of each month.

The Company accounts for revenue under (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606)”, using the modified retrospective method. The modified retrospective adoption used by the Company did not result in a material cumulative effect adjustment to the opening balance of accumulated deficit.

The Company determines the measurement of revenue and the timing of revenue recognition utilizing the following core principles:

1.       Identifying the contract with a customer;

2.       Identifying the performance obligations in the contract;

3.       Determining the transaction price;

4.       Allocating the transaction price to the performance obligations in the contract; and

5.       Recognizing revenue when (or as) the Company satisfies its performance obligations.

Patent Costs

Cardio accounts for patents in accordance with ASC 350-30, General Intangibles Other than Goodwill. The Company capitalizes patent costs representing legal fees associated with filing patent applications and amortize them on a straight-line basis. The Company are in the process of evaluating its patents’ estimated useful life and will begin amortizing the patents when they are brought to the market or otherwise commercialized.

Stock-Based Compensation

Cardio accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest. The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk-free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants. Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.

22 
 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Pursuant to Item 305(e) of Regulation S-K, the Company is not required to provide the information required by this Item as it is a “smaller reporting company.”

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the period covered by this Quarterly Report. Based on this evaluation, our principal executive officer and principal financial and accounting officer have concluded that during the period covered by this Report, our disclosure controls and procedures are not effective. As a result, we performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with U.S. generally accepted accounting principles. Accordingly, management believes that the financial statements included in this Form 10-Q present fairly in all material respects our financial position, results of operations and cash flows for the period presented.

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Control over Financial Reporting

There has not been any change in our internal control over financial reporting that occurred during the three months ended March 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

23 
 

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time-to-time, the Company is involved in various civil actions as part of its normal course of business. The Company is not a party to any litigation that is material to ongoing operations as defined in Item 103 of Regulation S-K as of the period ended March 31, 2023.

ITEM 1A. RISK FACTORS

Other than as set forth below, there have been no material changes to the risk factors previously described in Item 1A of Part I of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. These risk factors describe some of the assumptions, risks, uncertainties and other factors that could adversely affect our business or that could otherwise result in changes that differ materially from our expectations. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC, including as set forth below. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.

Future sales of Common Stock in the public market could cause our share price to decline significantly, even if our business is doing well.

The market price of our Common Stock could decline as a result of sales of a large number of shares of Common Stock in the market, or the perception that these sales could occur. There are a total 9,697,897 shares of Common Stock outstanding as of April 20, 2023. In November 2022, we filed a registration statement on Form S-1 under the Securities Act to register securities, including a primary offering of 3,486,686 shares issuable upon exercise of outstanding warrants and 11,883,256 shares registered for resale by selling stockholders. The SEC declared the registration statement effective on January 24, 2023 and subsequent to our filing a post-effective amendment to that registration statement, the SEC declared the post-effective amendment effective on April 28, 2023. As such, those securities are freely tradeable at any time. In addition, we registered the resale of an additional 236,686 warrants, which if exercised, will also result in freely-tradeable Common Stock. In addition, on March 22, 2023, we filed, and the SEC declared effective, a Form S-8 registration statement covering the Common Stock issuable upon exercise or conversion of stock-based grants and awards issued or issuable under the Company’s 2022 Equity Incentive Plan. Upon filing, the shares of Common Stock covered by the Form S-8 the registration statement became eligible for sale in the public market, subject to Rule 144 limitations applicable to affiliates.

Further, we filed a resale registration statement on April 5, 2023, which the SEC declared effective on April 11, 2023, to satisfy our obligation to register for resale up to 20,363,637 shares of Common Stock that are potentially issuable upon conversion of the Convertible Debentures. That number assumes conversion at the lowest possible conversion price of $0.55 per share, which we believe is an unlikely outcome but is contractually possible. Yorkville is required to use its commercially reasonable efforts to convert a minimum of at least $1,000,000 of principal amount in the aggregate of its Convertible Debentures per calendar month. In any event, it is possible that the shares of Common Stock issuable upon conversion of the Convertible Debentures will result in a substantial number of shares being held by a single investor who will be free to sell significant blocks of stock, if and when it elects to do so.

The current availability of our earlier registration statements that were declared effective in January 2023, March 2023 and April 2023, and the future availability of Rule 144 for resales of other securities after October 25, 2023, together result in virtually all of the shares of Common Stock we have issued in non-public transactions being eligible to be freely traded in the public market, subject to certain limitations applicable to our affiliates. The resale, or expected or potential resale, of a substantial number of our shares of Common Stock in the public market could adversely affect the market price for our shares of Common Stock and make it more difficult for investors to sell their shares of Common Stock at times and prices that they feel are appropriate. In particular, we expect that, because there will be a substantial number of shares registered pursuant to various registration statements, the applicable selling securityholders will continue to offer such covered securities for a significant period of time, the precise duration of which cannot be predicted. Accordingly, the adverse market and price pressures resulting from an offering pursuant to a registration statement may continue for an extended period of time.

Sales of Common Stock pursuant to these registration statements or pursuant to Rule 144 may make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. These sales also could cause the trading price of our Common Stock to fall and make it more difficult for investors to sell shares of our Common Stock at a time and price that they deem appropriate.

24 
 

We may issue additional shares of our Common Stock or other equity securities without your approval, which would dilute your ownership interests and may depress the market price of our Common Stock.

As of May 15, 2023, we have Warrants outstanding to purchase 7,854,627 shares of our Common Stock. We will also have the ability to initially issue an aggregate of 3,216,516 shares of our Common Stock under the Cardio Equity Incentive Plan, of which 1,759,599 options have been granted and are currently exercisable. We also have issued $5.0 million of Convertible Debentures and expect to issue an additional $6.2 million of Convertible Debentures in the second quarter of 2023, or as soon thereafter as all of the conditions precedent to such issuance are satisfied or waived. The Convertible Debentures are convertible at the option of the holder at varying rates depending on the trading price of our Common Stock. The maximum number of shares into which the Debentures could convert is 20,363,637 shares, if the Convertible Debentures were converted at the floor price of $0.55 per share (the “Floor Price”). We do not expect the conversions to take place at the Floor Price, although we cannot guarantee that our stock price will not, in the future, fall to a level that will result in conversions at the Floor Price. As of May 15, 2023, $700,000 in principal amount of Convertible Debentures have been converted into an aggregate of 361,094 shares of Common Stock.

We may issue additional shares of our Common Stock or other equity securities of equal or senior rank in the future in connection with, among other things, future acquisitions or repayment of outstanding indebtedness, without stockholder approval, in a number of circumstances. 

Our issuance of additional shares of Common Stock or other equity securities of equal or senior rank would have the following effects:

  •   our existing stockholders’ proportionate ownership interest in the Company will decrease;
  • the amount of cash available per share, including for payment of dividends (if any) in the future, may decrease;
  • the relative voting strength of each previously outstanding share of Common Stock may be diminished; and
  • the market price of our shares of Common Stock may decline.

 

A significant number of shares of our Common Stock are subject to issuance upon exercise of outstanding warrants and options and conversion of Convertible Debentures, which upon such exercise or conversion, as the case may be, may result in dilution to our security holders.

We have outstanding:

  •   3,249,993 public warrants, exercisable at a price of $11.50 per share, subject to adjustment and subject to Cardio having an effective registration on file with the SEC which allows for the exercise for cash of the Public Warrants;
  • 2,500,000 warrants issued to the Sponsor, exercisable at a price of $11.50 per share, subject to adjustment;
  • 1,759,600 Exchanged Options that were issued in exchange for Legacy Cardio options with an exercise price of $3.90 per share, subject to adjustment; and
  • 2,204,627 Legacy Cardio Private Placement Warrants that were issued in exchange for outstanding Cardio warrants, with exercise prices ranging between $3.90 and $6.21 per share, subject to adjustment; 100,000 of these warrants were exercised in March 2023.

 

In March 2023, we issued the First Convertible Debenture in the principal amount of $5.0 million, and we are obligated to issue a second Convertible Debenture in the principal amount of $6.2 million upon satisfaction or waiver of certain conditions. although given current trading prices of our Common Stock, we would expect, but cannot guarantee, any conversions to be at prices well above the Floor Price. Nevertheless, it is possible that conversions of the Convertible Debentures will result in substantial dilution to our securityholders. As of May 15, 2023, $700,000 in principal amount of Convertible Debentures have been converted into an aggregate of 361,094 shares of Common Stock.

 

25 
 

 

To the extent such warrants and options are exercised or debentures converted, additional shares of our Common Stock will be issued, which will result in dilution to the then existing holders of our Common Stock and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market could adversely affect the market price of our Common Stock.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q. 

        Incorporation by Reference
Exhibit Number   Description   Form   Exhibit   Filing
Date
                 
2.1   Agreement and Plan of Merger dated as of May 27, 2022 by and among Mana Capital Acquisition Corp., Mana Merger Sub, Inc., Cardio Diagnostics, Inc., and Meeshanthini (Meesha) Dogan, as representatives of the shareholders (included as Annex A to the Proxy Statement/Prospectus)   S-4/A   2.1   10/4/22
2.2   Amendment dated September 15, 2022 to Agreement and Plan of Merger dated as of May 27, 2022 by and among Mana Capital Acquisition Corp., Mana Merger Sub, Inc., Cardio Diagnostics, Inc., and Meeshanthini (Meesha) Dogan, as representatives of the shareholders   S-4/A   2.2   10/4/22
2.3   Waiver Agreement dated as of October 25, 2022 with respect to Agreement and Plan of Merger dated as of May 27, 2022, as amended on September 15, 2022   8-K   2.3   10/31/22
3.1   Second Amended and Restated Certificate of Incorporation of Cardio Diagnostics Holdings, Inc., dated October 25, 2022   8-K   3.1   10/31/22
3.2   By-laws   S-1   3.3   10/19/21
4.1   Specimen Stock Certificate   S-1/A   4.2   11/10/21
4.2   Specimen Warrant Certificate (contained in Exhibit 4.3)   8-K   4.1   11/26/21
4.3   Warrant Agreement, dated November 22, 2021, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent   8-K   4.1   11/26/21
4.4   Convertible Debenture, dated March 8, 2023   8-K   4.1   3/13/23
4.5   Description of Securities   10-K    4.5    3/31/23 
10.1   Securities Purchase Agreement, dated March 8, 2023, by and between the registrant and YA II PN, Ltd.   8-K   10.1   3/13/23
10.2   Form of Convertible Debenture   8-K   10.2   3/13/23
10.3   Registration Rights Agreement, dated March 8, 2023, by and between the registrant and YA II PN, Ltd.   8-K   4.1   3/13/23
31.1*   Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002            
31.2*   Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002            
32.1+   Certification of Principal Executive Officer pursuant to 18 U.S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002            
32.2+  

Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

            
101.INS*   Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)            
101.SCH*   XBRL Taxonomy Extension Schema Document.            
101.CAL*   XBRL Taxonomy Extension Calculation Linkbase Document            
101.DEF*   XBRL Taxonomy Extension Definition Linkbase Document            
101.LAB*   XBRL Taxonomy Extension Label Linkbase Document            
101.PRE*   XBRL Taxonomy Extension Presentation Linkbase Document            
104*   Cover Page Interactive Date File (embedded with the Inline XBRL document)            

 

*    Filed herewith.  
+ Furnished herewith. The certifications attached as Exhibit 32.1 and Exhibit 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Cardio Diagnostics Holdings, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.  
       
       

 

  

26 
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Cardio Diagnostics Holdings, Inc.
     
 Date: May 15, 2023 By:   /s/ Elisa Luqman
    Elisa Luqman
    Chief Financial Officer

 

 

 

 

27 
 

 

 

 

 EX-31.1 2 ex31x1.htm EXHIBIT 31.1

EXHIBIT 31.1

 

CERTIFICATION

 

I, Meeshanthini V. Dogan, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Cardio Diagnostics Holdings, Inc. for the quarter ended March 31, 2023;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: May 15, 2023 /s/ Meeshanthini V. Dogan  
  Meeshanthini V. Dogan  
 

Chief Executive Officer

(Principal Executive Officer)

  
   
       

 

 EX-31.2 3 ex31x2.htm EXHIBIT 31.2

 

 

EXHIBIT 31.2

 

CERTIFICATION

 

I, Elisa Luqman, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Cardio Diagnostics Holdings, Inc. for the quarter ended March 31, 2023;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: May 15, 2023 /s/ Elisa Luqman  
  Elisa Luqman, Chief Financial Officer  
  (Principal Financial Officer)  
   
       

 

 

 EX-32.1 4 ex32x1.htm EXHIBIT 32.1

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with this Quarterly Report on Form 10-Q, (the “Report”) of Cardio Diagnostics Holdings, Inc. (the “Company”) for the quarter ended March 31, 2023, the undersigned, Meeshanthini V. Dogan, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of the undersigned’s knowledge and belief:

 

(1)   the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
(2)   the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
     

 

May 15, 2023  
  /s/ Meeshanthini V. Dogan
 

Meeshanthini V. Dogan 

Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

 

 

 

 EX-32.2 5 ex32x2.htm EXHIBIT 32.2

EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with this Quarterly Report on Form 10-Q, (the “Report”) of Cardio Diagnostics Holdings, Inc. (the “Company”) for the quarter ended March 31, 2023, the undersigned, Elisa Luqman, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of the undersigned’s knowledge and belief:

 

(1)   the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
(2)   the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

May 15, 2023  
  /s/ Elisa Luqman
 

Elisa Luqman

Chief Financial Officer

(Principal Financial Officer)

 

 

 

 EX-101.SCH 6 cdio-20230331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Merger Agreement and Reverse Recapitalization link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Patent Costs link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Finance Agreement Payable link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Earnings (Loss) Per Common Share link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Derivative Liability link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Earnings (Loss) Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Stockholders’ Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Derivative Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Merger Agreement and Reverse Recapitalization (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Summary of Significant Accounting Policies (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Patent Costs (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Finance Agreement Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Earnings (Loss) Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Convertible Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Derivative Liability (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cdio-20230331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 cdio-20230331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 cdio-20230331_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, par value $0.00001 per share Redeemable Warrants, each whole warrant exercisable for one share of Common Stock Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Liability Class [Axis] Derivative Financial Instruments, Liabilities [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Finite-Lived Intangible Assets by Major Class [Axis] Know How License [Member] Antidilutive Securities [Axis] Stock Warrants [Member] Stock Options [Member] Sale of Stock [Axis] IPO [Member] Legal Entity [Axis] Legacy Cardio Stockholders [Member] Title of Individual [Axis] Legacy Cardio [Member] Manas Former Officers And Directors [Member] Plan Name [Axis] Plan 2022 [Member] Award Type [Axis] Restricted Stock Units (RSUs) [Member] Equity Option [Member] Warrant [Member] Convertible Common Stock [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets     Cash     Prepaid expenses and other current assets Total current assets Long-term assets     Intangible assets, net     Deposits     Patent costs, net Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities     Accounts payable and accrued expenses     Convertible notes payable, net     Derivative liability     Finance agreement payable Total liabilities Stockholders' equity Preferred stock, $.00001 par value; authorized - 100,000,000 shares;  0 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively Common stock, $.00001 par value; authorized - 300,000,000 shares; 9,615,835 and 9,514,743 shares issued and outstanding   as of March 31, 2023 and December 31, 2022, respectively     Additional paid-in capital     Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Operating expenses     Sales and marketing     Research and development     General and administrative expenses     Amortization Total operating expenses Other income (expenses)     Change in fair value of derivative liability     Interest income     Interest expense     Acquisition related expense Total other income (expenses) Loss from operations before provision for income taxes Provision for income taxes Net loss Basic and fully diluted income (loss) per common share: Earnings per share, basic Earnings per share, diluted Weighted average number of shares outstanding, basic Weighted average number of shares outstanding, diluted Beginning balance, value Beginning balance, shares     Warrants converted to common stock Warrants converted to common stock, shares     Restricted stock awards vested Restricted stock awards vested, shares     Placement agent fee     Adjustment to liabilities assumed in merger with Mana     Net loss Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES:     Net loss     Adjustments to reconcile net loss to net          cash used in operating activities             Amortization             Acquisition related expense             Stock-based compensation expense             Non-cash interest expense             Chain in fair value of derivative liability          Changes in operating assets and liabilities:             Accounts receivable             Prepaid expenses and other current assets             Deposits             Accounts payable and accrued expenses             NET CASH USED IN OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES:     Patent costs incurred             NET CASH USED IN INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES:     Proceeds from convertible notes payable, net of original issue discount of $500,000     Proceeds from exercise of warrants     Payments of finance agreement     Payments of placement agent fee             NET CASH PROVIDED BY FINANCING ACTIVITIES NET INCREASE (DECREASE) IN CASH CASH - BEGINNING OF PERIOD CASH - END OF PERIOD SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:     Cash paid during the year for:       Interest     Non-cash investing and financing activities:       Debt discount related to derivative liability       Adjustment to liabilities assumed in acquisition Original issue discount Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Basis of Presentation Merger Agreement And Reverse Recapitalization Merger Agreement and Reverse Recapitalization Accounting Policies [Abstract] Summary of Significant Accounting Policies Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Patent Costs Patent Costs Finance Agreement Payable Finance Agreement Payable Earnings Per Share [Abstract] Earnings (Loss) Per Common Share Equity [Abstract] Stockholders’ Equity Debt Disclosure [Abstract] Convertible Notes Payable Derivative Liability Derivative Liability Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Principles of Consolidation Use of Estimates in the Preparation of Financial Statements Fair Value Measurements Convertible Instruments Revenue Recognition Research and Development Advertising Costs Cash and Cash Equivalents Patent Costs Long-Lived Assets Stock-Based Compensation Income Taxes Recent Accounting Pronouncements Schedule of fair value measurements Schedule of fair value hierarchy level Schedule of intangible assets Schedule of anti dilutive earning per share Schedule of warrant activity Schedule of option liability Cash Acquired from Acquisition Assumed liabilities Stock redeemed Redemption percentage Redemption price per shre Redemption amount Reverse recapitalization shares Common shares reversed Recapitalization cost Derivative liabilities beginning Issued Converted Change in fair value recognized in operations Derivative liabilities ending Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Derivative liabilities ending Research and development expense Advertising costs Cash equivalents FDIC insured amount Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Intangible assets gross Intangible assets accumulated amortization Intangible assets net Weighted average useful life Amortization expense Patent costs Accumulated amortization Financing agreement entered into for prepaid insurance Interest rate Maturity date Finance agreement payable Prepaid expenses Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive shares Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Warrants outstanding, beginning Weighted average exercise price outstanding, beginning Weighted average remaining contractual life Warrant activity Weighted average exercise price warrant activity Warrants outstanding, ending Weighted average exercise price outstanding, ending Warrants exercised Weighted average exercise price exercised Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Number of shares issued Number of shares received Conversion shares Principal amount Number of shares transferred Common stock issuance Conversion of shares, shares Conversion of shares, Value Consultant for services Pre financing capitalization Warrant exercise price Expiration date Options issued Purchase aggrement description Convertible notes payable Debt discount net Annual dividend yield Expected life (years) Risk-free interest rate Expected volatility Exercise price Stock price Interest expense Converted common stock value Conversion of stock shares Assets, Current Assets Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity InterestExpensesRelatedParty Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net Income (Loss) Attributable to Parent Shares, Outstanding Net Income (Loss) Available to Common Stockholders, Basic Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expenses, Other Net Cash Provided by (Used in) Operating Activities Payments to Acquire Intangible Assets Net Cash Provided by (Used in) Investing Activities Payments to Acquire Finance Receivables PaymentsOfPlacementAgentFee Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents PatentCostsTextBlock FinanceAgreementPayableTextBlock Derivatives and Fair Value [Text Block] Revenue Recognition, Services, Licensing Fees [Policy Text Block] Class of Warrant or Right, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised EX-101.PRE 10 cdio-20230331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - shares
 3 Months Ended
Mar. 31, 2023
May 15, 2023
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2023  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 001-41097  
Entity Registrant Name Cardio Diagnostics Holdings, Inc.  
Entity Central Index Key 0001870144  
Entity Tax Identification Number 87-0925574  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 400 North Aberdeen Street  
Entity Address, Address Line Two Suite 900  
Entity Address, City or Town Chicago  
Entity Address, State or Province IL  
Entity Address, Postal Zip Code 60642  
City Area Code (855)  
Local Phone Number 226-9991  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   9,977,791
Common Stock, par value $0.00001 per share    
Title of 12(b) Security Common Stock, par value $0.00001 per share  
Trading Symbol CDIO  
Security Exchange Name NASDAQ  
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock    
Title of 12(b) Security Redeemable Warrants, each whole warrant exercisable for one share of Common Stock  
Trading Symbol CDIOW  
Security Exchange Name NASDAQ  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Current assets    
    Cash $ 6,707,770 $ 4,117,521
    Prepaid expenses and other current assets 1,430,261 1,768,366
Total current assets 8,138,031 5,885,887
Long-term assets    
    Intangible assets, net 33,333 37,333
    Deposits 7,050 4,950
    Patent costs, net 373,197 321,308
Total assets 8,551,611 6,249,478
Current liabilities    
    Accounts payable and accrued expenses 742,635 1,098,738
    Convertible notes payable, net 315,068 0
    Derivative liability 3,505,771 0
    Finance agreement payable 566,022 849,032
Total liabilities 5,129,496 1,947,770
Stockholders' equity    
Preferred stock, $.00001 par value; authorized - 100,000,000 shares;  0 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively
Common stock, $.00001 par value; authorized - 300,000,000 shares; 9,615,835 and 9,514,743 shares issued and outstanding   as of March 31, 2023 and December 31, 2022, respectively 96 95
    Additional paid-in capital 10,446,183 10,293,159
    Accumulated deficit (7,024,164) (5,991,546)
Total stockholders' equity 3,422,115 4,301,708
Total liabilities and stockholders' equity $ 8,551,611 $ 6,249,478
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.00001 $ 0.00001
Preferred stock, shares authorized 100,000,000 100,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.00001 $ 0.00001
Common stock, shares authorized 300,000,000 300,000,000
Common stock, shares issued 9,615,835 9,514,743
Common stock, shares outstanding 9,615,835 9,514,743
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Revenue $ 0 $ 0
Operating expenses    
    Sales and marketing 49,551 22,398
    Research and development 86,665 1,130
    General and administrative expenses 1,562,128 205,027
    Amortization 4,785 4,000
Total operating expenses 1,703,129 232,555
Other income (expenses)    
    Change in fair value of derivative liability 5,686,901 0
    Interest income 221 0
    Interest expense (5,016,611) 0
    Acquisition related expense 0 (57,500)
Total other income (expenses) 670,511 (57,500)
Loss from operations before provision for income taxes (1,032,618) (290,055)
Provision for income taxes 0 0
Net loss $ (1,032,618) $ (290,055)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) - $ / shares
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Earnings per share, basic $ (0.11) $ (0.07)
Earnings per share, diluted $ (0.11) $ (0.07)
Weighted average number of shares outstanding, basic 9,547,177 4,223,494
Weighted average number of shares outstanding, diluted 9,547,177 4,223,494
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2021 $ 42 $ 2,398,628 $ (1,330,561) $ 1,068,109
Beginning balance, shares at Dec. 31, 2021 4,223,494      
    Net loss (290,055) (290,055)
Ending balance, value at Mar. 31, 2022 $ 42 2,398,628 (1,620,616) 778,054
Ending balance, shares at Mar. 31, 2022 4,223,494      
Beginning balance, value at Dec. 31, 2022 $ 95 10,293,159 (5,991,546) 4,301,708
Beginning balance, shares at Dec. 31, 2022 9,514,743      
    Warrants converted to common stock $ 1 389,999 390,000
Warrants converted to common stock, shares 100,000      
    Restricted stock awards vested 4,000 4,000
Restricted stock awards vested, shares 1,092      
    Placement agent fee (315,000) (315,000)
    Adjustment to liabilities assumed in merger with Mana 74,025 74,025
    Net loss (1,032,618) (1,032,618)
Ending balance, value at Mar. 31, 2023 $ 96 $ 10,446,183 $ (7,024,164) $ 3,422,115
Ending balance, shares at Mar. 31, 2023 9,615,835      
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
    Net loss $ (1,032,618) $ (290,055)
         cash used in operating activities    
            Amortization 4,785 4,000
            Acquisition related expense (0) 57,500
            Stock-based compensation expense 4,000 0
            Non-cash interest expense 5,007,740 0
            Chain in fair value of derivative liability (5,686,901) 0
         Changes in operating assets and liabilities:    
            Accounts receivable 0 901
            Prepaid expenses and other current assets 338,105 20,358
            Deposits (2,100) 0
            Accounts payable and accrued expenses (282,078) 21,206
            NET CASH USED IN OPERATING ACTIVITIES (1,649,067) (186,090)
CASH FLOWS FROM INVESTING ACTIVITIES:    
    Patent costs incurred (52,674) (16,436)
            NET CASH USED IN INVESTING ACTIVITIES (52,674) (16,436)
CASH FLOWS FROM FINANCING ACTIVITIES:    
    Proceeds from convertible notes payable, net of original issue discount of $500,000 4,500,000 0
    Proceeds from exercise of warrants 390,000
    Payments of finance agreement (283,010)
    Payments of placement agent fee (315,000) 0
            NET CASH PROVIDED BY FINANCING ACTIVITIES 4,291,990 0
NET INCREASE (DECREASE) IN CASH 2,590,249 (202,526)
CASH - BEGINNING OF PERIOD 4,117,521 512,767
CASH - END OF PERIOD 6,707,770 310,241
    Cash paid during the year for:    
      Interest 8,871 0
    Non-cash investing and financing activities:    
      Debt discount related to derivative liability 9,192,672 0
      Adjustment to liabilities assumed in acquisition $ 74,025 $ 0
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical)
 3 Months Ended
Mar. 31, 2023
USD ($)
Statement of Cash Flows [Abstract]  
Original issue discount $ 500,000
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Organization and Basis of Presentation
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Basis of Presentation

Note 1 - Organization and Basis of Presentation

 

The unaudited condensed consolidated financial statements presented are those of Cardio Diagnostics Holdings, Inc., (the “Company”) and its wholly-owned subsidiary, Cardio Diagnostics, Inc. (“Legacy Cardio”). The Company was incorporated as Mana Capital Acquisition Corp. (“Mana”) under the laws of the state of Delaware on May 19, 2021, and Legacy Cardio was formed on January 16, 2017 as an Iowa limited liability company (Cardio Diagnostics, LLC) and was subsequently incorporated as a Delaware C-Corp on September 6, 2019 (Legacy Cardio). The Company was formed to develop and commercialize a patent-pending Artificial Intelligence (“AI”)-driven DNA biomarker testing technology (“Core Technology”) for cardiovascular disease invented at the University of Iowa by the Company’s Founders, with the goal of becoming one of the leading medical technology companies for enabling precision prevention, early detection and treatment of cardiovascular disease. The Company is transforming the approach to cardiovascular disease from reactive to proactive. The Core Technology is being incorporated into a series of products for major types of cardiovascular disease and associated co-morbidities including coronary heart disease (“CHD”), stroke, heart failure and diabetes.

 

Interim Financial Statements

 

The unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of results that may be expected for the year ending December 31, 2023. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023.

 

Business Combination

 

On May 27, 2022, Mana, Mana Merger Sub, Inc. (“Merger Sub”), Meeshanthini Dogan, the Shareholders’ Representative and Legacy Cardio entered into the Business Combination Agreement (the “Merger Agreement”). On October 25, 2022, pursuant to the Merger Agreement, Legacy Cardio merged with and into Merger Sub, with Legacy Cardio surviving as the wholly-owned subsidiary of Mana. Subsequent to the merger, Mana changed its name to Cardio Diagnostics Holdings, Inc

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Merger Agreement and Reverse Recapitalization
 3 Months Ended
Mar. 31, 2023
Merger Agreement And Reverse Recapitalization  
Merger Agreement and Reverse Recapitalization

Note 2 – Merger Agreement and Reverse Recapitalization

 

As discussed in Note 1, on October 25, 2022, the Company and Mana entered into the Merger Agreement, which has been accounted for as a reverse recapitalization in accordance with US Generally Accepted Accounting Principles (GAAP). Pursuant to the Merger Agreement, the Company acquired cash of $4,021 and assumed liabilities of $928,500 from Mana. The liabilities assumed of $854,775, net of an early payment discount of $74,025 issued by a vendor on March 22, 2023, are payable to two investment bankers and due on October 25, 2023. On March 27, 2023, the Company accepted the early pay discount and paid Ladenburg the net balance due and payable of $419,475. As of March 31, 2023, the remaining assumed liabilities balance was $435,000.

 

Mana’s common stock had a redemption right in connection with the business combination. Mana’s stockholders exercised their right to redeem 6,465,452 shares of common stock, which constituted approximately 99.5% of the shares with redemption rights, for cash at a redemption price of approximately $10.10 per share, for an aggregate redemption amount of $65,310,892. In accounting for the reverse recapitalization, the Company’s legacy issued and outstanding 1,976,749 shares of common stock were reversed,  and the Mana shares of common stock totaling 9,514,743 were recorded, as described in Note 7. Transactions costs incurred in connection with the recapitalization totaled $1,535,035 and were recorded as a reduction to additional paid in capital.

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 3 – Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Cardio Diagnostics, Inc.  All intercompany accounts and transactions have been eliminated.

 

Use of Estimates in the Preparation of Financial Statements

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

 

Fair Value Measurements

 

The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

 

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.

 

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

 

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

 

The estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level 3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the three months ended March 31, 2023 and 2022.

 

         
   2023   2022 
Liabilities:          
Balance of derivative liabilities - beginning of period  $—     $—   
Issued   9,192,672    —   
Converted   —      —   
Change in fair value recognized in operations   (5,686,901)   —   
Balance of derivative liabilities - end of period  $3,505,771   $—   

 

 

 

The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of March 31, 2023, for each fair value hierarchy level:

 

Schedule of fair value hierarchy level      
March 31, 2023  Derivative Liabilities  Total
Level I  $—     $—   
Level II  $—     $—   
Level III  $3,505,771   $3,505,771 

 

Convertible Instruments

 

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

 

Revenue Recognition

 

The Company will host its product, Epi+Gen CHD on InTeleLab’s Elicity platform (the “Lab”). The Lab will collect payments from patients upon completion of eligibility screening. Patients then send their samples to MOgene, a high complexity CLIA lab, which perform the biomarker assessments. Upon receipt of the raw biomarker data from MOgene, the Company performs all quality control, analytical assessments and report generation and shares test reports with the Elicity healthcare provider via the Elicity platform. Revenue is recognized upon receipt of payments from the Lab for each test at the end of each month.

 

The Company will account for revenue under (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606)”, using the modified retrospective method. The modified retrospective adoption used by the Company did not result in a material cumulative effect adjustment to the opening balance of accumulated deficit.

 

The Company determines the measurement of revenue and the timing of revenue recognition utilizing the following core principles:

 

1. Identifying the contract with a customer;

2. Identifying the performance obligations in the contract;

3. Determining the transaction price;

4. Allocating the transaction price to the performance obligations in the contract; and

5. Recognizing revenue when (or as) the Company satisfies its performance obligations.

 

Research and Development

 

Research and development costs are expensed as incurred. Research and development costs charged to operations for the three months ended March 31, 2023 and 2022 were $86,665 and $1,130, respectively.

 

Advertising Costs

 

The Company expenses advertising costs as incurred. Advertising costs of $49,551 and $22,398 were charged to operations for the three months ended March 31, 2023 and 2022, respectively.

 

Cash and Cash Equivalents

 

Cash and cash equivalents are comprised of cash and highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does not have any cash equivalents as of March 31, 2023 and December 31, 2022. Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. The Company is exposed to credit risk in the event of default by the financial institutions or the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured.

 

Patent Costs

 

The Company accounts for patents in accordance with ASC 350-30, General Intangibles Other than Goodwill. The Company capitalizes patent costs representing legal fees associated with filing patent applications and amortize them on a straight-line basis. The Company is in the process of evaluating its patents' estimated useful life and will begin amortizing the patents when they are brought to the market or otherwise commercialized.

 

Long-Lived Assets

 

The Company assesses the valuation of components of long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.

 

Stock-Based Compensation

 

The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest.  The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants.  Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.

 

Income Taxes

 

The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.

 

The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position.

 

Recent Accounting Pronouncements

 

We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets
 3 Months Ended
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

Note 4 – Intangible Assets

 

The following tables provide detail associated with the Company’s acquired identifiable intangible assets:

                 
   As of March 31, 2023 
    Gross Carrying
Amount		    Accumulated Amortization    Net Carrying Amount    Weighted Average Useful life (in years) 
Amortized intangible assets:                    
Know-how license  $80,000   $(46,667)  $33,333    5 
Total  $80,000   $(46,667)  $33,333      

 

Amortization expense charged to operations was $4,000 for the three months ended March 31, 2023 and 2022, respectively.

 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Patent Costs
 3 Months Ended
Mar. 31, 2023
Patent Costs  
Patent Costs

Note 5 – Patent Costs

 

As of March 31, 2023, the Company has three pending patent applications. The initial patent applications consist of a US patent and international patents filed in six countries. The US patent was granted on August 16, 2022. The EU patent was granted on March 31, 2021. The validation of the EU patent in each of the six countries is pending. Legal fees associated with the patents totaled $373,197, net of accumulated amortization of $785 and $321,308 as of March 31, 2023 and December 31, 2022, respectively and are presented in the balance sheet as patent costs. Amortization expense charged to operations was $785 for the three months ended March 31, 2023.

 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Finance Agreement Payable
 3 Months Ended
Mar. 31, 2023
Finance Agreement Payable  
Finance Agreement Payable

Note 6 – Finance Agreement Payable

 

On October 31, 2022, the Company entered into an agreement with a premium financing company to finance its Directors and Officers insurance premiums for 12-month policies effective October 25, 2022. The amount financed of $1,037,706 is payable in 11 monthly installments plus interest at a rate of 6.216% through September 28, 2023. Finance agreement payable was $566,022 and $849,032 at March 31, 2023 and December 31, 2022, respectively. $646,795 has been recorded in prepaid expenses and is being amortized over the life of the policy.

 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings (Loss) Per Common Share
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Earnings (Loss) Per Common Share

Note 7 - Earnings (Loss) Per Common Share

 

The Company calculates net income (loss) per common share in accordance with ASC 260 “Earnings Per Share” (“ASC 260”). Basic and diluted net earnings (loss) per common share was determined by dividing net earnings (loss) applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, common stock warrants, and convertible debt have not been included in the computation of diluted net loss per share for the three months ended March 31, 2023 and 2022 as the result would be anti-dilutive.

 Schedule of anti dilutive earning per share        
   Three Months Ended 
   March 31, 
   2023   2022 
         
Stock warrants   7,854,620    215,654 
Stock options   1,759,599    —   
Total shares excluded from calculation   9,614,219    215,654 

  
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders’ Equity
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Stockholders’ Equity

Note 8 – Stockholders’ Equity

 

Stock Transactions

 

Pursuant to the Business Combination Agreement on October 25, 2022, the Company issued the following securities:

 

Holders of conversion rights issued as a component of units in Mana’s initial public offering (the “Public Rights”) were issued an aggregate of 928,571 shares of the Company’s common stock;

 

Holders of existing shares of common stock of Legacy Cardio and the holder of equity rights of Legacy Cardio (together, the “Legacy Cardio Stockholders”) received an aggregate of 6,883,306 shares of the Company’s Common Stock, calculated based on the exchange ratio of 3.427259 pursuant to the Merger Agreement (the “Exchange Ratio”) for each share of Legacy Cardio Common Stock held or, in the case of the equity rights holder, that number of shares of the Company’s Common Stock equal to 1% of the Aggregate Closing Merger Consideration, as defined in the Merger Agreement;

 

The Legacy Cardio Stockholders received, in addition, an aggregate of 43,334 shares of the Company’s Common Stock (“Conversion Shares”) upon conversion of an aggregate of $433,334 in principal amount of promissory notes issued by Mana to Legacy Cardio in connection with its loan of such amount in order to extend Mana’s duration through October 26, 2022 (the “Extension Notes”), which Conversion Shares were distributed to the Legacy Cardio Stockholders in proportion to their respective interest in Legacy Cardio.

 

Mana public stockholders (excluding Mana Capital, LLC, the SPAC sponsor (the “Sponsor”), and Mana’s former officers and directors) own 34,548 shares of the Company’s Common Stock and the Sponsor, Mana’s former officers and directors and certain permitted transferees own 1,625,000 shares of the Company’s Common Stock.

 

Immediately after giving effect to the Business Combination, there were 9,514,743 issued and outstanding shares of the Company’s Common Stock.

 

On October 25, 2022, in connection with the approval of the Business Combination, the Company’s stockholders approved the Cardio Diagnostics Holdings, Inc. 2022 Equity Incentive Plan (the “2022 Plan”). The purpose of the 2022 Plan is to promote the interests of the Company and its stockholders by providing eligible employees, officers, directors and consultants with additional incentives to remain with the Company and its subsidiaries, to increase their efforts to make the Company more successful, to reward such persons by providing an opportunity to acquire shares of Common Stock on favorable terms and to attract and retain the best available personnel to participate in the ongoing business operations of the Company. The 2022 Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Performance Units and Performance Shares.

 

The 2022 Plan, as approved, permits the issuance of up to 3,256,383 shares of Common Stock (the “Share Reserve”) upon exercise or conversion of grants and awards made from time to time to officers, directors, employees and consultants, however that the Share Reserve will increase on January 1st of each calendar year and ending on and including January 1, 2027 (each, an “Evergreen Date”), in an amount equal to the lesser of (i) 7% of the total number of shares of Common Stock outstanding on the December 31st immediately preceding the applicable Evergreen Date and (ii) such lesser number of shares of Common Stock as determined to be appropriate by the Compensation Committee, which administers the 2022 Plan, in its sole discretion. There was no increase in the Share Reserve on January 1, 2023.

 

Common Stock Issued

 

On March 2, 2023, a stockholder exercised warrants in exchange for 100,000 common shares for proceeds of $390,000.

 

During the three months ended March 31, 2023, the Company issued 1,092 common shares to a consultant for services pursuant to vesting of Restricted Stock Units granted, valued at $4,000.

 

Warrants

 

On October 1, 2019, the Company issued warrants to a seed funding firm equivalent to 2% of the fully-diluted equity of the Company, or 22,500 common shares at the time of issuance. The warrant is exercisable on the earlier of the closing date of the next Qualified Equity Financing occurring after the issuance of the warrant, and immediately before a Change of Control. The exercise price is the price per share of the shares sold to investors in the next Qualified Equity Financing, or if the warrant becomes exercisable in connection with a Change in Control before the next Qualified Equity Financing, the greater of the quotient obtained by dividing $150,000 by the Pre-financing Capitalization, and the price per share paid by investors in the then-most recent Qualified Equity Financing, if any. The warrant will expire upon the earlier of the consummation of any Change of Control, or 15 years after the issuance of the warrant.

 

In April 2022, the Company issued fully vested warrants to investors as part of private placement subscription agreements pursuant to which the Company issued common stock. Each stockholder received warrants to purchase 50% of the common stock issued at an exercise price of $3.90 per share with an expiration date of June 30, 2027.

 

As of May 23, 2022, the Company issued fully vested warrants to investors as part of an additional private placement subscription agreements pursuant to which the Company issued common stock. Each stockholder received warrants to purchase 50% of the common stock issued at an exercise price of $6.21 per share with an expiration date of five years from the date of issue.

 

All of the warrants issued by Legacy Cardio were exchanged in the Business Combination for warrants of the Company based on the merger exchange ratio.

 

Warrant activity during the three months ended March 31, 2023 and 2022 follows:

             
       Weighted   Average Remaining 
  

Warrants

Outstanding

   Average Exercise Price   Contractual Life (Years) 
Warrants outstanding at December 31, 2021   215,654   $13.35    5.90 
No warrant activity   —      —        
Warrants outstanding at March 31, 2022   215,654   $13.35    5.07 
Warrants outstanding at December 31, 2022   7,954,620    9.63    4.46 
Warrants exercised   (100,000)   13.35      
Warrants outstanding at March 31, 2023   7,854,620   $9.70    4.22 

 

Options

 

In May 6, 2022, the Company granted 513,413 stock options to the board of directors pursuant to the Cardio Diagnostics, Inc. 2022 Equity Incentive Plan. All of the options granted under this legacy plan were exchanged for options under the Plan adopted by the Company’s stockholders on October 25, 2022, and based on the exchange ratio for the merger, resulted in a total of 1,759,599 options issued upon closing. Each exchanged option has an exercise price of $3.90 per share with an expiration date of May 6, 2032. The exchanged options fully vested upon the merger with Mana.

 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Convertible Notes Payable
 3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Convertible Notes Payable

Note 9 – Convertible Notes Payable

 

On March 8, 2023, the Company entered into a securities purchase agreement (“Securities Purchase Agreement”) with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”) under which the Company agreed to sell and issue to Yorkville convertible debentures (“Convertible Debentures”) in a gross aggregate principal amount of up to $11.2 million (“Subscription Amount”). The Convertible Debentures are convertible into shares of common stock of the Company and are subject to various contingencies being satisfied as set forth in the Securities Purchase Agreement. The notes are convertible at any time through the maturity date, which, in each case, is one year from the date of issuance. The conversion price shall be determined on the basis of 92% of the two lowest VWAP (Volume Weighted Average Prices) of the Common Stock during the prior seven (7) trading day period. On March 8, 2023, the Company issued and sold to Yorkville a Convertible Debenture in the principal amount of $5.0 million, for which it received $4.5 million, with a $500,000 original issue discount (“OID”). Interest on the outstanding principal balance accrues at a rate of 0% and will increase to 15% upon an Event of Default for so long as it remains uncured

 

The Company recorded a debt discount related to identified embedded derivatives relating to the conversion features (see Note 10) based on fair values as of the inception date of the Note. The calculated debt discount, including the OID equaled the face of the Note and is being amortized over the term of the note.

 

Convertible notes payable of $315,068 at March 31, 2023 is presented net of debt discount of $4,684,932.

 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Derivative Liability
 3 Months Ended
Mar. 31, 2023
Derivative Liability  
Derivative Liability

Note 10 – Derivative Liability

 

The Company has determined that the conversion feature embedded in the convertible notes described in Note 9 contain a potential variable conversion amount which constitutes a derivative which has been bifurcated from the note and recorded as a derivative liability at fair value, with a corresponding discount recorded to the associated debt. The excess of the derivative value over the face amount of the note is recorded immediately to interest expense at inception which aggregated $4,692,672. The Company used the Binomial Black-Scholes Option Pricing model to value the conversion features. The Company used the Binomial Option Pricing model to value the conversion features.

 

The Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using a Black-Scholes option-pricing model with the following assumption inputs:

 Schedule of option liability      
   March 8,  March 31,
   2023  2023
Annual dividend yield   —      —   
Expected life (years)   1.0    1.0 
Risk-free interest rate   5.28%   4.89%
Expected volatility   164%   169%
Exercise price  $2.20   $3.53 
Stock price  $5.32   $3.91 

  

Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.

 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 11 – Commitments and Contingencies

 

Prior Relationship of Cardio with Boustead Securities, LLC

At the commencement of efforts to pursue what ultimately ended in the terminated business acquisition, Legacy Cardio entered into a Placement Agent and Advisory Services Agreement (the “Placement Agent Agreement”), dated April 12, 2021, with Boustead Securities, LLC ("Boustead Securities”). This agreement was terminated in April 2022, when Legacy Cardio terminated the underlying agreement and plan of merger and the accompanying escrow agreement relating to that proposed business acquisition after efforts to complete the transaction failed, despite several extensions of the closing deadline.

Under the terminated Placement Agent Agreement, Legacy Cardio agreed to certain future rights in favor of Boustead Securities, including (i) a two-year tail period during which Boustead Securities would be entitled to compensation if Cardio were to close on a transaction (as defined in the Placement Agent Agreement) with any party that was introduced to Legacy Cardio by Boustead Securities; and (ii) a right of first refusal to act as the Company’s exclusive placement agent for 24-months from the end of the term of the Placement Agent Agreement (the “right of first refusal”). Cardio has taken the position that due to Boustead Securities’ failure to perform as contemplated by the Placement Agent Agreement, these provisions purporting to provide future rights are null and void.

Boustead Securities responded to the termination of the Placement Agent Agreement by disputing Legacy Cardio’s contention that it had not performed under the Placement Agent Agreement because, among other things, Boustead Securities had never sought out prospective investors. In its response, Boustead Securities included a list of funds that they had supposedly contacted on Legacy Cardio’s behalf. While Boustead Securities’ contention appears to contradict earlier communications from Boustead Securities in which they indicated that they had not made any such contacts or introductions, Boustead Securities is currently contending that they are due success fees for two years following the termination of the Placement Agent Agreement on any transaction with any person on the list of supposed contacts or introductions. Legacy Cardio strongly disputes this position. Notwithstanding the foregoing, the Company has not consummated any transaction, as defined, with any potential party that purportedly was a contact of Boustead Securities in connection with the Placement Agent Agreement and has no plans to do so at any time during the tail period. No legal proceedings have been instigated by either party, and Cardio believes that the final outcome will not have a material adverse impact on its financial condition.

The Benchmark Company, LLC Right of First Refusal

As noted in Note 1, the Company completed a business combination with Mana on October 25, 2022. In connection with the proposed business combination, by agreement dated May 13, 2022, Mana engaged The Benchmark Company, LLC (“Benchmark”) as its M&A advisor. Upon closing of the business combination, Cardio assumed the contractual engagement entered into by Mana. On November 14, 2022, Cardio and Benchmark entered into Amendment No. 1 Engagement Letter (the “Amendment Engagement”). Pursuant to the Amendment Engagement, Benchmark has been granted a right of first refusal to act as lead or joint-lead investment banker, lead or joint-lead book-runner and/or lead or joint-lead placement agent for all future public and private equity and debt offerings through October 25, 2023. In this regard, the Company and Benchmark are in discussions regarding the convertible debenture financing the Company entered into in March 2023 whether Benchmark might be entitled to compensation arising from the Company having entered into the convertible debenture financing in March 2023 without first consulting Benchmark. No legal proceedings have been instigated, and the parties are continuing to discuss a resolution to this matter.

Demand Letter and Potential Mootness Fee Claim

On June 25, 2022, a plaintiffs’ securities law firm sent a demand letter to the Company alleging that the Company’s Registration Statement on Form S-4 filed (the “S-4 Registration Statement”) with the Securities and Exchange Commission (“SEC”) on May 31, 2022 omitted material information with respect to the Business Combination and demanding that the Company and its Board of Directors immediately provide corrective disclosures in an amendment or supplement to the Registration Statement. Subsequent thereto, the Company filed amendments to the S-4 Registration Statement on July 27, 2022, August 23, 2022, September 15, 2022, October 4, 2022 and October 5, 2022 in which it responded to various comments of the SEC staff and otherwise updated its disclosure. In October 2023, the SEC completed its review and declared the S-4 registration statement on October 6, 2022. On February 23, 2023 and February 27, 2023, plaintiffs’ securities law firm contacted the Company’s counsel asking who will be negotiating a mootness fee relating to the purported claims set forth in the June 25, 2022 demand letter. The Company vigorously denies that the S-4 Registration Statement, as amended and declared effective, is deficient in any respect and that no additional supplemental disclosures are material or required. The Company believes that the claims asserted in the Demand Letter are without merit and that no further disclosure is required to supplement the S-4 Registration Statement under applicable laws. As of the date of filing of this Quarterly Report on Form 10-Q, no lawsuit has been filed against the Company by that firm. The firm has indicated its willingness to litigate the matter if a mutually satisfactory resolution cannot be agreed upon; however, Cardio believes that the final outcome will not have a material adverse impact on its financial condition. The Company cannot preclude the possibility that claims or lawsuits brought relating to any alleged securities law violations or breaches of fiduciary duty could potentially require significant time and resources to defend and/or settle and distract its management and board of directors from focusing on its business.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events
 3 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events

Note 12 – Subsequent Events

 

The Company evaluated its March 31, 2023 consolidated financial statements for subsequent events through the date the consolidated financial statements were issued.

 

Common Stock Issued

 

Subsequent to the end of the period through the date of this report, Yorkville converted $700,000 of principal to 361,094 shares of the Company’s common stock.

 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Cardio Diagnostics, Inc.  All intercompany accounts and transactions have been eliminated.

 
Use of Estimates in the Preparation of Financial Statements

Use of Estimates in the Preparation of Financial Statements

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

 
Fair Value Measurements

Fair Value Measurements

 

The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

 

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.

 

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

 

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

 

The estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level 3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the three months ended March 31, 2023 and 2022.

 

         
   2023   2022 
Liabilities:          
Balance of derivative liabilities - beginning of period  $—     $—   
Issued   9,192,672    —   
Converted   —      —   
Change in fair value recognized in operations   (5,686,901)   —   
Balance of derivative liabilities - end of period  $3,505,771   $—   

 

 

 

The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of March 31, 2023, for each fair value hierarchy level:

 

Schedule of fair value hierarchy level      
March 31, 2023  Derivative Liabilities  Total
Level I  $—     $—   
Level II  $—     $—   
Level III  $3,505,771   $3,505,771 

 
Convertible Instruments

Convertible Instruments

 

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

 
Revenue Recognition

Revenue Recognition

 

The Company will host its product, Epi+Gen CHD on InTeleLab’s Elicity platform (the “Lab”). The Lab will collect payments from patients upon completion of eligibility screening. Patients then send their samples to MOgene, a high complexity CLIA lab, which perform the biomarker assessments. Upon receipt of the raw biomarker data from MOgene, the Company performs all quality control, analytical assessments and report generation and shares test reports with the Elicity healthcare provider via the Elicity platform. Revenue is recognized upon receipt of payments from the Lab for each test at the end of each month.

 

The Company will account for revenue under (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606)”, using the modified retrospective method. The modified retrospective adoption used by the Company did not result in a material cumulative effect adjustment to the opening balance of accumulated deficit.

 

The Company determines the measurement of revenue and the timing of revenue recognition utilizing the following core principles:

 

1. Identifying the contract with a customer;

2. Identifying the performance obligations in the contract;

3. Determining the transaction price;

4. Allocating the transaction price to the performance obligations in the contract; and

5. Recognizing revenue when (or as) the Company satisfies its performance obligations.

 
Research and Development

Research and Development

 

Research and development costs are expensed as incurred. Research and development costs charged to operations for the three months ended March 31, 2023 and 2022 were $86,665 and $1,130, respectively.

 
Advertising Costs

Advertising Costs

 

The Company expenses advertising costs as incurred. Advertising costs of $49,551 and $22,398 were charged to operations for the three months ended March 31, 2023 and 2022, respectively.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

Cash and cash equivalents are comprised of cash and highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does not have any cash equivalents as of March 31, 2023 and December 31, 2022. Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. The Company is exposed to credit risk in the event of default by the financial institutions or the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured.

 
Patent Costs

Patent Costs

 

The Company accounts for patents in accordance with ASC 350-30, General Intangibles Other than Goodwill. The Company capitalizes patent costs representing legal fees associated with filing patent applications and amortize them on a straight-line basis. The Company is in the process of evaluating its patents' estimated useful life and will begin amortizing the patents when they are brought to the market or otherwise commercialized.

 
Long-Lived Assets

Long-Lived Assets

 

The Company assesses the valuation of components of long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.

 
Stock-Based Compensation

Stock-Based Compensation

 

The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest.  The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants.  Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.

 
Income Taxes

Income Taxes

 

The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.

 

The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Schedule of fair value measurements
         
   2023   2022 
Liabilities:          
Balance of derivative liabilities - beginning of period  $—     $—   
Issued   9,192,672    —   
Converted   —      —   
Change in fair value recognized in operations   (5,686,901)   —   
Balance of derivative liabilities - end of period  $3,505,771   $—   
Schedule of fair value hierarchy level
Schedule of fair value hierarchy level      
March 31, 2023  Derivative Liabilities  Total
Level I  $—     $—   
Level II  $—     $—   
Level III  $3,505,771   $3,505,771 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets (Tables)
 3 Months Ended
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangible assets
                 
   As of March 31, 2023 
    Gross Carrying
Amount		    Accumulated Amortization    Net Carrying Amount    Weighted Average Useful life (in years) 
Amortized intangible assets:                    
Know-how license  $80,000   $(46,667)  $33,333    5 
Total  $80,000   $(46,667)  $33,333      
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings (Loss) Per Common Share (Tables)
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Schedule of anti dilutive earning per share
 Schedule of anti dilutive earning per share        
   Three Months Ended 
   March 31, 
   2023   2022 
         
Stock warrants   7,854,620    215,654 
Stock options   1,759,599    —   
Total shares excluded from calculation   9,614,219    215,654 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders’ Equity (Tables)
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Schedule of warrant activity
             
       Weighted   Average Remaining 
  

Warrants

Outstanding

   Average Exercise Price   Contractual Life (Years) 
Warrants outstanding at December 31, 2021   215,654   $13.35    5.90 
No warrant activity   —      —        
Warrants outstanding at March 31, 2022   215,654   $13.35    5.07 
Warrants outstanding at December 31, 2022   7,954,620    9.63    4.46 
Warrants exercised   (100,000)   13.35      
Warrants outstanding at March 31, 2023   7,854,620   $9.70    4.22 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Derivative Liability (Tables)
 3 Months Ended
Mar. 31, 2023
Derivative Liability  
Schedule of option liability
 Schedule of option liability      
   March 8,  March 31,
   2023  2023
Annual dividend yield   —      —   
Expected life (years)   1.0    1.0 
Risk-free interest rate   5.28%   4.89%
Expected volatility   164%   169%
Exercise price  $2.20   $3.53 
Stock price  $5.32   $3.91 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Merger Agreement and Reverse Recapitalization (Details Narrative)
 3 Months Ended
Mar. 31, 2023
USD ($)
$ / shares
shares
Merger Agreement And Reverse Recapitalization  
Cash Acquired from Acquisition $ 4,021
Assumed liabilities $ 928,500
Stock redeemed | shares 6,465,452
Redemption percentage 99.50%
Redemption price per shre | $ / shares $ 10.10
Redemption amount $ 65,310,892
Reverse recapitalization shares | shares 1,976,749
Common shares reversed | shares 9,514,743
Recapitalization cost $ 1,535,035
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Accounting Policies [Abstract]    
Derivative liabilities beginning $ 0 $ 0
Issued 9,192,672 0
Converted 0 0
Change in fair value recognized in operations (5,686,901) 0
Derivative liabilities ending $ 3,505,771 $ 0
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Details 1) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]        
Derivative liabilities ending $ 3,505,771 $ 0 $ 0 $ 0
Fair Value, Inputs, Level 1 [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Derivative liabilities ending      
Fair Value, Inputs, Level 1 [Member] | Derivative Financial Instruments, Liabilities [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Derivative liabilities ending      
Fair Value, Inputs, Level 2 [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Derivative liabilities ending      
Fair Value, Inputs, Level 2 [Member] | Derivative Financial Instruments, Liabilities [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Derivative liabilities ending      
Fair Value, Inputs, Level 3 [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Derivative liabilities ending 3,505,771      
Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Derivative liabilities ending $ 3,505,771      
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Accounting Policies [Abstract]      
Research and development expense $ 86,665 $ 1,130  
Advertising costs 49,551 $ 22,398  
Cash equivalents 0   $ 0
FDIC insured amount $ 250,000    
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Intangible assets gross $ 80,000  
Intangible assets accumulated amortization (46,667)  
Intangible assets net 33,333 $ 37,333
Know How License [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets gross 80,000  
Intangible assets accumulated amortization (46,667)  
Intangible assets net $ 33,333  
Weighted average useful life 5 years  
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization expense $ 4,785 $ 4,000
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Patent Costs (Details Narrative) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Patent Costs      
Patent costs $ 373,197 $ 321,308  
Accumulated amortization $ 785   $ 321,308
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Finance Agreement Payable (Details Narrative) - USD ($)
Oct. 31, 2022
Mar. 31, 2023
Dec. 31, 2022
Finance Agreement Payable      
Financing agreement entered into for prepaid insurance $ 1,037,706    
Interest rate 6.216%    
Maturity date Sep. 28, 2023    
Finance agreement payable   $ 566,022 $ 849,032
Prepaid expenses $ 646,795    
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Earnings (Loss) Per Common Share (Details) - shares
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive shares 9,614,219 215,654
Stock Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive shares 7,854,620 215,654
Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive shares 1,759,599 0
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' Equity (Details) - Warrant [Member] - $ / shares
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Warrants outstanding, beginning 7,954,620 215,654 215,654  
Weighted average exercise price outstanding, beginning $ 9.63 $ 13.35 $ 13.35  
Weighted average remaining contractual life 4 years 2 months 19 days 5 years 25 days 4 years 5 months 15 days 5 years 10 months 24 days
Warrant activity      
Weighted average exercise price warrant activity      
Warrants outstanding, ending 7,854,620 215,654 7,954,620 215,654
Weighted average exercise price outstanding, ending $ 9.70 $ 13.35 $ 9.63 $ 13.35
Warrants exercised (100,000)      
Weighted average exercise price exercised $ 13.35      
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders’ Equity (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended
Mar. 02, 2023
Oct. 25, 2022
May 06, 2022
Mar. 15, 2021
Apr. 30, 2022
Mar. 31, 2023
May 23, 2022
Oct. 01, 2019
Subsidiary, Sale of Stock [Line Items]                
Common stock issuance               22,500
Conversion of shares, shares       100,000        
Conversion of shares, Value $ 390,000              
Pre financing capitalization           $ 150,000    
Warrant exercise price     $ 3.90       $ 6.21  
Expiration date         Jun. 30, 2027      
Restricted Stock Units (RSUs) [Member]                
Subsidiary, Sale of Stock [Line Items]                
Consultant for services           $ 4,000    
Equity Option [Member]                
Subsidiary, Sale of Stock [Line Items]                
Warrant exercise price         $ 3.90      
Expiration date   May 06, 2032            
Options issued   1,759,599 513,413          
Common Stock [Member]                
Subsidiary, Sale of Stock [Line Items]                
Restricted stock awards vested, shares           1,092    
Plan 2022 [Member]                
Subsidiary, Sale of Stock [Line Items]                
Common stock issuance           3,256,383    
Legacy Cardio [Member]                
Subsidiary, Sale of Stock [Line Items]                
Conversion shares           43,334    
Principal amount           $ 433,334    
Manas Former Officers And Directors [Member]                
Subsidiary, Sale of Stock [Line Items]                
Number of shares transferred           1,625,000    
Legacy Cardio Stockholders [Member]                
Subsidiary, Sale of Stock [Line Items]                
Number of shares received           $ 6,883,306    
IPO [Member]                
Subsidiary, Sale of Stock [Line Items]                
Number of shares issued           928,571    
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Convertible Notes Payable (Details Narrative) - USD ($)
Mar. 08, 2023
Mar. 31, 2023
Debt Disclosure [Abstract]    
Purchase aggrement description the Company entered into a securities purchase agreement (“Securities Purchase Agreement”) with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”) under which the Company agreed to sell and issue to Yorkville convertible debentures (“Convertible Debentures”) in a gross aggregate principal amount of up to $11.2 million (“Subscription Amount”). The Convertible Debentures are convertible into shares of common stock of the Company and are subject to various contingencies being satisfied as set forth in the Securities Purchase Agreement. The notes are convertible at any time through the maturity date, which, in each case, is one year from the date of issuance. The conversion price shall be determined on the basis of 92% of the two lowest VWAP (Volume Weighted Average Prices) of the Common Stock during the prior seven (7) trading day period. On March 8, 2023, the Company issued and sold to Yorkville a Convertible Debenture in the principal amount of $5.0 million, for which it received $4.5 million, with a $500,000 original issue discount (“OID”). Interest on the outstanding principal balance accrues at a rate of 0% and will increase to 15% upon an Event of Default for so long as it remains uncured  
Convertible notes payable   $ 315,068
Debt discount net   $ 4,684,932
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Derivative Liability (Details) - $ / shares
Mar. 31, 2023
Mar. 08, 2023
Derivative Liability    
Annual dividend yield
Expected life (years) 1 year 1 year
Risk-free interest rate 4.89% 5.28%
Expected volatility 169.00% 164.00%
Exercise price $ 3.53 $ 2.20
Stock price $ 3.91 $ 5.32
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Derivative Liability (Details Narrative)
 3 Months Ended
Mar. 31, 2023
USD ($)
Derivative Liability  
Interest expense $ 4,692,672
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Converted common stock value $ 96 $ 95
Convertible Common Stock [Member]    
Converted common stock value $ 700,000  
Conversion of stock shares 361,094  
XML 52 cdio_10q_htm.xml IDEA: XBRL DOCUMENT 0001870144 2023-01-01 2023-03-31 0001870144 CDIO:CommonStockParValue0.00001PerShareMember 2023-01-01 2023-03-31 0001870144 CDIO:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember 2023-01-01 2023-03-31 0001870144 2023-05-15 0001870144 2023-03-31 0001870144 2022-12-31 0001870144 2022-01-01 2022-03-31 0001870144 us-gaap:CommonStockMember 2022-12-31 0001870144 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001870144 us-gaap:RetainedEarningsMember 2022-12-31 0001870144 us-gaap:CommonStockMember 2021-12-31 0001870144 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001870144 us-gaap:RetainedEarningsMember 2021-12-31 0001870144 2021-12-31 0001870144 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001870144 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001870144 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001870144 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001870144 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001870144 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001870144 us-gaap:CommonStockMember 2023-03-31 0001870144 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001870144 us-gaap:RetainedEarningsMember 2023-03-31 0001870144 us-gaap:CommonStockMember 2022-03-31 0001870144 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001870144 us-gaap:RetainedEarningsMember 2022-03-31 0001870144 2022-03-31 0001870144 us-gaap:FairValueInputsLevel1Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-03-31 0001870144 us-gaap:FairValueInputsLevel1Member 2023-03-31 0001870144 us-gaap:FairValueInputsLevel2Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-03-31 0001870144 us-gaap:FairValueInputsLevel2Member 2023-03-31 0001870144 us-gaap:FairValueInputsLevel3Member us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-03-31 0001870144 us-gaap:FairValueInputsLevel3Member 2023-03-31 0001870144 CDIO:KnowHowLicenseMember 2023-03-31 0001870144 CDIO:KnowHowLicenseMember 2023-01-01 2023-03-31 0001870144 2022-10-30 2022-10-31 0001870144 2022-10-31 0001870144 CDIO:StockWarrantsMember 2023-01-01 2023-03-31 0001870144 CDIO:StockWarrantsMember 2022-01-01 2022-03-31 0001870144 CDIO:StockOptionsMember 2023-01-01 2023-03-31 0001870144 CDIO:StockOptionsMember 2022-01-01 2022-03-31 0001870144 us-gaap:IPOMember 2023-01-01 2023-03-31 0001870144 CDIO:LegacyCardioStockholdersMember 2023-01-01 2023-03-31 0001870144 CDIO:LegacyCardioMember 2023-01-01 2023-03-31 0001870144 CDIO:LegacyCardioMember 2023-03-31 0001870144 CDIO:ManasFormerOfficersAndDirectorsMember 2023-01-01 2023-03-31 0001870144 CDIO:Plan2022Member 2023-03-31 0001870144 2021-03-14 2021-03-15 0001870144 2023-03-01 2023-03-02 0001870144 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001870144 2019-10-01 0001870144 us-gaap:StockOptionMember 2022-04-30 0001870144 2022-04-01 2022-04-30 0001870144 2022-05-23 0001870144 us-gaap:StockOptionMember 2022-05-01 2022-05-06 0001870144 us-gaap:StockOptionMember 2022-10-24 2022-10-25 0001870144 2022-05-06 0001870144 us-gaap:WarrantMember 2021-12-31 0001870144 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001870144 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001870144 us-gaap:WarrantMember 2022-03-31 0001870144 us-gaap:WarrantMember 2022-12-31 0001870144 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001870144 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001870144 us-gaap:WarrantMember 2023-03-31 0001870144 2023-03-01 2023-03-08 0001870144 2023-03-07 2023-03-08 0001870144 2023-03-30 2023-03-31 0001870144 2023-03-08 0001870144 us-gaap:ConvertibleCommonStockMember 2023-03-31 0001870144 us-gaap:ConvertibleCommonStockMember 2023-01-01 2023-03-31 iso4217:USD shares iso4217:USD shares pure 0001870144 false --12-31 2023 Q1 10-Q true 2023-03-31 false 001-41097 Cardio Diagnostics Holdings, Inc. DE 87-0925574 400 North Aberdeen Street Suite 900 Chicago IL 60642 (855) 226-9991 Common Stock, par value $0.00001 per share CDIO NASDAQ Redeemable Warrants, each whole warrant exercisable for one share of Common Stock CDIOW NASDAQ Yes Yes Non-accelerated Filer true true false false 9977791 6707770 4117521 1430261 1768366 8138031 5885887 33333 37333 7050 4950 373197 321308 8551611 6249478 742635 1098738 315068 0 3505771 0 566022 849032 5129496 1947770 0.00001 0.00001 100000000 100000000 0 0 0 0 0.00001 0.00001 300000000 300000000 9615835 9615835 9514743 9514743 96 95 10446183 10293159 -7024164 -5991546 3422115 4301708 8551611 6249478 0 0 49551 22398 86665 1130 1562128 205027 4785 4000 1703129 232555 5686901 0 221 0 5016611 -0 -0 57500 670511 -57500 -1032618 -290055 0 0 -1032618 -290055 -0.11 -0.11 -0.07 -0.07 9547177 9547177 4223494 4223494 9514743 95 10293159 -5991546 4301708 100000 1 389999 390000 1092 4000 4000 -315000 -315000 74025 74025 -1032618 -1032618 9615835 96 10446183 -7024164 3422115 4223494 42 2398628 -1330561 1068109 -290055 -290055 4223494 42 2398628 -1620616 778054 1032618 290055 4785 4000 0 57500 4000 0 5007740 0 5686901 -0 -0 -901 -338105 -20358 -2100 0 -282078 21206 -1649067 -186090 52674 16436 -52674 -16436 500000 4500000 0 390000 283010 315000 -0 4291990 0 2590249 -202526 4117521 512767 6707770 310241 8871 0 9192672 0 74025 0 <p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zs3G1ToQtNQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 1 - <span id="xdx_821_zYGXbxY1Exji">Organization and Basis of Presentation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The <span style="font-family: Times New Roman, Times, Serif">unaudited condensed consolidated financial statements presented are those of Cardio Diagnostics Holdings, Inc., (the “Company”) and its wholly-owned subsidiary, Cardio Diagnostics, Inc. (“Legacy Cardio”). The Company was incorporated as Mana Capital Acquisition Corp. (“Mana”) under the laws of the state of Delaware on May 19, 2021, and Legacy Cardio was formed on January 16, 2017 as an Iowa limited liability company (Cardio Diagnostics, LLC) and was subsequently incorporated as a Delaware C-Corp on September 6, 2019 (Legacy Cardio)</span><span style="font-family: Calibri, Helvetica, Sans-Serif">.</span> <span style="font-family: Times New Roman, Times, Serif">The Company was formed to develop and commercialize a patent-pending Artificial Intelligence (“AI”)-driven DNA biomarker testing technology (“Core Technology”) for cardiovascular disease invented at the University of Iowa by the Company’s Founders, with the goal of becoming one of the leading medical technology companies for enabling precision prevention, early detection and treatment of cardiovascular disease. The Company is transforming the approach to cardiovascular disease from reactive to proactive. The Core Technology is being incorporated into a series of products for major types of cardiovascular disease and associated co-morbidities including coronary heart disease (“CHD”), stroke, heart failure and diabetes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Interim Financial Statements</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by US Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of results that may be expected for the year ending December 31, 2023. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Business Combination</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman PS Std,serif; background-color: white">On May 27, 2022, Mana, Mana Merger Sub, Inc. (“Merger Sub”), Meeshanthini Dogan, the Shareholders’ Representative and Legacy Cardio entered into the Business Combination Agreement (the “Merger Agreement”). </span><span style="font-family: Times New Roman, Times, Serif">On October 25, 2022, pursuant to the Merger Agreement, Legacy Cardio merged with and into Merger Sub, with Legacy Cardio surviving as the wholly-owned subsidiary of Mana. Subsequent to the merger, Mana changed its name to Cardio Diagnostics Holdings, Inc</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_809_ecustom--MergerAgreementAndReverseRecapitalizationTextBlock_zn9a6yz4nX2e" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 2 –<span id="xdx_824_zNesu86r1cGf"> Merger Agreement and Reverse Recapitalization</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">As discussed in Note 1, on October 25, 2022, the Company and Mana entered into the Merger Agreement, which has been accounted for as a reverse recapitalization in accordance with US Generally Accepted Accounting Principles (GAAP). Pursuant to the Merger Agreement, the Company acquired cash of $<span id="xdx_90D_eus-gaap--CashAcquiredFromAcquisition_c20230101__20230331_pp0p0">4,021 </span></span><span style="background-color: white">and assumed liabilities of $<span id="xdx_900_ecustom--AssumedLiabilities_c20230101__20230331_pp0p0">928,500 </span></span><span style="background-color: white">from Mana. The liabilities assumed of $854,775, net of an early payment discount of $74,025 issued by a vendor on March 22, 2023, are payable to two investment bankers and due on October 25, 2023. </span>On March 27, 2023, the Company accepted the early pay discount and paid Ladenburg the net balance due and payable of $419,475. <span style="font-family: Times New Roman, Times, Serif">As of March 31, 2023, the remaining assumed liabilities balance was $435,000. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Mana’s common stock had a redemption right in connection with the business combination. Mana’s stockholders exercised their right to redeem <span id="xdx_90F_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20230101__20230331_pdd" title="Stock redeemed">6,465,452</span> shares of common stock, which constituted approximately <span id="xdx_909_eus-gaap--DebtInstrumentRedemptionPricePercentage_dp_uPure_c20230101__20230331_zJSfZva3FJ0e" title="Redemption percentage">99.5</span>% of the shares with redemption rights, for cash at a redemption price of approximately $<span id="xdx_901_ecustom--RedemptionPricePerShre_c20230331_pdd" title="Redemption price per shre">10.10</span> per share, for an aggregate redemption amount of $<span id="xdx_90F_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20230101__20230331_pp0p0" title="Redemption amount">65,310,892</span>. In accounting for the reverse recapitalization, the Company’s legacy issued and outstanding <span id="xdx_90A_ecustom--ReverseRecapitalizationShares_c20230101__20230331_pdd" title="Reverse recapitalization shares">1,976,749</span> shares of common stock were reversed,  and the Mana shares of common stock totaling <span id="xdx_90C_ecustom--CommonSharesReversed_c20230101__20230331_pdd" title="Common shares reversed">9,514,743</span> were recorded, as described in Note 7. Transactions costs incurred in connection with the recapitalization totaled $<span id="xdx_905_eus-gaap--RecapitalizationCosts_c20230101__20230331_pp0p0" title="Recapitalization cost">1,535,035</span> and were recorded as a reduction to additional paid in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 4021 928500 6465452 0.995 10.10 65310892 1976749 9514743 1535035 <p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_zlQATeVkHY8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 3 –<span id="xdx_82A_zFmZs9fW8eyk"> Summary of Significant Accounting Policies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_z6wO9KY7NqMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_868_zVFo7qwZuZD">Principles of Consolidation</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Cardio Diagnostics, Inc.  All intercompany accounts and transactions have been eliminated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b/></p> <p id="xdx_844_eus-gaap--UseOfEstimates_zarT8gVPJzbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_868_zsXCvp2bVvl1">Use of Estimates in the Preparation of Financial Statements</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> <p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zMYxni7hg2X7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_864_zWDE9aOA5Ezi">Fair Value Measurements</span> </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company adopted the provisions of ASC Topic 820, <i>Fair Value Measurements and Disclosures, </i>which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt; text-align: justify">Level 1 – quoted prices in active markets for identical assets or liabilities</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt; text-align: justify">Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt; text-align: justify">Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level 3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the three months ended March 31, 2023 and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--FairValueOptionQuantitativeTextBlock_zD5NcFagDksf" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold"> <span id="xdx_8BA_zRzMc7AOGtua" style="display: none">Schedule of fair value measurements</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Balance of derivative liabilities - beginning of period</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_d0_c20230101__20230331_z6NoEP3tZm7l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities beginning">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_d0_c20220101__20220331_zt6VBBVxeTe2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities beginning">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%">Issued</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98E_ecustom--DerivativeLiabilitiesIssued_c20230101__20230331_z5w9Dz5Mygc2" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Issued">9,192,672</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--DerivativeLiabilitiesIssued_d0_c20220101__20220331_zhr8J5zrDr14" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Issued">—  </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Converted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--DerivativeLiabilitiesConverted_d0_c20230101__20230331_zIDfXPcHdvw7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Converted">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--DerivativeLiabilitiesConverted_d0_c20220101__20220331_zFmsc3yQ3WUd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Converted">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Change in fair value recognized in operations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--ChangeInFairValueRecognizedInOperations_c20230101__20230331_zOPPO3AwbZE2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value recognized in operations">(5,686,901</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--ChangeInFairValueRecognizedInOperations_d0_c20220101__20220331_zgIAuBqcXpfk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value recognized in operations">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance of derivative liabilities - end of period</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_c20230101__20230331_zaKXcn5K4PD9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities ending">3,505,771</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_d0_c20220101__20220331_zhE1LkxRVgqb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities ending">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of March 31, 2023, for each fair value hierarchy level:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zkDry567Kfu" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 1)"> <tr style="vertical-align: bottom"> <td id="xdx_8BC_zdy68YuH40z2" style="color: White">Schedule of fair value hierarchy level</td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid"><span style="font-size: 8pt"><b>March 31, 2023</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Derivative Liabilities</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Total</b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zzDnc7irHEW8" style="text-align: right" title="Derivative liabilities ending"><span style="-sec-ix-hidden: xdx2ixbrl0435">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3HBwGTUVcgc" style="text-align: right" title="Derivative liabilities ending"><span style="-sec-ix-hidden: xdx2ixbrl0437">—</span>  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z8LyxFH1ADD6" style="text-align: right" title="Derivative liabilities ending"><span style="-sec-ix-hidden: xdx2ixbrl0439">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z3a051ouWcp" style="text-align: right" title="Derivative liabilities ending"><span style="-sec-ix-hidden: xdx2ixbrl0441">—</span>  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Level III</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zL4Ei6SQwje4" style="width: 14%; text-align: right" title="Derivative liabilities ending">3,505,771</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5wm2Mad5MH6" style="width: 14%; text-align: right" title="Derivative liabilities ending">3,505,771</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_845_ecustom--ConvertibleInstrumentsPolicyTextBlock_zMV55Xtd5dW1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_867_zNd1W8oFhN9a">Convertible Instruments</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, <i>Derivatives and Hedging Activities.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p id="xdx_840_ecustom--RevenueRecognitionsPolicyTextBlock_zQVnaJ1Ea6Oe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_863_zYGdTfdA3xOb">Revenue Recognition</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will host its product, Epi+Gen CHD on InTeleLab’s Elicity platform (the “Lab”). The Lab will collect payments from patients upon completion of eligibility screening. Patients then send their samples to MOgene, a high complexity CLIA lab, which perform the biomarker assessments. Upon receipt of the raw biomarker data from MOgene, the Company performs all quality control, analytical assessments and report generation and shares test reports with the Elicity healthcare provider via the Elicity platform. Revenue is recognized upon receipt of payments from the Lab for each test at the end of each month.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will account for revenue under (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606)”, using the modified retrospective method. The modified retrospective adoption used by the Company did not result in a material cumulative effect adjustment to the opening balance of accumulated deficit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determines the measurement of revenue and the timing of revenue recognition utilizing the following core principles:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">1. Identifying the contract with a customer;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2. Identifying the performance obligations in the contract;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">3. Determining the transaction price;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">4. Allocating the transaction price to the performance obligations in the contract; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">5. Recognizing revenue when (or as) the Company satisfies its performance obligations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_z7uOUBlU0ZJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_865_zcxdAC6us9me">Research and Development</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred. Research and development costs charged to operations for the three months ended March 31, 2023 and 2022 were $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331_pp0p0" title="Research and development expense">86,665</span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331_pp0p0" title="Research and development expense">1,130</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--AdvertisingCostsPolicyTextBlock_z869WaHhBTLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86C_zEPt4qeVSfm1">Advertising Costs</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses advertising costs as incurred. Advertising costs of $<span id="xdx_907_eus-gaap--SellingAndMarketingExpense_c20230101__20230331_pp0p0" title="Advertising costs">49,551</span> and $<span id="xdx_905_eus-gaap--SellingAndMarketingExpense_c20220101__20220331_pp0p0" title="Advertising costs">22,398</span> were charged to operations for the three months ended March 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6GZdRI8UINf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_863_zHgt1gNCfJT2">Cash and Cash Equivalents</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">Cash and cash equivalents are comprised of cash and highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does <span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_do_c20230331_z78MPrtDQice" title="Cash equivalents"><span id="xdx_900_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_do_c20221231_z4l2HzJCHALj" title="Cash equivalents">no</span></span>t have any cash equivalents as of March 31, 2023 and December 31, 2022. Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions are insured by the FDIC up to $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_c20230331_pp0p0" title="FDIC insured amount">250,000</span>. The Company is exposed to credit risk in the event of default by the financial institutions or the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p id="xdx_845_eus-gaap--RevenueRecognitionServicesLicensingFees_zZVvKfRHya73" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_864_z2lR5cSBkfIc">Patent Costs</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for patents in accordance with ASC 350-30, <i>General Intangibles Other than Goodwill</i>. The Company capitalizes patent costs representing legal fees associated with filing patent applications and amortize them on a straight-line basis. The Company is in the process of evaluating its patents' estimated useful life and will begin amortizing the patents when they are brought to the market or otherwise commercialized.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zTbN8Sv1sYnj" style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b><span style="text-decoration: underline"><span id="xdx_861_zdhwfrHxHKu3">Long-Lived Assets</span></span></b></p> <p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company assesses the valuation of components of long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zQLZS5LERXlg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_869_z3T2UuK0oU3e">Stock-Based Compensation</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, <i>Awards Classified as Equity,</i> which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest.  The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants.  Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zT51ybn1QiO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_860_zIOhp9nidQD4">Income Taxes</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, <i>Income Taxes</i>. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements<i>.</i> In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zNfl6vcNn2F9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_862_zUSyWou7jqt3">Recent Accounting Pronouncements</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_z6wO9KY7NqMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_868_zVFo7qwZuZD">Principles of Consolidation</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Cardio Diagnostics, Inc.  All intercompany accounts and transactions have been eliminated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b/></p> <p id="xdx_844_eus-gaap--UseOfEstimates_zarT8gVPJzbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_868_zsXCvp2bVvl1">Use of Estimates in the Preparation of Financial Statements</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> <p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zMYxni7hg2X7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_864_zWDE9aOA5Ezi">Fair Value Measurements</span> </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company adopted the provisions of ASC Topic 820, <i>Fair Value Measurements and Disclosures, </i>which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt; text-align: justify">Level 1 – quoted prices in active markets for identical assets or liabilities</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt; text-align: justify">Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt; text-align: justify">Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level 3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the three months ended March 31, 2023 and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--FairValueOptionQuantitativeTextBlock_zD5NcFagDksf" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold"> <span id="xdx_8BA_zRzMc7AOGtua" style="display: none">Schedule of fair value measurements</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Balance of derivative liabilities - beginning of period</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_d0_c20230101__20230331_z6NoEP3tZm7l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities beginning">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_d0_c20220101__20220331_zt6VBBVxeTe2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities beginning">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%">Issued</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98E_ecustom--DerivativeLiabilitiesIssued_c20230101__20230331_z5w9Dz5Mygc2" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Issued">9,192,672</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--DerivativeLiabilitiesIssued_d0_c20220101__20220331_zhr8J5zrDr14" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Issued">—  </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Converted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--DerivativeLiabilitiesConverted_d0_c20230101__20230331_zIDfXPcHdvw7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Converted">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--DerivativeLiabilitiesConverted_d0_c20220101__20220331_zFmsc3yQ3WUd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Converted">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Change in fair value recognized in operations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--ChangeInFairValueRecognizedInOperations_c20230101__20230331_zOPPO3AwbZE2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value recognized in operations">(5,686,901</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--ChangeInFairValueRecognizedInOperations_d0_c20220101__20220331_zgIAuBqcXpfk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value recognized in operations">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance of derivative liabilities - end of period</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_c20230101__20230331_zaKXcn5K4PD9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities ending">3,505,771</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_d0_c20220101__20220331_zhE1LkxRVgqb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities ending">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The following table represents the Company’s derivative instruments that are measured at fair value on a recurring basis as of March 31, 2023, for each fair value hierarchy level:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zkDry567Kfu" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 1)"> <tr style="vertical-align: bottom"> <td id="xdx_8BC_zdy68YuH40z2" style="color: White">Schedule of fair value hierarchy level</td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid"><span style="font-size: 8pt"><b>March 31, 2023</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Derivative Liabilities</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Total</b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zzDnc7irHEW8" style="text-align: right" title="Derivative liabilities ending"><span style="-sec-ix-hidden: xdx2ixbrl0435">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3HBwGTUVcgc" style="text-align: right" title="Derivative liabilities ending"><span style="-sec-ix-hidden: xdx2ixbrl0437">—</span>  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z8LyxFH1ADD6" style="text-align: right" title="Derivative liabilities ending"><span style="-sec-ix-hidden: xdx2ixbrl0439">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z3a051ouWcp" style="text-align: right" title="Derivative liabilities ending"><span style="-sec-ix-hidden: xdx2ixbrl0441">—</span>  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Level III</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zL4Ei6SQwje4" style="width: 14%; text-align: right" title="Derivative liabilities ending">3,505,771</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5wm2Mad5MH6" style="width: 14%; text-align: right" title="Derivative liabilities ending">3,505,771</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--FairValueOptionQuantitativeTextBlock_zD5NcFagDksf" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold"> <span id="xdx_8BA_zRzMc7AOGtua" style="display: none">Schedule of fair value measurements</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: bold 8pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Balance of derivative liabilities - beginning of period</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_d0_c20230101__20230331_z6NoEP3tZm7l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities beginning">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_d0_c20220101__20220331_zt6VBBVxeTe2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities beginning">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%">Issued</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98E_ecustom--DerivativeLiabilitiesIssued_c20230101__20230331_z5w9Dz5Mygc2" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Issued">9,192,672</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--DerivativeLiabilitiesIssued_d0_c20220101__20220331_zhr8J5zrDr14" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Issued">—  </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Converted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_ecustom--DerivativeLiabilitiesConverted_d0_c20230101__20230331_zIDfXPcHdvw7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Converted">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--DerivativeLiabilitiesConverted_d0_c20220101__20220331_zFmsc3yQ3WUd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Converted">—  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Change in fair value recognized in operations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_ecustom--ChangeInFairValueRecognizedInOperations_c20230101__20230331_zOPPO3AwbZE2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value recognized in operations">(5,686,901</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_ecustom--ChangeInFairValueRecognizedInOperations_d0_c20220101__20220331_zgIAuBqcXpfk" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in fair value recognized in operations">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance of derivative liabilities - end of period</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_c20230101__20230331_zaKXcn5K4PD9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities ending">3,505,771</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_d0_c20220101__20220331_zhE1LkxRVgqb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Derivative liabilities ending">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0 0 9192672 0 0 0 -5686901 0 3505771 0 <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zkDry567Kfu" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details 1)"> <tr style="vertical-align: bottom"> <td id="xdx_8BC_zdy68YuH40z2" style="color: White">Schedule of fair value hierarchy level</td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid"><span style="font-size: 8pt"><b>March 31, 2023</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Derivative Liabilities</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Total</b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Level I</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zzDnc7irHEW8" style="text-align: right" title="Derivative liabilities ending"><span style="-sec-ix-hidden: xdx2ixbrl0435">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3HBwGTUVcgc" style="text-align: right" title="Derivative liabilities ending"><span style="-sec-ix-hidden: xdx2ixbrl0437">—</span>  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Level II</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z8LyxFH1ADD6" style="text-align: right" title="Derivative liabilities ending"><span style="-sec-ix-hidden: xdx2ixbrl0439">—</span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z3a051ouWcp" style="text-align: right" title="Derivative liabilities ending"><span style="-sec-ix-hidden: xdx2ixbrl0441">—</span>  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Level III</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zL4Ei6SQwje4" style="width: 14%; text-align: right" title="Derivative liabilities ending">3,505,771</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5wm2Mad5MH6" style="width: 14%; text-align: right" title="Derivative liabilities ending">3,505,771</td><td style="width: 1%; text-align: left"> </td></tr> </table> 3505771 3505771 <p id="xdx_845_ecustom--ConvertibleInstrumentsPolicyTextBlock_zMV55Xtd5dW1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_867_zNd1W8oFhN9a">Convertible Instruments</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, <i>Derivatives and Hedging Activities.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p id="xdx_840_ecustom--RevenueRecognitionsPolicyTextBlock_zQVnaJ1Ea6Oe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_863_zYGdTfdA3xOb">Revenue Recognition</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will host its product, Epi+Gen CHD on InTeleLab’s Elicity platform (the “Lab”). The Lab will collect payments from patients upon completion of eligibility screening. Patients then send their samples to MOgene, a high complexity CLIA lab, which perform the biomarker assessments. Upon receipt of the raw biomarker data from MOgene, the Company performs all quality control, analytical assessments and report generation and shares test reports with the Elicity healthcare provider via the Elicity platform. Revenue is recognized upon receipt of payments from the Lab for each test at the end of each month.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will account for revenue under (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606)”, using the modified retrospective method. The modified retrospective adoption used by the Company did not result in a material cumulative effect adjustment to the opening balance of accumulated deficit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determines the measurement of revenue and the timing of revenue recognition utilizing the following core principles:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">1. Identifying the contract with a customer;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2. Identifying the performance obligations in the contract;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">3. Determining the transaction price;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">4. Allocating the transaction price to the performance obligations in the contract; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">5. Recognizing revenue when (or as) the Company satisfies its performance obligations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84F_eus-gaap--ResearchAndDevelopmentExpensePolicy_z7uOUBlU0ZJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_865_zcxdAC6us9me">Research and Development</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred. Research and development costs charged to operations for the three months ended March 31, 2023 and 2022 were $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230331_pp0p0" title="Research and development expense">86,665</span> and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20220331_pp0p0" title="Research and development expense">1,130</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 86665 1130 <p id="xdx_843_eus-gaap--AdvertisingCostsPolicyTextBlock_z869WaHhBTLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline"><span id="xdx_86C_zEPt4qeVSfm1">Advertising Costs</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses advertising costs as incurred. Advertising costs of $<span id="xdx_907_eus-gaap--SellingAndMarketingExpense_c20230101__20230331_pp0p0" title="Advertising costs">49,551</span> and $<span id="xdx_905_eus-gaap--SellingAndMarketingExpense_c20220101__20220331_pp0p0" title="Advertising costs">22,398</span> were charged to operations for the three months ended March 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 49551 22398 <p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6GZdRI8UINf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_863_zHgt1gNCfJT2">Cash and Cash Equivalents</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify">Cash and cash equivalents are comprised of cash and highly liquid investments with original maturities of 90 days or less at the date of purchase. The Company does <span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_do_c20230331_z78MPrtDQice" title="Cash equivalents"><span id="xdx_900_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_do_c20221231_z4l2HzJCHALj" title="Cash equivalents">no</span></span>t have any cash equivalents as of March 31, 2023 and December 31, 2022. Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions are insured by the FDIC up to $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_c20230331_pp0p0" title="FDIC insured amount">250,000</span>. The Company is exposed to credit risk in the event of default by the financial institutions or the issuers of these investments to the extent the amounts on deposit or invested are in excess of amounts that are insured.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> 0 0 250000 <p id="xdx_845_eus-gaap--RevenueRecognitionServicesLicensingFees_zZVvKfRHya73" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_864_z2lR5cSBkfIc">Patent Costs</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for patents in accordance with ASC 350-30, <i>General Intangibles Other than Goodwill</i>. The Company capitalizes patent costs representing legal fees associated with filing patent applications and amortize them on a straight-line basis. The Company is in the process of evaluating its patents' estimated useful life and will begin amortizing the patents when they are brought to the market or otherwise commercialized.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zTbN8Sv1sYnj" style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: left"><b><span style="text-decoration: underline"><span id="xdx_861_zdhwfrHxHKu3">Long-Lived Assets</span></span></b></p> <p style="font: 10pt/12.95pt Times New Roman, Times, Serif; margin: 0; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company assesses the valuation of components of long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zQLZS5LERXlg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_869_z3T2UuK0oU3e">Stock-Based Compensation</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, <i>Awards Classified as Equity,</i> which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest.  The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants.  Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zT51ybn1QiO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_860_zIOhp9nidQD4">Income Taxes</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, <i>Income Taxes</i>. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements<i>.</i> In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zNfl6vcNn2F9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline"><span id="xdx_862_zUSyWou7jqt3">Recent Accounting Pronouncements</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p id="xdx_803_eus-gaap--IntangibleAssetsDisclosureTextBlock_znBeLXxLE9ca" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 4 –<span id="xdx_829_zuPaK3PB2IRj"> Intangible Assets</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The following tables provide detail associated with the Company’s acquired identifiable intangible assets:</p> <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zcrtuCw2sCc3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left"> <span id="xdx_8BE_zJHPl2Qe4HNb" style="display: none">Schedule of intangible assets</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">As of March 31, 2023</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Gross Carrying <br/>Amount</b></span></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Accumulated Amortization</b></span></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Net Carrying Amount</b></span></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Weighted Average Useful life (in years)</b></span></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Amortized intangible assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; padding-bottom: 1pt">Know-how license</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowHowLicenseMember_pp0p0" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Intangible assets gross">80,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowHowLicenseMember_pp0p0" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Intangible assets accumulated amortization">(46,667</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowHowLicenseMember_pp0p0" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Intangible assets net">33,333</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span id="xdx_90E_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20230101__20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowHowLicenseMember_zioyn6XE3Uqf" title="Weighted average useful life">5</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets gross">80,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets accumulated amortization">(46,667</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_c20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets net">33,333</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Amortization expense charged to operations was $<span id="xdx_90E_eus-gaap--DepreciationAndAmortization_pp0p0_c20220101__20220331_zark9K6lRaH8" title="Amortization expense">4,000</span> for the three months ended March 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/> <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zcrtuCw2sCc3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left"> <span id="xdx_8BE_zJHPl2Qe4HNb" style="display: none">Schedule of intangible assets</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">As of March 31, 2023</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Gross Carrying <br/>Amount</b></span></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Accumulated Amortization</b></span></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Net Carrying Amount</b></span></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="text-align: center; font-size: 8pt; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 8pt; font-weight: bold; text-align: center"><span style="font-size: 8pt"><b>Weighted Average Useful life (in years)</b></span></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Amortized intangible assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; padding-bottom: 1pt">Know-how license</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowHowLicenseMember_pp0p0" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Intangible assets gross">80,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowHowLicenseMember_pp0p0" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Intangible assets accumulated amortization">(46,667</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_c20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowHowLicenseMember_pp0p0" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Intangible assets net">33,333</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span id="xdx_90E_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20230101__20230331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--KnowHowLicenseMember_zioyn6XE3Uqf" title="Weighted average useful life">5</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets gross">80,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets accumulated amortization">(46,667</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_c20230331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets net">33,333</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 80000 -46667 33333 P5Y 80000 -46667 33333 4000 <p id="xdx_806_ecustom--PatentCostsTextBlock_zWWDI3z0ON26" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 5 –<span id="xdx_827_zUkYP9UzQEe1"> Patent Costs</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2023, the Company has three pending patent applications. The initial patent applications consist of a US patent and international patents filed in six countries. The US patent was granted on August 16, 2022. The EU patent was granted on March 31, 2021. The validation of the EU patent in each of the six countries is pending. Legal fees associated with the patents totaled $<span id="xdx_90E_eus-gaap--OtherIntangibleAssetsNet_c20230331_pp0p0" title="Patent costs">373,197</span>, net of accumulated amortization of $<span id="xdx_901_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_c20230331_zmCuit23YFuj" title="Accumulated amortization">785</span> and $<span id="xdx_906_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_c20220331_zm0YWTtlZtFe" title="Accumulated amortization">321,308</span> as of March 31, 2023 and December 31, 2022, respectively and are presented in the balance sheet as patent costs. Amortization expense charged to operations was $<span id="xdx_901_eus-gaap--AccumulatedAmortizationOfOtherDeferredCosts_iI_c20230331_zCTAHJxk2R1a" title="Accumulated amortization">785</span> for the three months ended March 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 373197 785 321308 785 <p id="xdx_80A_ecustom--FinanceAgreementPayableTextBlock_zNYInrq4pGZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 6 –<span id="xdx_829_zC01L6xUQqR9"> Finance Agreement Payable</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 31, 2022, the Company entered into an agreement with a premium financing company to finance its Directors and Officers insurance premiums for 12-month policies effective October 25, 2022. The amount financed of $<span id="xdx_902_ecustom--FinancingAgreementEnteredIntoForPrepaidInsurance_c20221030__20221031_pp0p0" title="Financing agreement entered into for prepaid insurance">1,037,706</span> is payable in 11 monthly installments plus interest at a rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20221030__20221031_z8GUVLcnLXGk" title="Interest rate">6.216</span>% through <span id="xdx_907_eus-gaap--LongTermDebtMaturityDate_c20221031" title="Maturity date">September 28, 2023</span>. Finance agreement payable was $<span id="xdx_905_ecustom--FinanceAgreementPayable_c20230331_pp0p0" title="Finance agreement payable">566,022</span> and $<span id="xdx_902_ecustom--FinanceAgreementPayable_c20221231_pp0p0" title="Finance agreement payable">849,032</span> at March 31, 2023 and December 31, 2022, respectively. $<span id="xdx_904_eus-gaap--PrepaidExpenseCurrent_c20221031_pp0p0" title="Prepaid expenses">646,795</span> has been recorded in prepaid expenses and is being amortized over the life of the policy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> 1037706 0.06216 2023-09-28 566022 849032 646795 <p id="xdx_80A_eus-gaap--EarningsPerShareTextBlock_zb6J9nlBDjNb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 7 -<span id="xdx_829_zAztVCAlevN8"> Earnings (Loss) Per Common Share</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The Company calculates net income (loss) per common share in accordance with ASC 260 “<i>Earnings Per Share</i>” (“ASC 260”). Basic and diluted net earnings (loss) per common share was determined by dividing net earnings (loss) applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options, common stock warrants, and convertible debt have not been included in the computation of diluted net loss per share for the three months ended March 31, 2023 and 2022 as the result would be anti-dilutive.</p> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zS2wrmOdgiC8" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings (Loss) Per Common Share (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8B7_z01pavae5qVg" style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> <span style="display: none">Schedule of anti dilutive earning per share</span></b></span></td><td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="font: 12pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="font: 12pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Three Months Ended</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>March 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td style="font: 12pt Times New Roman, Times, Serif"> </td><td style="font: 12pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 12pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 12pt Times New Roman, Times, Serif"> </td><td style="font: 12pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 12pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 12pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left">Stock warrants</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Anti-dilutive shares">7,854,620</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Anti-dilutive shares">215,654</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Stock options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive shares">1,759,599</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zjz1Fy1HsFY6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive shares">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total shares excluded from calculation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331_pdd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive shares">9,614,219</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_pdd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive shares">215,654</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zS2wrmOdgiC8" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Earnings (Loss) Per Common Share (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8B7_z01pavae5qVg" style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> <span style="display: none">Schedule of anti dilutive earning per share</span></b></span></td><td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="font: 12pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="font: 12pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Three Months Ended</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>March 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td style="font: 12pt Times New Roman, Times, Serif"> </td><td style="font: 12pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 12pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 12pt Times New Roman, Times, Serif"> </td><td style="font: 12pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 12pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 12pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left">Stock warrants</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Anti-dilutive shares">7,854,620</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockWarrantsMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Anti-dilutive shares">215,654</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Stock options</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive shares">1,759,599</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zjz1Fy1HsFY6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive shares">—  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total shares excluded from calculation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230331_pdd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive shares">9,614,219</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220331_pdd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Anti-dilutive shares">215,654</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 7854620 215654 1759599 0 9614219 215654 <p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zNEVOsF0V5D" style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0"><b>Note 8 –<span id="xdx_82E_zEnfGZxaHiae"> Stockholders’ Equity</span></b></p> <p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Stock Transactions</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Pursuant to the Business Combination Agreement on October 25, 2022, the Company issued the following securities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Holders of conversion rights issued as a component of units in Mana’s initial public offering (the “Public Rights”) were issued an aggregate of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Number of shares issued">928,571</span> shares of the Company’s common stock;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Holders of existing shares of common stock of Legacy Cardio and the holder of equity rights of Legacy Cardio (together, the “Legacy Cardio Stockholders”) received an aggregate of <span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20230101__20230331__dei--LegalEntityAxis__custom--LegacyCardioStockholdersMember_pp0p0" title="Number of shares received">6,883,306</span> shares of the Company’s Common Stock, calculated based on the <span style="color: #212529">exchange ratio of 3.427259 pursuant to the Merger Agreement </span>(the “Exchange Ratio”) for each share of Legacy Cardio Common Stock held or, in the case of the equity rights holder, that number of shares of the Company’s Common Stock equal to 1% of the Aggregate Closing Merger Consideration, as defined in the Merger Agreement;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Legacy Cardio Stockholders received, in addition, an aggregate of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20230331__srt--TitleOfIndividualAxis__custom--LegacyCardioMember_pdd" title="Conversion shares">43,334</span> shares of the Company’s Common Stock (“Conversion Shares”) upon conversion of an aggregate of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_c20230331__srt--TitleOfIndividualAxis__custom--LegacyCardioMember_pp0p0" title="Principal amount">433,334</span> in principal amount of promissory notes issued by Mana to Legacy Cardio in connection with its loan of such amount in order to extend Mana’s duration through October 26, 2022 (the “Extension Notes”), which Conversion Shares were distributed to the Legacy Cardio Stockholders in proportion to their respective interest in Legacy Cardio.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Mana public stockholders (excluding Mana Capital, LLC, the SPAC sponsor (the “Sponsor”), and Mana’s former officers and directors) own 34,548 shares of the Company’s Common Stock and the Sponsor, Mana’s former officers and directors and certain permitted transferees own <span id="xdx_90E_ecustom--NumberOfSharesTransferred_c20230101__20230331__srt--TitleOfIndividualAxis__custom--ManasFormerOfficersAndDirectorsMember_pdd" title="Number of shares transferred">1,625,000</span> shares of the Company’s Common Stock.</span></p> <p style="font: 10pt TimesNewRoman,serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Immediately after giving effect to the Business Combination, there were 9,514,743 issued and outstanding shares of the Company’s Common Stock.</span></p> <p style="font: 10pt TimesNewRoman,serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 25, 2022, in connection with the approval of the Business Combination, the Company’s stockholders approved the Cardio Diagnostics Holdings, Inc. 2022 Equity Incentive Plan (the “2022 Plan”). The purpose of the 2022 Plan is to promote the interests of the Company and its stockholders by providing eligible employees, officers, directors and consultants with additional incentives to remain with the Company and its subsidiaries, to increase their efforts to make the Company more successful, to reward such persons by providing an opportunity to acquire shares of Common Stock on favorable terms and to attract and retain the best available personnel to participate in the ongoing business operations of the Company. The 2022 Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Performance Units and Performance Shares.</p> <p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2022 Plan, as approved, permits the issuance of up to <span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20230331__us-gaap--PlanNameAxis__custom--Plan2022Member_pdd" title="Common stock issuance">3,256,383</span> shares of Common Stock (the “Share Reserve”) upon exercise or conversion of grants and awards made from time to time to officers, directors, employees and consultants, however that the Share Reserve will increase on January 1st of each calendar year and ending on and including January 1, 2027 (each, an “Evergreen Date”), in an amount equal to the lesser of (i) 7% of the total number of shares of Common Stock outstanding on the December 31st immediately preceding the applicable Evergreen Date and (ii) such lesser number of shares of Common Stock as determined to be appropriate by the Compensation Committee, which administers the 2022 Plan, in its sole discretion. There was no increase in the Share Reserve on January 1, 2023.</p> <p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Common Stock Issued</span></b></p> <p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 2, 2023, a stockholder exercised warrants in exchange for <span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_c20210314__20210315_pdd" title="Conversion of shares, shares">100,000</span> common shares for proceeds of $<span id="xdx_90A_eus-gaap--ConversionOfStockAmountIssued1_pp0p0_c20230301__20230302_zYVbJC2cW8vc" title="Conversion of shares, Value">390,000</span>.</p> <p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2023, the Company issued <span id="xdx_904_ecustom--RestrictedStockAwardsVestedShares_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqnweyTG7Q5c" title="Restricted stock awards vested, shares">1,092</span> common shares to a consultant for services pursuant to vesting of Restricted Stock Units granted, valued at $<span id="xdx_90E_ecustom--ConsultantForServices_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRQgclBFbkt" title="Consultant for services">4,000</span>.</p> <p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Warrants</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 1, 2019, the Company issued warrants to a seed funding firm equivalent to 2% of the fully-diluted equity of the Company, or <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20191001_pdd" title="Common stock issuance">22,500</span> common shares at the time of issuance. The warrant is exercisable on the earlier of the closing date of the next Qualified Equity Financing occurring after the issuance of the warrant, and immediately before a Change of Control. The exercise price is the price per share of the shares sold to investors in the next Qualified Equity Financing, or if the warrant becomes exercisable in connection with a Change in Control before the next Qualified Equity Financing, the greater of the quotient obtained by dividing $<span id="xdx_904_ecustom--PreFinancingCapitalization_c20230331_pp0p0" title="Pre financing capitalization">150,000</span> by the Pre-financing Capitalization, and the price per share paid by investors in the then-most recent Qualified Equity Financing, if any. The warrant will expire upon the earlier of the consummation of any Change of Control, or 15 years after the issuance of the warrant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2022, the Company issued fully vested warrants to investors as part of private placement subscription agreements pursuant to which the Company issued common stock. Each stockholder received warrants to purchase 50% of the common stock issued at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxftDMN6CuG" title="Warrant exercise price">3.90</span> per share with an expiration date of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220401__20220430_zBNjZVGyHg85" title="Expiration date">June 30, 2027</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of May 23, 2022, the Company issued fully vested warrants to investors as part of an additional private placement subscription agreements pursuant to which the Company issued common stock. Each stockholder received warrants to purchase 50% of the common stock issued at an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220523_zJswvE1WDy3k" title="Warrant exercise price">6.21</span> per share with an expiration date of five years from the date of issue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the warrants issued by Legacy Cardio were exchanged in the Business Combination for warrants of the Company based on the merger exchange ratio.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Warrant activity during the three months ended March 31, 2023 and 2022 follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTableTextBlock_z5hlXMwYxtL3" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details)"> <tr style="vertical-align: bottom"> <td><span style="font-size: 8pt"><b> <span id="xdx_8BB_zGdZcZ48u5A3" style="display: none">Schedule of warrant activity</span></b></span></td><td><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2"><span style="font-size: 8pt"><b> </b></span></td><td><span style="font-size: 8pt"><b> </b></span></td><td><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2"><span style="font-size: 8pt"><b> </b></span></td><td><span style="font-size: 8pt"><b> </b></span></td><td><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2"><span style="font-size: 8pt"><b> </b></span></td><td><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 8pt"><b> </b></span></td><td><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2"><span style="font-size: 8pt"><b> </b></span></td><td><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Weighted</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Average Remaining</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Average Exercise Price</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Contractual Life (Years)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 61%">Warrants outstanding at December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zyzgL7xlNTt3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Warrants outstanding, beginning">215,654</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9Z3eSi76q22" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price outstanding, beginning">13.35</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z74GUgVDlYE" title="Weighted average remaining contractual life">5.90</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">No warrant activity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantActivity_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGFKrcaiziHb" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant activity"><span style="-sec-ix-hidden: xdx2ixbrl0588">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageWarrantActivity_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7Zai5WS9sq" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price warrant activity"><span style="-sec-ix-hidden: xdx2ixbrl0590">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 12pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 12pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Warrants outstanding at March 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4990QoNyJe4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants outstanding, ending">215,654</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zhKs3w2zzSs" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price outstanding, ending">13.35</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCnYtAgZUaUa" title="Weighted average remaining contractual life">5.07</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding at December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zyisFZdPYfr7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants outstanding, beginning">7,954,620</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmo6FnA6Bkq1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price outstanding, beginning">9.63</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUXO5RDnqmi4" title="Weighted average remaining contractual life">4.46</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Warrants exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJ2T9bITPDjb" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants exercised">(100,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price exercised">13.35</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 12pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 12pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Warrants outstanding at March 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKAFcJ5HZSIg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants outstanding, ending">7,854,620</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMt3KC4GOmd5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price outstanding, ending">9.70</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUtrqK3FtcKg" title="Weighted average remaining contractual life">4.22</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Options</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-right: 0; margin-bottom: 0">In May 6, 2022, the Company granted <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220501__20220506__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4QL6gVorxU6" title="Options issued">513,413</span> stock options to the board of directors pursuant to the Cardio Diagnostics, Inc. 2022 Equity Incentive Plan. All of the options granted under this legacy plan were exchanged for options under the Plan adopted by the Company’s stockholders on October 25, 2022, and based on the exchange ratio for the merger, resulted in a total of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20221024__20221025__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Options issued">1,759,599</span> options issued upon closing. Each exchanged option has an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220506_zekfBFVZHYV6" title="Warrant exercise price">3.90</span> per share with an expiration date of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221024__20221025__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z0zsDwE31Ijb" title="Expiration date">May 6, 2032</span>. The exchanged options fully vested upon the merger with Mana.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="margin-top: 0pt; margin-bottom: 0pt"/> 928571 6883306 43334 433334 1625000 3256383 100000 390000 1092 4000 22500 150000 3.90 2027-06-30 6.21 <table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTableTextBlock_z5hlXMwYxtL3" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details)"> <tr style="vertical-align: bottom"> <td><span style="font-size: 8pt"><b> <span id="xdx_8BB_zGdZcZ48u5A3" style="display: none">Schedule of warrant activity</span></b></span></td><td><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2"><span style="font-size: 8pt"><b> </b></span></td><td><span style="font-size: 8pt"><b> </b></span></td><td><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2"><span style="font-size: 8pt"><b> </b></span></td><td><span style="font-size: 8pt"><b> </b></span></td><td><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2"><span style="font-size: 8pt"><b> </b></span></td><td><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-size: 8pt"><b> </b></span></td><td><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2"><span style="font-size: 8pt"><b> </b></span></td><td><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Weighted</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Average Remaining</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 8pt"><b>Outstanding</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Average Exercise Price</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 8pt"><b>Contractual Life (Years)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 61%">Warrants outstanding at December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zyzgL7xlNTt3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Warrants outstanding, beginning">215,654</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9Z3eSi76q22" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted average exercise price outstanding, beginning">13.35</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z74GUgVDlYE" title="Weighted average remaining contractual life">5.90</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">No warrant activity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantActivity_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGFKrcaiziHb" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant activity"><span style="-sec-ix-hidden: xdx2ixbrl0588">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageWarrantActivity_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7Zai5WS9sq" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price warrant activity"><span style="-sec-ix-hidden: xdx2ixbrl0590">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 12pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 12pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Warrants outstanding at March 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4990QoNyJe4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants outstanding, ending">215,654</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zhKs3w2zzSs" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price outstanding, ending">13.35</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zCnYtAgZUaUa" title="Weighted average remaining contractual life">5.07</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding at December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zyisFZdPYfr7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants outstanding, beginning">7,954,620</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmo6FnA6Bkq1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price outstanding, beginning">9.63</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUXO5RDnqmi4" title="Weighted average remaining contractual life">4.46</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Warrants exercised</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJ2T9bITPDjb" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants exercised">(100,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price exercised">13.35</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 12pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 12pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Warrants outstanding at March 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zKAFcJ5HZSIg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants outstanding, ending">7,854,620</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMt3KC4GOmd5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price outstanding, ending">9.70</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUtrqK3FtcKg" title="Weighted average remaining contractual life">4.22</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 215654 13.35 P5Y10M24D 215654 13.35 P5Y25D 7954620 9.63 P4Y5M15D 100000 13.35 7854620 9.70 P4Y2M19D 513413 1759599 3.90 2032-05-06 <p id="xdx_80E_eus-gaap--DebtDisclosureTextBlock_zOmf2zyfh66d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 9 – <span id="xdx_821_z575mRZUcz2f">Convertible Notes Payable</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 8, 2023, <span id="xdx_909_eus-gaap--SignificantPurchaseCommitmentDescription_c20230301__20230308_ztpcB1aot0Ua" title="Purchase aggrement description">the Company entered into a securities purchase agreement (“Securities Purchase Agreement”) with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”) under which the Company agreed to sell and issue to Yorkville convertible debentures (“Convertible Debentures”) in a gross aggregate principal amount of up to $11.2 million (“Subscription Amount”). The Convertible Debentures are convertible into shares of common stock of the Company and are subject to various contingencies being satisfied as set forth in the Securities Purchase Agreement. The notes are convertible at any time through the maturity date, which, in each case, is one year from the date of issuance. The conversion price shall be determined on the basis of 92% of the two lowest VWAP (Volume Weighted Average Prices) of the Common Stock during the prior seven (7) trading day period. On March 8, 2023, the Company issued and sold to Yorkville a Convertible Debenture in the principal amount of $5.0 million, for which it received $4.5 million, with a $500,000 original issue discount (“OID”). Interest on the outstanding principal balance accrues at a rate of 0% and will increase to 15% upon an Event of Default for so long as it remains uncured</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded a debt discount related to identified embedded derivatives relating to the conversion features (see Note 10) based on fair values as of the inception date of the Note. The calculated debt discount, including the OID equaled the face of the Note and is being amortized over the term of the note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Convertible notes payable of $<span id="xdx_90C_eus-gaap--ConvertibleNotesPayable_iI_c20230331_zuS5SXdkBtTa" title="Convertible notes payable">315,068</span> at March 31, 2023 is presented net of debt discount of $<span id="xdx_908_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20230331_zR69WVYuiQt8" title="Debt discount net">4,684,932</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> the Company entered into a securities purchase agreement (“Securities Purchase Agreement”) with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”) under which the Company agreed to sell and issue to Yorkville convertible debentures (“Convertible Debentures”) in a gross aggregate principal amount of up to $11.2 million (“Subscription Amount”). The Convertible Debentures are convertible into shares of common stock of the Company and are subject to various contingencies being satisfied as set forth in the Securities Purchase Agreement. The notes are convertible at any time through the maturity date, which, in each case, is one year from the date of issuance. The conversion price shall be determined on the basis of 92% of the two lowest VWAP (Volume Weighted Average Prices) of the Common Stock during the prior seven (7) trading day period. On March 8, 2023, the Company issued and sold to Yorkville a Convertible Debenture in the principal amount of $5.0 million, for which it received $4.5 million, with a $500,000 original issue discount (“OID”). Interest on the outstanding principal balance accrues at a rate of 0% and will increase to 15% upon an Event of Default for so long as it remains uncured 315068 4684932 <p id="xdx_809_eus-gaap--DerivativesAndFairValueTextBlock_zIH9f2O1uVrd" style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 10 – <span><span id="xdx_822_zht6N6Re9kQ4">Derivative Liability</span></span></b></p> <p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has determined that the conversion feature embedded in the convertible notes described in Note 9 contain a potential variable conversion amount which constitutes a derivative which has been bifurcated from the note and recorded as a derivative liability at fair value, with a corresponding discount recorded to the associated debt. The excess of the derivative value over the face amount of the note is recorded immediately to interest expense at inception which aggregated $<span id="xdx_900_eus-gaap--InterestExpense_c20230101__20230331_zopRSGGSx3Qb" title="Interest expense">4,692,672</span>. The Company used the Binomial Black-Scholes Option Pricing model to value the conversion features. The Company used the Binomial Option Pricing model to value the conversion features.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using a Black-Scholes option-pricing model with the following assumption inputs:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--FairValueOptionQuantitativeDisclosuresTextBlock_zBokoEmu7m9f" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Derivative Liability (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8B8_zmyDc9HoJ0v"> <span style="color: White">Schedule of option liability</span></td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 8pt"><b>March 8,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-size: 8pt"><b>March 31,</b></span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Annual dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230307__20230308_znuxz2Oflvfg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Annual dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0639">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230330__20230331_zIj2MPH1Nnc9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Annual dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0641">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left">Expected life (years)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230307__20230308_zFpyEJs4xq15" title="Expected life (years)">1.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230330__20230331_zjV4k65MNVce" title="Expected life (years)">1.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230307__20230308_zeFvB86WUpNf" title="Risk-free interest rate">5.28</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230330__20230331_z9UL7KLGYbha" title="Risk-free interest rate">4.89</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230307__20230308_zGp4Hl67mZY3" title="Expected volatility">164</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230330__20230331_zCi0ieYe511e" title="Expected volatility">169</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20230308_zsD1l3If5cL7" title="Exercise price">2.20</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20230331_zpAboRKduzHa" title="Exercise price">3.53</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Stock price</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_uUSDPShares_c20230308_zz2TaCv0L12e" title="Stock price">5.32</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_uUSDPShares_c20230331_zuM90ghA6zth" title="Stock price">3.91</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 4692672 <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--FairValueOptionQuantitativeDisclosuresTextBlock_zBokoEmu7m9f" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Derivative Liability (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8B8_zmyDc9HoJ0v"> <span style="color: White">Schedule of option liability</span></td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 8pt"><b>March 8,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-size: 8pt"><b>March 31,</b></span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"><span style="font-size: 8pt"><b> </b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 8pt"><b>2023</b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Annual dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230307__20230308_znuxz2Oflvfg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Annual dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0639">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20230330__20230331_zIj2MPH1Nnc9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Annual dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0641">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left">Expected life (years)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230307__20230308_zFpyEJs4xq15" title="Expected life (years)">1.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230330__20230331_zjV4k65MNVce" title="Expected life (years)">1.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230307__20230308_zeFvB86WUpNf" title="Risk-free interest rate">5.28</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230330__20230331_z9UL7KLGYbha" title="Risk-free interest rate">4.89</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230307__20230308_zGp4Hl67mZY3" title="Expected volatility">164</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230330__20230331_zCi0ieYe511e" title="Expected volatility">169</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20230308_zsD1l3If5cL7" title="Exercise price">2.20</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_uUSDPShares_c20230331_zpAboRKduzHa" title="Exercise price">3.53</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Stock price</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_uUSDPShares_c20230308_zz2TaCv0L12e" title="Stock price">5.32</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_uUSDPShares_c20230331_zuM90ghA6zth" title="Stock price">3.91</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> P1Y P1Y 0.0528 0.0489 1.64 1.69 2.20 3.53 5.32 3.91 <p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z77wtk8by7h9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 11 – <span id="xdx_82D_zZDvwwLHy2S1">Commitments and Contingencies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><b><span style="text-decoration: underline">Prior Relationship of Cardio with Boustead Securities, LLC</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">At the commencement of efforts to pursue what ultimately ended in the terminated business acquisition, Legacy Cardio entered into a Placement Agent and Advisory Services Agreement (the “Placement Agent Agreement”), dated April 12, 2021, with Boustead Securities, LLC ("Boustead Securities”). This agreement was terminated in April 2022, when Legacy Cardio terminated the underlying agreement and plan of merger and the accompanying escrow agreement relating to that proposed business acquisition after efforts to complete the transaction failed, despite several extensions of the closing deadline.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Under the terminated Placement Agent Agreement, Legacy Cardio agreed to certain future rights in favor of Boustead Securities, including (i) a two-year tail period during which Boustead Securities would be entitled to compensation if Cardio were to close on a transaction (as defined in the Placement Agent Agreement) with any party that was introduced to Legacy Cardio by Boustead Securities; and (ii) a right of first refusal to act as the Company’s exclusive placement agent for 24-months from the end of the term of the Placement Agent Agreement (the “right of first refusal”). Cardio has taken the position that due to Boustead Securities’ failure to perform as contemplated by the Placement Agent Agreement, these provisions purporting to provide future rights are null and void.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Boustead Securities responded to the termination of the Placement Agent Agreement by disputing Legacy Cardio’s contention that it had not performed under the Placement Agent Agreement because, among other things, Boustead Securities had never sought out prospective investors. In its response, Boustead Securities included a list of funds that they had supposedly contacted on Legacy Cardio’s behalf. While Boustead Securities’ contention appears to contradict earlier communications from Boustead Securities in which they indicated that they had not made any such contacts or introductions, Boustead Securities is currently contending that they are due success fees for two years following the termination of the Placement Agent Agreement on any transaction with any person on the list of supposed contacts or introductions. Legacy Cardio strongly disputes this position. Notwithstanding the foregoing, the Company has not consummated any transaction, as defined, with any potential party that purportedly was a contact of Boustead Securities in connection with the Placement Agent Agreement and has no plans to do so at any time during the tail period. No legal proceedings have been instigated by either party, and Cardio believes that the final outcome will not have a material adverse impact on its financial condition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><b><span style="text-decoration: underline">The Benchmark Company, LLC Right of First Refusal</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">As noted in Note 1, the Company completed a business combination with Mana on October 25, 2022. In connection with the proposed business combination, by agreement dated May 13, 2022, Mana engaged The Benchmark Company, LLC (“Benchmark”) as its M&amp;A advisor. Upon closing of the business combination, Cardio assumed the contractual engagement entered into by Mana. On November 14, 2022, Cardio and Benchmark entered into Amendment No. 1 Engagement Letter (the “Amendment Engagement”). Pursuant to the Amendment Engagement, Benchmark has been granted a right of first refusal to act as lead or joint-lead investment banker, lead or joint-lead book-runner and/or lead or joint-lead placement agent for all future public and private equity and debt offerings through October 25, 2023. In this regard, the Company and Benchmark are in discussions regarding the convertible debenture financing the Company entered into in March 2023 whether Benchmark might be entitled to compensation arising from the Company having entered into the convertible debenture financing in March 2023 without first consulting Benchmark. No legal proceedings have been instigated, and the parties are continuing to discuss a resolution to this matter.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><b><span style="text-decoration: underline">Demand Letter and Potential Mootness Fee Claim</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">On June 25, 2022, a plaintiffs’ securities law firm sent a demand letter to the Company alleging that the Company’s Registration Statement on Form S-4 filed (the “S-4 Registration Statement”) with the Securities and Exchange Commission (“SEC”) on May 31, 2022 omitted material information with respect to the Business Combination and demanding that the Company and its Board of Directors immediately provide corrective disclosures in an amendment or supplement to the Registration Statement. Subsequent thereto, the Company filed amendments to the S-4 Registration Statement on July 27, 2022, August 23, 2022, September 15, 2022, October 4, 2022 and October 5, 2022 in which it responded to various comments of the SEC staff and otherwise updated its disclosure. In October 2023, the SEC completed its review and declared the S-4 registration statement on October 6, 2022. On February 23, 2023 and February 27, 2023, plaintiffs’ securities law firm contacted the Company’s counsel asking who will be negotiating a mootness fee relating to the purported claims set forth in the June 25, 2022 demand letter. The Company <span style="background-color: white">vigorously denies that the S-4 </span>Registration Statement, as amended and declared effective, <span style="background-color: white">is deficient in any respect and that no additional supplemental disclosures are material or required. The Company believes that the claims asserted in the Demand Letter are without merit and that no further disclosure is required to supplement the S-4 Registration Statement under applicable laws. </span>As of the date of filing of this Quarterly Report on Form 10-Q, no lawsuit has been filed against the Company by that firm. The firm has indicated its willingness to litigate the matter if a mutually satisfactory resolution cannot be agreed upon; however, Cardio believes that the final outcome will not have a material adverse impact on its financial condition. The Company cannot preclude the possibility that claims or lawsuits brought relating to any alleged securities law violations or breaches of fiduciary duty could potentially require significant time and resources to defend and/or settle and distract its management and board of directors from focusing on its business.</p> <p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zRtdRigUzMfj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 12 – <span id="xdx_824_zLBe5xL5ewJ1">Subsequent Events</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluated its March 31, 2023 consolidated financial statements for subsequent events through the date the consolidated financial statements were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">Common Stock Issued</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to the end of the period through the date of this report, Yorkville converted $<span id="xdx_907_eus-gaap--CommonStockValue_iI_c20230331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertibleCommonStockMember_zQwTPNX0VxX9" title="Converted common stock value">700,000</span> of principal to <span id="xdx_902_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20230331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertibleCommonStockMember_zfCdFy9nBfve" title="Conversion of stock shares">361,094</span> shares of the Company’s common stock.</p> <p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><b> </b></p> 700000 361094 EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( '2$KU8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !TA*]6BRJU;^\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M3L,P#(=?!>7>NG\HAZC+98@32$A, G&+'&^+:-HH,6KW]J1EZX3@ 3C&_N7S M9\DM>HE#H.

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�-$73Z"'JE784' ML^3!/)4'OL",\'<1L<6V*D08IN59-39:<\C6\TN^Q#,RU.2"S0E;$VWTTP_( M@;^HQ-8E6- 16(5[J^3>.A>]>9S(%U],.5>5X8PP0+4V=(3C6PU9] P/0MNN M:?JX7857N^35;M5TD(;JB7V'6:EG0T6D?7QBVXVQZRK;H FX:6"9$+^VH%]DLB^MV\691,]!M) M>3:R7,NLT=&:PZDB[!(LZ BLPKU7!@1M,U87(G"@25@WQ# MR;,-I:I 7G,_4BN-URBAV??DIZ;3,YY$]=()%.'DNP1"M8H1W&WR8:N.C]/S M)FSEKATJYFLEK6);WIK$J4+N%"WH"JU:@+TN"W4GYD?"!8MF697RV@"\P2SD M8"VODU!9H3.B*W=/!5!E(6T4VN\J7' L7)7M75^$VANC=@);I6XHI.[5]T_M MX4\6>I=H05=H5>IWK1@ZN]MH'A]B:9B05 \SXZOA"B+,'1>-4R[-HTU-JG==?_GA-'S6Q' M0#Y2M7_0-!Q4ZQ.#]UA6^=VU@.BT'E#9!YM*0IUF(^+4%_*F#8*6)?,VZT)L M6O9<:%C(L>ID-"U-V7PB=$AKNZX,M;=E[^N'U60T&R3/07;?K+=F[2F<_&KK M$BWH"FU+O[[WHWGVGXCD4#9[',3D5<+#"U>*FFW_9M@.!%WFOZ._4"%HDI\N M" X)RPSD_5=*Q=L@^VF^_+-G]#]02P,$% @ =(2O5BJQ*0;B!@ %2, M !@ !X;"]W;W)KGBB?$?8DFI!,]A$(G+VE+*U7FC(=PE#8GXS%8T4O_,&0^)5)=\T1 K3HD7 M#PJ#!H:PU0B)']6Z%_&]*>]>L+4,_(A..1#K,"3\Y8H&[.FRAFJO-V[]Q5+J M&XWNQ8HLZ(S*^]64JZM&JL7S0QH)GT6 T_EEK8?.^Y:E!\02#SY]$COG0+OR MR-@/?3'R+FM06T0#ZDJM@JB?#>W3(-":E!T_MTIKZ3/UP-WS5^W7L?/*F4R0,1'\+25A37@KH5DX7:PLB#T MH^27/&^!V!F@])@'X.T G!_0+!E@;0?$R#42RV*W!D22[@5G3X!K::5-G\38 MQ*.5-WZD7^-,4;6NO^_AMJP3],/E>D; ^!9HI \UCMQ>-8S5(W;JB'WH5;[/D<-'EX@E6 OJ 3\":B;F M1/K1(IG*?.E3H_]VE1%1D;(](%LID*WJ(N*]QU[(N/3_)CHWF%!,3&ON!$?3 M:=NY"#((00C-X>.D7CLG]-K]N?:%+Y.<&A U+0/ZK%*\H"80G()_,(= 4<)V M[#((VBD$[=-!,)/,_5'7F=P#+@NU[W$0',*A??@])U 4A4I@Z*0P=$X'PYA% M]7AZ\2-)E79YR/].\2U#Z#C-/ 1%N1(($,SH!CP="/VEXJUZ;IT3GX,-"=84 ML+EB==S?$$T70>"31S_PY8N1LL""OW6[U6YU(,H!8Y L0V:'B*'_*\\H'*(% M%;DL(P25 I#(2U%0&<=(0K:65I1SJM*VCRO.<,6GG(!=MHX4K)RZ5 798V#\ MX+8F'IIY#2*[<;?O?$9#T=$<[[\?IYRNB)]FG"2VF%Q2KBH7SFDDMT%GA,0J M^&M9;03S.=D@AZ%EMTN0R>@IJI"?OOB$Q'0\ MO$OJYWM=9(_&QE+0"$N1C=91J]F!+2>/BTFRW8*=LH#)N"MRWE7&CL8/P]E; MREAT-"DV9I"*M.VCD-%75"%_G2H2KB8^EPFI$W \$7I&B(H$LV[CEM/,OUV# MG(H#JRSL,SJ*3LE'\V%O"ATC+$72:8;%('< %IPQ5 S?%?/7HW%OW']#S..C MF:^Q7U61MGT4,C:*CV9E)B+ 7$H] >:2*I@EA>CMY& U44KCZTSBW&F$I,K\F[J!.IP!+ M4; ,EHP>XH/TL*LM'XW[M\/>; @^#H;)V2>=U+1#1GN+C S;'8B;G;R]!NJ& M(58)K\3JC+KA@Z0H26-U<#7\,AJ/-<*3:Z"8YV@R,!I<;/PU$7)LG.]\& 1M MA)T=3KIO;T:R\$&2]6KO<#SX%TN+=*CE0,=Q"J%0%+20>@4E-37.>!/N5->H MZ>N>7%PE>VNNVS"J/ 8OE' P9]Q,(XYF;48:49&V_56PC$Q9OZC=-]JV,8UK M9,7N6[OMY"/5(%4R%5@9*[(J[-'MM&0WRI.X!Z=*XB05[J_[F)<"*^W"5:5M M'[F,/EF_J LWH(\R8XBOBQR2O;FK:QD::ZBC*@J<#YA#3;I]MW>6@7]1_ZWG M_;46,B8,RM>=AJUNJ:W#9 F19,L_1L^MPHJHTU3))>]W42SO=V-G@T%(^2+> M=R% _$Z2-?KT;KJWHQ?O:,C=OT+G_62'1J8FV3!R0[BJ"00(Z%RIA)\=]0WR M9 ]&E.F.X_4$L#!!0 ( M '2$KU8,F3R;5 ( ,\$ 8 >&PO=V]R:W-H965T&UL M?51M;YLP$/XK)S9-K30%0IITZ@A27M5*;1.5=/TP[8,#EV#58&:;I/OW.YN$ M95(;/N [^Y[GGC-W1'NI7G6.:."M$*4>>KDQU8WOZS3'@NF.K+"DDXU4!3/D MJJVO*X4LW5'$D:R-XB4L%NBX*IOZ,4H$5A )38QD8+3NN!!6FLCBP.8%!2\;%;V=KB' M$T 8?@ (#X#0Z6X2.9539E@<*;D'9:.)S1JN5(2U1DWF%W"Q9(I M+$V.AJ=,7$:^(4&6UD\/R<=-\O"#Y#UXD(37,"LSS/['^U1(6TUXK&8Y7"(.P!\_)%"X^7Y[A[;6WU'.\_0]X$\,,4BL:D!N8,)W#G+I9P\_1 M6AM%G?7KO>(;SM[[G';:;G3%4AQZ-$X:U0Z]^,NG[B#X?D;Q5:OXZAQ[O%!\ MRTLF@&M=(V1\TV5V_O#CC#D<]VUCW MQ1=$07PKM?'G_2*$ZM5X[+."2NE'MB*#E95UI0QX=.NQKQS)/!J5>CR;3)Z/ M2ZE,_^(LOKMS%V>V#EH9NG/"UV4IW?:2M-V<]Z?]]L5'M2X"OQA?G%5R30L* MGZH[AZ=QYR57)1FOK!&.5N?]^?35Y5/>'S?\0]'&[_T6G,G2VB_\<).?]R<, MB#1E@3U(_'-/5Z0U.P*,KXW/?A>2#?=_M][?QMR1RU)ZNK+ZGRH/Q7G_95_D MM)*U#A_MYATU^3QC?YG5/OX5FV;OI"^RV@=;-L9 4"J3_I7?&AY^Q&,PB M[A0HHKR605Z<.;L1CG?#&_^(J49K@%.&B[((#JL*=N'B@UM+H_Z4B2*3BTOI ME1=V)>X<>3(AKIR- V*QQ3AK_%XFO[/O^#T5M]:$PHLW)J?\T'X,C!W060OT MST$7^G7>*GT=^S'TA\(*ZL\5:K?,?#?OI,QUMEI,F4 MU&*!EP1=!B_^/5_ZX*"L_QQC* $X/0Z 3]LK7\F,SOL5QW+WU+_X^:?I\\GK M1])[VJ7W]#'O_T=='_5['/7O-I"8BJ'XL:CBCX)$;62=JT"YR"PD8CSEO:RK M EZO.L+]CO JN<&R="1"83VQ]ROI/Q/:UEMFWVM7Y',=$FF-A(+Y3)K*NLBPGB^58:":-*!:0YS[[6RJO(T!6V M[;SSMM9IKP9;3G V6FXBM_P[_ J$J0S;]N"GLBJ*A/;(R*7FG3AWF8H7,7XQRM@U23J4 M-*?07K%@/& T"'Q8.=CQ1 ^+A_Z %FH\%S!RB3595<[*K.!R'OKHM62MG"TQ M%:1;G?=%"WYHW1_PSV&6Q/X/%*@,+*5 '^.4@1A>\CH+,7W'H2T\GP[Q'_QUJ3>#F$2J-0WL-5P$AJ8L]HY?@=*72VU?Q)KI7"L M =A01MZS>!B/9$6X]C),%'!]>K$^#5?Y2'RHD'@,A)T84Y.J&6LH')$HTXA& M/*+ALG X<.V$%>]7T-E%5K%Y<[^(!P[(6Y^A0+\J<=4L2="W"KT +:P-M(6 M1=-MK^$J=O4V2#RI. +?D>=16?K"UCKG6/P-PAJ$S>?:I [4B;!1_@^,%*R= MI!O8.8)@'V*'Y4/HLXYE1G"L)<\-;E,-A:/5A!Z@M\YKW;+I$LI&3#Z;'@\#L M14(^B%-'^BMNR:V1U:)>/AAH=@N[IG1+Y($L%-"YN+88]08)?P&Q8'3B&ZC) MG_/NU'E/>[-'KYD7^*9S;0=F+T>QS]?0:;Q-]N>W!ERWN!NXD.N'+%BNU.Q9 MFV]5.U\#MV@B/30?/!B+2EYOZA-'0X:XSU1<.;3QM;M7]_'\1B'U]F=)L9LE M^> P\R/VU(Q%+:X8US6521I(8*XY].(SW/@YC!/X$]B(VP/2= MV+WMOK+GZ>-RMSU]HD-N:W1WS \KF$Y&+_!QY=)G;WH(MHJ?FDL;\.$:?^(& M@RYX ]:Y1[+_P)02P,$% @ =(2O5B&2D5G% P 8P@ !D M !X;"]W;W)K&ULI59M;^,V#/Z>7T'X#H<-,.+W MO+1)@+3;;OO0+6AWVV?99F*AMN23E*3=KQ\IIUE7M,4.^Q)+%/GP(2F*61RU MN;<-HH.'KE5V&33.]1=19*L&.V''ND=%)UMM.N%H:W:1[0V*VAMU;93&\23J MA%3!:N%E&[-:Z+UKI<*- ;OO.F$>K[#5QV60!$^"6[EK' NBU:(7.[Q#]Z7? M&-I%9Y1:=JBLU H,;I?!.KFXREG?*_PA\6B?K8$C*;6^Y\TO]3*(F1"V6#E& M$/0YX#6V+0,1C:\GS.#LD@V?KY_0?_*Q4RREL'BMVS]E[9IE, N@QJW8M^Y6 M'W_&4SP%XU6ZM?X7CH-N/@F@VENGNY,Q,>BD&K[BX92'9P:S^ V#]&20>MZ# M(\_R!^'$:F'T$0QK$QHO?*C>FLA)Q46Y"O!OCT#?@,;K1RC84?58WUO^TCHGKF MFS[QO4K?!;P19@Q9$D(:I]D[>-DY_LSC%?\U_O4WQC_ 9Z_#O2H-T()(!=HO+'37N,E M@1".C:P::(2%$I'[OM)[LJJ!GC @J1B9$S_SDI\4#+>Y$C2T3FVZNM> M"4O/)9VU4I2RE4Z2&Z\R3V=A$<>P-;H;<6K&\#NY M>J[W9,OZLR(/IU/*K:*'G@1" 0I#(?7BT=>-Z\(A>>TI$RA $@#9E\01#JAJ MRA\EB5J0\LL5XAX,01@<$8HH6_0!'S7E\8#6>=Q2J'M*MJ]@O<=72IV-Z5ZP M6P\\>FKNX0(8Y,G">7XM$Z5HATI163_F61'&<3SV%\7?S^FEA4IW'?FDA[2Z MITM14RB4:^QZ+OC(\*/-9:^T4J=!XMM%MS2'B M YI*\M4F:VE@ *>4L$/L8!+FDR+,BQ3F\W$!23Q.8B!)EL3A;)Y2(\RGDW": MSV$>%@G5*\](5G!860&OO1?1LX>_XTO&XXWY4B&'&7"6GB?H>A@<_Z@/XY>2 MOY/*0HM;,HW'4WHQS3#2AHW3O1\CI78TE/RRH7\!:%B!SK>:FOFT80?G_Q6K MOP%02P,$% @ =(2O5NN@@;JF#P J"D !D !X;"]W;W)K&ULI5I;<]NV$G[GK\"XG8X]1Y8E^9+$3C*C.&GJF:3UU$G[ M<.8\0"0DH:8(!B M*[_^?+L 2="2W)XY+PDM HN][[<+OEX;>^^62E7B<947 M[LW!LJK*RY,3ER[52KJA*56!-W-C5[+"GW9QXDJK9,:;5OG)9#2Z.%E)71R\ M?K62=O-.Y6;]YF!\T/SPNUXL*_KAY.WK4B[4G:J^ MEK<6?YVT5#*]4H73IA!6S=\<3,>7[\YH/2_X0ZNUBYX%23(SYI[^N,G>'(R( M(96KM"(*$O\]J&N5YT0(;'P+- _:(VEC_-Q0_YEEARPSZ=2UR?_46;5\<_#R M0&1J+NN\^MVL?U%!GG.BEYK<\;]B[=>>G1Z(M':5687-X&"E"_^_? QZB#:\ M'.W9, D;)LRW/XBY?"\K^?:U-6MA:36HT0.+RKO!G"[(*'>5Q5N-?=7;.V\, M8>;B3B\*/=>I+"HQ35-3%Y4N%N+6Y#K5RKT^J7 >[3I) ^UWGO9D#^U3\=D4 MU=*)#T6FLO[^$_#9,CMIF'TW>9;@9VF'XG0\$)/1Y/09>J>M\*=,[WP/O1U2 MBG]/9ZZR<);_[!+8TSO=38\"Z-*5,E5O#A A3MD'=?#VIQ_&%Z.K9[@]:[D] M>X[Z_VFJ9VGOYOQ74REQ*G[ZX>5D/+X2__Q\<6MUD>HRQR-67YO"X4TF.0Z_ M+)5(VU]4)N:ZD%@M<^$J_("(KYS _KS.E*BP6OH3F!;]?6U6I2PVB2PRH?'S M>FGR?'-LU@6HN7KF=*;!Z$!<2YMI(]YKN2B,JW3J!N*F2(=BFNU6LI*R/D<&9.E 9/&\B&KU@!8KX*> MC040LZ1$C MMM^W2H2S$O6&">B#MCTP#Z1?92L4W4A+ND#FJIG4( 00!$]2Z99,FA_(,4## M+VK=OI0;.4 MD/PQ^!<4 8X[METR4ZFL76MNMX0-CQ&'*X' "HZ#%U@1"3/T.0,<;,B0D<%- M;0,-[URF6'AJJ569KH29Y7HAO7-'G"61)AN.B!W%K@^4(#9:Y1F.* (W$:%& MTB9#D9]3O:AER"DPF+!>?H0;*)B% A7K0]CPXURQN"YQ-2F-7+!(:VLI6C0B M$A;UN7,-J67PC1-CA5K-5(9J2AL>E&5L9,K &!N*G-&R,1'PG@\.#9P'+2"= MQ*JE5PYI+964]IDN)^*:TDRJ?.]8<2#.* MSE1!CUE"Y\G"9P"!YU+JC!CC'$OA)MN4L!&'6*D>P0.3/&J2:LAKT"\(K,CE M9/8 I2"QF9I2G+T'<3J)JT5S5$=7%\@(^"E3-M_$Z1VL5FO*[8$&-(AG*HZW0(P8XY0,G]3? MO0.&T# SJL!L0UV4=<@,*#Y;*^MB>^UZ20(QUQ0N'4NQ55UJ]0R\5$NKE,B1 M.'-VAD"#K;F2&[(ECF*3!45$!"_%)]HHQBU&^%8;RE1L/ZY@'G4'_3IV!YV1 M])0^0EV(;$5EP=.<[*%)%(+'AOW)T[JR=:Q@I^\$HSB)].8/[(#.TZ6QDI-# M8D ]RA7JK,^HO1L/N=2B/KT()GUUGN3-:4' MF:=USKMJUU2S=[E,[X_O4L ?"G(^A-5$"YBA8:\^U:[5[FDKI D<$)#:<;Q6 M/OW"(:XFZF%+@I.V%2-"ZI%4$ON4UL3K2OY M%Y[2G$SY#+YHG"]+8)-(;UX9+H*CNR+B, A]Q&31]E%/Z,0"Y3.<9/CXABD? M%"O?O"AJ7L1G"N6V]V"7P\-DF$#]*JMS-F'$6)0U7$);>'GRJ1/I,GGGE4$[ M=VM>'$=:Q"H/7\2/WE,G5]U3<@,W YNO!N-7D\'%BTG[XIKK!#E.LZE]X],W M08B.;[(EE/D=ZS55%F5#^3P\'UR\O!B\&HW%44OBGT@ _?5X/QV!1)U)4+@;]O./%5<]7XWK6!FWC,*+O,!21)"1JK?='8!>J M:."P;^(!YRHE\=.NI.Y3YN4^\S]9E_1IB_<=\Y%' ")6,D^\L][L-'-X]_S+ MFR=:[IZ#,VC2[TVDM3A+*)*@:P\:A$C:V,8<+1Y)?+?24H]MPODX1?EE7V$4 MQ(5H?#Z(-.'/^T5E"S+,E!)X2#_3LD1?R4[Q<3J][9H;W[V1YI#&9GI>VY1Z MB6TVDP#J"8XN"4#$[$5B-AE@12XQ1Q(X1G7WF2ORMYV(.XC("=*TX!Q5%HA0 M2Y]#F[\Z[*AM6J_HC% N/5(XE$<>8D$2LT+7 *1%$!-[N8OU:0PXK6V)6UBX M,RPX( I3(<\J:7/?.5.7H0"'K/)UA4#9_W0F*[)!OP-Q./-,+S$^ UTK4-*)N]A?W-0U6WE>Q"#XF? MH1A*LT 3G&\VPJ1($LS%88K"(9SOV'L\,FUN9.0*90.=AVOA\?,6:9$R=;RH MHRQ(M#;IUO:+^(Z W(ZX0\: -)+<$/#"^B8N-,%MZ>A\7ZFEZ"NBA@D78/) M-K8R\4PD'7'4"57?N[/Q>1.3,UZT>Y!V1UZ5%]XIM]Q7'7- %TTC8F8X?*N?-$O@$H$&A_ MT_MF>D&_Z:KM#II=Q'^OTVCLQ.PD2WT+%_#(<;3&T!\5;_.@ I:A=C@PU80Z*\?'.Z3EX4K&W"?<*6;* ]9G'"_,:EH+ MS'O&8_IL:AE+&1!JXY.Q5W6@-HRX +%I>E2CL6+=@H@_&;\6QPW77KG* .? M!DA'G5<%EZ?M!)$):G*? Z!)&*0O71+L4ZU-EV:BP5X/C/_NAUSXGY%:.U-M M[+36>1Y"DP8[UF0UI>C*Z"@LGXZLC;P#\X$]*$>\T+RSEQOLA)X@21N"_.."H3N>J:0[0 M)RUTZ,S1AL(3(.-0W(8M":D9:O"&(?_D7HLSQ.??R#T&4.A2+Y:![B,1NOYT M,Q6YG#7--N F"\&=B#;<"/J&T;DP5/I:\KU2JG19M1$BU]WR!"$AO3S-P1$2 M;8Z >:&&;[5D@;A0F1PL%C+?=&UN.#4T(%1V@J>WR2%X8,7C(U[AV+%('Z(Q MSE+)O%JFY)^A 8,3 E#$:QH#=JZB78SKZR=R]RU7!>.VZ)<9DA6S$; \_\[M MT7#;]6(H%0:R(6D=!F>:WGUMG EP>'QV/'HU2,*[AF7FY3I4?:\(<!TB!*(6A]T0TJ4C1LXJ6M+P]\O^)3S!I53%,X_9IF?O M3&]#4F%&MH$;>$A($C*/^G(CX# ]:?X'?9O).A.@F-6J"N=M-PT9.7G,R M8%^E;=UV6\.H;N#=9K&*;B@6T9O$1EFBKA!TWQLM=0T]$I6*+@\NQ7@H;GA( M,]\TJUL YG-=N)I4]DI,MA>'R/!"1B/84-<:6E?BE,J;%[#9&]=,+HM7XHPO M; PJQ=Y%C8J?/SGI3B:-G0^;),I*:93)A>N0YI;NJ.< #L3BRQZ06-T7[#"S)VKAO83X6RX=V/B-Q)27W@$'S7L M_WB8(9IAAEBC=J%?1)M_<7$NQH/QZ4A,,R[K'%S7?%RO66SO"*)E09Q8@NG6 M:S-/?A1GKP;GYV,QF0Q.7[T4U\U%!3]\Z"XJNC=/KS#:D3WQZ/CH^'0W$1P^(DIL"$&A!^,J) MW[B] 9 OQ$=C,LZ[G^CRXQ,-W<74S]!Z)W,-"EG$=_@M<%NA(#27 7R%DC.5 M,(FC<(#+V83"P\]2^VUKIE-"D%U?T=[4A%$8?1C1=!*4CT",FOF^#@F?^\!2 M$7MH8M!^(_(-LC[=E83VK']=%%CUY7E>\YNVCYV!_;FNGBZE,Z.;+$@5-J*N M8GES=;!Z>C_'G64"_*:L]QZ^.,!AF?9Q1Y208HCA>(H>AEE(EG,6I%T4!-RE M/P]2N4Y$5RC^86%-729$?%NS?9P2E1#8DCT'Y#1>:LOIAP Y=[O6%SV&+M_] MY+8=5_O;AJ8/H4;0JXOB+:$1>!LK>";(P(,O=O1P7^:+A.8Y3CLX=W3AX[Q: MJF@ZOG5P6!'XYDCI8=[ADO[BNNQ4R$X!FY-SDU MPOEQ\]AV%]N41?.QPJ[Q_Z"[V._:CH ^@M_TF>V(=&H9BCOJ2X_?<:-+,B S MRZWVH)>"B"'N9H]]>RS7U&+!MR3KW,,VYAI VVP45="(+I!FL2]]>83VJQF* M%^.7QW3K/?7$KVG6[\$7_.X#]V_\60;@A/@B']4S*5/[516OZ@!?I^'NSL^C MO>3ON3L;/73]K,%$<&P00_$;7\W41?-\!!BBM*X MD%?ZD_E=(_&=WTLPQE%/OM.QR(UTCE_RI_)?N0 :;56(<=QBT +4 M?WW7+???, )8+>A.*5=S;!T-7YP?".N_"_1_5*;D;_%FI@)\YD>T=(@R6H#W M^ON H3&A(C:5(*@K92 M@8VA"83X& _3'MSDIK%P[& [#>S7[]HI 43I]I+8OO><>ZYCGXP:I>]-@6CA ML132C(/"VNH@#$U:8,G,CJI04B17NF26IGH>FDHCRSRH%&$<1<.P9%P&DY%? MN]23D:JMX!(O-9BZ+)E^.D*AFG'0#YX7KOB\L&XAG(PJ-L=KM+?5I:99V+%D MO$1IN)*@,1\'T_[!T<#E^X2?'!OS:@RNDYE2]VYREHV#R E"@:EU#(Q>"SQ& M(1P1R7A8<@9=20=\/7YF_^9[IUYFS."Q$G<\L\4XV \@PYS5PEZIYCLN^]EU M?*D2QC^A:7-WDP#2VEA5+L&DH.2R?;/'Y3Z\ NQ''P#B)2#VNMM"7N4)LVPR MTJH![;*)S0U\JQY-XKAT'^7::HIRPMG)F;1,SOE,($R-06M&H25:%PS3)<51 M2Q%_0)' N9*V,/!59IB]Q8?; M_8#O5*FLX4( DQF\:QA.N$F%,K5&^#6=&:OII/Q>M0UME61U%7=[#DS%4AP' M=#T,Z@4&D\V-_C Z7-/#H.MAL([]_[[36HK5 B^411C YL9^W.\?KMB=FP(A M5X(N+Y=SL(Q"!BJM%CQ#.OZ6<=I78U3*F<6LUW!;@"7,L2HK)I\\\=ZAH>OW M4'.-&1!.6IYSQP3\I1[S]0YZU^0[64T+*G\?[DV-6Z<3DA;=$>F=:F4,'#.M MGYS(:9K692V<'IB62EO^AWD+N""3>\DJ52TMW/E[ZS(7J,F&X-9@7@L0/$?X MS"4\(=-FJ[2,?'RA.G!=-S$F$5D#%K'S30,$.X@>=:==C"5P91(A$X M&S20NAUHO:);[9QVVAK,2WIKT[3U8$C7;VZ-;IUOK:B565MYN9LF1> M?EC0WP*U2Z!XKNC(+2>N0/?_F?P%4$L#!!0 ( '2$KU;4I0%FL ( $(& M 9 >&PO=V]R:W-H965T5=8YP,6M8B?=H'YJU M)BL<6')>HS1<2=!8S(-E?+4Z=_$^X!?'UNRLP57RJ-23,[[E\R!R@E!@9AT# MH]*/$;Y[;:AY, \BQ8!MA[U3[ M%?MZ+AQ?IH3Q3VB[V#@-(-L8J^H>3 IJ+KLW>^G/80O M.G3R#CJ%6R5M9>"SS#'?QX>D9)"3;.6LDJ.$MTR/(8U'D$1)>H0O'G!C738&#_=#C,P)9E%+'S> #11\"VI*S4CAAR4/%EN2NH.B"]])4D7_?GAPKOI2@=0 M$2#+^-Q5]0 M2P,$% @ =(2O5M*^B[&@ @ \@4 !D !X;"]W;W)K&ULK53+;MLP$+SW*Q9*D9-K2;0MNXEM((\&[2&-D?1QIJ65140D M59*.D[_ODI)5%T@,%.A%XE(SL[,B=^<[;1YMA>C@6=;*+J+*N>8LCFU>H>1V MJ!M4]*741G)'H=G$MC'(BT"2=RBSG>NMJH7!EP&ZEY.;E M$FN]6T1IM-^X%YO*^8UX.6_X!A_0?6]6AJ*X5RF$1&6%5F"P7$07Z=GEV.,# MX(? G3U8@Z]DK?6C#[X4BRCQAK#&W'D%3J\GO,*Z]D)DXU>G&?4I/?%PO5>_ M";53+6MN\4K7/T7AJD4TBZ# DF]K=Z]WG[&K9^+U:$\H?R MX Q]%<1SRQNAN,H1+C8&D7ZV@Q5_X>L:Y[$C>0^*\T[JLI5B;TB-X%8K5UGX MI HL_N;'9*OWQO;>+ME1P5MNAC!*!\ 2-CJB-^IK'06]R?^HM94:O2[E6^7, M-CS'142]8-$\8;0\/4FSY/R(T7%O='Q,_=^,'I5ZW>A7[1 R.#V9L30]AS?3 MP9V"N]SI-9K].; !N KA2LN&JQ<@,!HL0"BG@5.3]1([X2K@0$FEV,IW9<@A MU ;RCDJ$LDLLG(5K8:A1M;$D4\!=68H<*1#*;DT =4H6:!)!RCY(?]F@T;7( M!5K LL30X;UC-FD=#^$;.>92;Y7K?)!C7<)[2 ?):#J8)AED0Y9F\("-0QG( ML_;:P23+!B0"L_%' C/(QME@^G$"KQUS?-"'$LTF3!M+%5/FMB7[W7Z@7;1] M_ ?>3D.Z^QNJ'6HLB9H,IW2I33MAVL#I)G3U6CN:$6%9T5!&XP'TO=1TR%W@ M$_1C?OD;4$L#!!0 ( '2$KU:\57=ORP( "<& 9 >&PO=V]R:W-H M965T(Y/)1(9EH+^:!R1 U/!>-JYN=: MEU=AJ-(<"Z(N18G*M3I8@\UD(\2#-3YE,S^R@I!AJBT#,9]'O$'&+)&1\:OE M]+N0%GBXWK-_<+F;7#9$X8U@WVFF\YD_]B'#+:F8OA/U1VSS&5B^5##E?J%N M?'L]'])*:5&T8*.@H+SYDJ?V'@X X^@%0-("$J>[">14OB.:S*=2U""MMV&S M"Y>J0QMQE-M'66MI3JG!Z?E[(CGE.P47GX52;V"%$FY$49@+6^=$XC34)HKU M#=.6<=DP)B\P]N!6<)TK>,\SS/[&AT9=)S'92UPF)PEOB;R$7AQ $B6]$WR] M+N6>XQN\EK+-U24)/Q8;I:6ID)_'\FWH>L?I;-=+T(CC. MO!8/[G.T&R7ASY 2EE:,:%3 S?R@ M/!4%P@5SR-(@TP:I')+:'DR%S A/T:NISF&QOH%D&,'YV3A)HFOX]VF\M1E# M6<40Q!8(UQ0RRBK;R8"-LPOD(GCWN41LR\]SY>>9XDESSU2/9ZO'EE#BK;5( M'Z F4AI"!:-@/.@'PR2")!X$PT&_=1"EG1L*XF TF 2#R<3)C)-K[UYHPIJ8 M"O I994)!5LIBNY*[,29!,.X'R3Q9$\,QPHB/&C> N7.C2AEKJ[BNNGC;K>; M@HNF^?^X-R/4)+NC1C'#K8%&ER/3 K(92XVA1>E&P49H,UC<,C>3'*5U,.=; M8>J@-6R [K]A_AM02P,$% @ =(2O5M7+:7FR!P M!, !D !X;"]W M;W)K&ULO5A9C]M&$G[GKV@H!\8 5^(AZI@+T(P= M9 */+7B2-1:+/+3(EM0PR6:ZFY+U[U-535+':"8QLM@7B7U4U5=WD==;I;^8 MM1"6?2WRTMSTUM96EX.!2=>BX*:O*E'"R5+I@EM8ZM7 5%KPC(B*?! %P6A0 M<%GV;J]I;ZYOKU5MI10X<_C;B7N0Y,@(8?S0\>YU()#Q\;KG_1+J#+@MNQ+W*/\O,KF]ZDQ[+ MQ)+7N?VDMC^+1I\$^:4J-_3+MNYN!!+3VEA5-,2P+F3I_OG7Q@X'!)/@!8*H M(8@(MQ-$*-]RRV^OM=HRC;>!&SZ0JD0-X&2)3GFR&DXET-G;)ZO2+VN59T*; M'[^;1.'XBKW[HY9V=SVPP!]O#=*&UYWC%;W *V:/JK1KP]Z5F JP,7 MM>#NHE<9/G+=9W'HLRB(XE?XQ9VR,?%+7N#G%&/_G2V,U1 /OY_3T;&(S[/ M'+DT%4_%30^2P B]$;W;'[\+1\'5*P"''<#A:]R_T1NO\CJ/](.R@DT8\0ZO MV,ORW!'[5?/2<$H@P^:U-C4O+;.*V;5@=[4!F<:P>U4L9,GQEC=;:2$@:RV# MG/N86K40FD4)^3#RB0ZN5[S<,6E,+3+:6JHBH*KN3NCRD3VB,*K-VPKM&BQ3V(^#$:!/U[Q<"4^C._$L[@^C<91,P7+' M[G\4>@5X]P[_%39?1M%)]SWP#<\RB?'B/S/I$(#$0_AS_^C$UFGFD-T%0,WK M#"SMT9U[7DG+P=A';'YYX\WR13Z^A&O/\-(FD%VQ;:+*N$ M+J2UF#J8GA#( A$ IM ?0:H%0< >BD)D$DR:[QA?6F"\DAN,2@&!GZ(/O9=2 MF(P'(4]Q/_63<.B/A_$^ S(&S=U8>#B.\K_2O\\^GJL(H! D=]ETZ:VT:^+$ MJTJK#21LP_DLTK,V/XH2QZ:I,DU4OI5\52I(TM10XH(:QF[^+&M\["1F(-)A/(&N-,VV;=V!8 MV>I'X+3 $6YO_V=XZH4!^5Q+E <$0 Y3H"%UI,:X4MH2JX)_$8>>886"2#)U MFH+_EG7N.WE;\ ;NKC&@#3:8(S7!;*JJ@"?6\QV2\!0<@YRZD#M*+WA8\HW2 M'&T#UBW(!!X26FKWI(L6E$,(;P'V9WS#94XD#D4IG9 M)X"L98JY3R?/=]AOV/[\9C&#\!>I))1-7_.]N= TS0, =YL,<[C[1!8^40/* MY#Z?_%8I%\T&.T-*D5]7:+_8CY*1'T_B8Q\]N"+R$9NS!L]';K8#UHAH%A4XBS;2VE'R M[!@2^L$T8D-B]KF5>E"QB#:EU(6'#1UJF7#-,_JA MC1=(AGSWKTSF-?JO:?O'L02Y#=4R\A. %29.UX<2'*ME_O),18P9I+8]02=+ MW*3R8#P, M<;AUZ-QV#NAP88H"8W N5),DZ*QSR*=K/YC%77P@\!$3:>[D4[.(_@L/@;9O9""=ZM*ZCRK=;O=) M:N:^Q.RON^]9H-)* MI<+($TZ(^3GGNC:Q=65?1=9J&L504]K@6'-,<+<+Y4 M,"PV"Q30?:B[_1-02P,$% @ =(2O5M\D/OPW!0 =0L !D !X;"]W M;W)K&ULE5;;;MM&$'W75PR4"VI D"C*M\070([3 MUD"3"'&:("CZL")'TC8DE]E=2E&_OF>6%\F%[*(O$I><.3-G;CN7&V._N16S MIQ]Y5KBK_LK[\O5HY)(5Y\H-33&ZOBS5DN_9_U[. M+$ZC#B75.1=.FX(L+Z[ZT_'KFV.1#P*?-6_,W)ONB4[^ZZI_W*>6%JC+_ MT6Q^Y8;/B> E)G/AES:U;'S6IZ1RWN2-,CS(=5'_JQ]-'/84SJ-'%.)&(0Y^ MUX:"E[?*J^M+:S9D11IH\A"H!FTXIPM)RKVW^*JAYZ_?F&+-UNMYQO3>>'8T M4UN%T^7( UZ$1DD#=5-#Q8] 3>B=*?S*T=LBY?2A_@AN=;[%K6\W\9. [Y0= MTF0\H#B*)T_@33JNDX!W\@C>+<\]W6J79,95ENF/Z=QYB[KX\Q#9&FMR&$MZ MY;4K5<)7?32#8[OF_O7+9^/3Z.()3X\[3X^?0O]_67D2ZK"C@DFOZ.6S\W@\ MOJ!'S=&'@I"%9$7G=18&Y%<,^;Q4Q9:X\&PY)5UX0XH<)Y757D._K*"$9B&U MM,QH8M_[2:S%T<7]3FK62DU;J2 SOCA"%_@5?9W2W1W-W@_H-Y\.!Z0*F%JS M\R)*BZI(T0H%9D=*\RU]1?NO=0:OI^E:.V,=_9*9NFPS7$%*3@/5*H2#FDG T *8RB)F:"VX(':+W*G[1!LUO#.'R M0]W2YR]3E.)GDU5P^4NX,J [!3RJF&:"[HYZNV!+ NY# E(P0B3E/9PPN%=Y MS:B!LR/"#$OE6ZJV5#(^IL/_:-Q0QVG(HC-9^K"BU7Z]]+IZ:;-UJ#J?GPRC MMBP'DMRFG;3'Q9TP[MV4GA\/3W8RH;\5%*-H$$41&:N7N@!HW6(IIG0 ;VO\ MP]WMKJ;OPMQ!.)N@8]EP'F0D"#OWT/F20US\B:VD>E M9)L,1R\"^PW\ ;$$ M^XP+C3T^>8%>,T4/L^;MFFMZM_4M'X@YR27LH) #.UE\'%4%2A@D/^T%&+AKR;P'2O%!>LFE'C MN![;-(Z.PHH2JG&AM$539H&Z:VL17+D>%&VMRUO1;FI=94D5W.L]<%K:)\FJ MM*U!Y(/X>Z4RX8'S C?,/EHS+IO^1Z6@G/X6Q^!^W11HG%:A".;WIU3=[V5S M"TF%81$X&42GYW0\.#T_'KR:Q'3HHAWMK4(YVV58^&0H@4.]%75ONYUR6J]2 M._%Z(47_+"6W&2^@&@W/L%?8>LFK#]Z48;&:&X\U+3RNL!>S%0%\7QBP: YB MH-NTK_\!4$L#!!0 ( '2$KU:IT)!=>@0 *0) 9 >&PO=V]R:W-H M965TB!1Q9DE_JI+:!.$VQ .T0 M)-WVF19/%A&*5$G*CO]]CY2L.%L:#-@'6Q+O[KGG7GCD8J_-@RT1'3Q64MGE MH'2NOAB-;%YBQ6RL:U0D*;2IF*-/LQW9VB#CP:B2HRQ)9J.*"358+<+:K5DM M=..D4'AKP#95Q$O@7M[\@X^DHW6#_[CAB\'B2>$$G/G$1@]=GB%4GH@ MHO&CPQST+KWAZ?L1_4N(G6+9,(M76OXMN"N7@_D .!:LD>Y.[W_'+IZIQ\NU MM.$?]JUN1A[SQCI==<;T70G5/MECEX<3@WGR"X.L,\@"[]918/F9.;9:&+T' MX[4)S;^$4(,UD1/*%^7>&9(*LG.KSVC$COG,P%?!-D(*=UB,'"%[^2CO4-8M M2O8+E#%\T\J5%JX51_[EK9D=8Z>Q7P&S,QC-,A9$DV?@5OW(X^0U]/_,\564ESG^ MH1U"FL"[-_,L33_!2Z[@>XEPI:N:J0.4S%)O.S34N$:SPHB_A3$*W8D]X@*MB(HC$Y<^2Q,+H*M#P58(K3 M),FU\7Q)F\$)B.PS0<$63!@B)!L'O.)CCM:"+H+*B=/@ C2%&R0%%>X8Z%RK,/4:S/#MEN#V\#I-Y@,9^?9U;QQI+P*^Y0 MPICLZ\99H)D/@IZ>)/-P486NU%Q+O3T$Z?.> -TZ?D@\16@1#=5Z[#E>Q$1!/*& M.HAR]T\N$:&,HY3.-L#F]A$L_/X>T3QDY+ M2FI(4SJ;D$(Z:^5H95-X?WWS_0O<4+(0$EH\'T+-#-L:5I=1FGX(63W=]XQ3 MZOS^ (L_&E2A"JRNC6;42KZ/##\6DY:ER$-O^)P'S^1VDH3.I-:A>X!U+&R9 M?T^&&&X;8QNF7-1MGA<\#I\1Q+87J4T\NI\BA@YV&T[F+GPJBA0^^<)Z;,H4 M)X,87AK1HY.3LT*S#?<#CTL;L#U$^]7^"G+9GKQ/ZNW]A;IJ*Y0%B069)O%' M.HM,>R=H/YRNPSF\T8Y.]?!:TC4*C5<@>:$I)]V'=]!?S%8_ 5!+ P04 M" !TA*]6U3X"[FD* E&P &0 'AL+W=O\[-'>WMM:I_K4CU: MX>JBD'9[IW*SN1G-1NV#)[W*/#V8WEY7E?^C>K3X-NVD)+I0I=.F%%:E M-Z/%[./=):WG!?_4:N,&GP5YLC3FA;[\G-R,SLD@E:O8DP2)/VMUK_*; MW/'_8A/6OIV/1%P[;XIF,RPH=!G^RF]-' 8;/IP?V3!O-LS9[J"(K?PDO;R] MMF8C+*V&-/K KO)N&*=+2LJSMWBKL<_?WINBT!Y1]D[(,A'WIO2Z7*DRULI= M3SU4T,)IW(B["^+F1\1=B <(R)SX7"8JV=T_A6F=??/6OKOY28$/TD[$Q6PL MYN?SBQ/R+CI_+UC>V__'7_%)NS@WKK9*_&NQ=-X"-/\^%(6@Y.*P$BJDCZZ2 ML;H9H5*B=E,O/KIPWPV MNQ*GP_9HM;'B2>62*LUENA(F%??2)MH SSX3=P90!F>(9Q775GOL&HNO7^_% MP@N?*1%#/H0ITD![50J^@2YO1%5;5RNQR:07*#6-2E3Y5B@"F-!E1-N]LJ@- MO$C$LG9PT,',^*]:.TT6095:R7C;F@0ERO)NR)?B,9=!<[18D7YR<)&LM3-V M"X/M6L=PQ*60X,K9VLLXP!O$%Q/6:NLJ8P[DALA4U@S M3#C)SA7P!U412K!T,C!X*G6N$@14N4KCO5-K964NU#\3\0>Y*/:P2$VC!<*S-%HO Y@1;Y%):W?Q2S5UA%PTMHAGU24,2#0:"Q/SR31$Z4&I-P0+ %"TN*/?MYZ/N[M3W81/[2FR< MS"A+U2&"9=KNB\B9*D6M'V(E26.Z"8[!GRSI=73$IHI61\P \MICR2'R6*I-Y.A%_9J# 4U : M!%)6%1BFH504JDQT[",\RC6\I8Y;ESH.+3M4RV%W&D)BRW69T!;N&T-O*%&% M!+R()%R-Y8U3H&3;T02KZJ,6#=4 [6U,+T)"*J6D=NI(:A2*4%Z3#TD5=A& M)0\N%5OV-#4Y#AEAVVF,[N,FHGC!]"%%]J2GK",9@2:;I'8)/.[I9(\1,4\" MDWE;#8H@ ;];MI@(3%VDU'G)SC.7P$.U,O@V'K(A$PX%'(0WDN%:8;73JO5RU1*LU5S^Z-P[C: MM"0%Z*]57XI@]1)"4?(H!\R8&DQ(467)4E!8+45*)B (L*M&\&,&"_$ ;<8 MC/<(1=+D\'=(O<,HF^&,^]*F*\RZ3VTO^<*]Y*EI=PO.9.C#8>[>2774SD/$ M*-T$A8?+%MP<_0=92H+H;[$W2W@_?\N3YIQ9ZU"JOI_*!C+'%,=^I.,1-GJ0 M6S&[&#=C)2M4Y0J]-SGE]5G32;O7;?,D>%(8'U[)HKI:4)!IY,:L!G;M1KBF MQK&@S9.O9@9^2';V3]1/Q&$5^K@@(VNVP]:Z4" M.+U/0P'1 C(3EONKF8@93KN=HJ_*TSP[G"'ZU?VZ?H)XI/.-Q,NFM1Y:/1X8 M0D5$H(]6*/6 BK^=HW*J7M#3?T D_@U_"VTM]$Q9OB@[/K2*KE/>V!KHX>E_ MBK??KXJZ04ST@YA$*36S1E4OFS6MZ!WD0.J#M&AO9!*=K)AI>LT%9>+DA"ZM9EQWXVG/Z&L^3@W5_8BM M>R:AO&F"821$W!URGKLZ&XE,Q8^1Z;@[\1&7$NU39&,^^]?-7-D$F5"HG,GK M,,.9D"H0*+R9B$^J($E-;=#'QZX+/1CCF7Z^* 0CE[J@LORE+E7'8;"#F@9" MHM.T&W5[K\85^>/4(1 M[B5*03>!XOG-);11JX=]!(R<[/W^),EBL5KED8L1UM/G^^ M[PC34*JW[7787)A">V* KD_I,ES3=D1/HRJ(OPW!7[Z(C;7-Y)QTMVD\+TC\Z[C-6!Z@\C!] M->8=#M]$/-=+!\:@?51ORIO=Z@_)Z(2[UMWC*:%0_E+#[/G[%F*+>H4Q)YIW M#>Y95;YI#1T.6U9J>@4'IWW6+.HG9NUW#TYKU#Y&J>:RRW>W%4@Q9D.9IBR. MCRP;[5145^'JB*+?QY*)L&/'<[*W%=)/"N&8LJ9;\9#>.)>VZ9 4%3N,BAM& MI97\KAD?(A3C%[6TM;2(5@C.!0OMGX88XMV/%6E_WCE4?+&I<;;"S.5>PFV( MX;F,2+7$) S.8#[#=-82!TX">Y=.JA]H,4B 4AP,X;Z$FFBN.W881NPP1ICB M6G2M]6EMN9?UY@CN MM<$ "FMO]=\55SBHX_R)MB_1MR*D'J>A0W??T\%/%WS+2#_0!!#X\"M&][3[ M#6@1?OKHEXLT[*38>CYY_W84)J/VBS<5_Q"R--Z;@C]F&%^4I05X MGP)0[1=2T/TR=OM?4$L#!!0 ( '2$KU9$JM:JD@( .<% 9 >&PO M=V]R:W-H965T2X_?>C9-?+T#3KQ:+X^/A1-#EME'XP!:*%IU)( M,PL*:ZOS,#19@24S0U6A),M*Z9)9NNIU:"J-+/=!I0B3*)J$)>,R2*=>=Z?3 MJ:JMX!+O-)BZ+)E^GJ-0S2R(@Q?%/5\7UBG"=%JQ-2[0?JON--W"'B7G)4K# ME02-JUEP&9_/Q\[?.WSGV)@M&5PE2Z4>W.4FGP61(X0",^L0&!T;O$(A'!#1 M>.PP@SZE"]R67] _^=JIEB4S>*7$#Y[;8A:[*E[AZV T^B-@*0+2#SO-I%G^9%9EDZU:D [ M;T)S@B_51Q,Y+EU3%E:3E5.<31?UTN!CC=+"]8:^9AI:@G7&,.L@YBU$\@;$ M"&Z5M(6!:YEC_F]\2'1Z3LD+IWFR%_"6Z2&,X@$D43+:@S?J:QQYO./WU@B_ M+I?&:OHC?N\JMT4;[49S4W)N*I;A+* Q,*@W&*1'A_$DNMC#==QS'>]#?U\_ M]D+L)OA%680X@:/#TR2.+^#UFWPM$*Y463'Y#+AAHF86<^!DH7YD1=\0R)0T M2O#X,8KMTNQRH.BS$&MO%BAYBI_G=N;N:&]4BEM!_"3=L>&"X$' MQ&B#VM'Y "=1-(BB"$:3>!"=C6%7@\.MX2M1K_V*,518+6T[A[VVWV*7[?#^ M=6]7(#WTFDL# E<4&@U/Z(_6[5II+U95?I27RM)B\&)!FQBU]NA$ %S$ !D !X;"]W;W)K&ULI5M=<]LXLGWGKT!YI[;LNK(MR;%CQTFJ'"Z#RLWVW='LJ'GQBUZM*WIQ_OYM M*5?J456_EE\M?IVW5#*]4873IA!6+=\=W?)A=T00>\7>MMBYZ%K25A3'? MZ<=#]NYH2ARI7*45D9#X\Z3N59X3)?#Q6R!ZU*Y)$^/GAOJ/O'EL9B&=NC?Y M/W16K=\=71^)3"UEG5>_F.W/*FSHDNBE)G?\K]CZL5?3(Y'6KC*;,!D<;'3A M_\KG((AHPO6A"?,P86QLOBJ M,:]Z_^BU(% \^9)#L?8G64V#"K(RN(;VLE MTO:-RL12%Q*C92YVDS;<1'+5>%<95.W40\%.F9N,MSK% IFWI2W1)$ M$UHKG&2_=V(MGY18*%4(E6NX$+%\)D:T<-EJX7)4"[\Z11OZ!+X0'A1MF7?W MU:I26B\K?/^QE)=6-U:IUBGQ,Z?@P- M$."X8]LE"Y7*VK7VZ-8PLE-$NXU ^ J6C0\8$6WFS$=F<+ C2XLLTM0VT/#6 M;XJ5IY9:E>E*F$6N5])[7\19$DFRX8C84>R;0%-BIU6>88DB)J$AKY2)'6UI([:X0,:-1G MJ"UV+8-MG!LKU&:A,D -FO"D+(-(4P;&6%%DC):5B8CD^6#?Q7J0 N)=+%KZ MY) \+;4\Z+ZSG="T1@"@NILH'MRU[^H+"1ZH@ MQRRA]63A0Y3 P0.3/&FB?@B\D"\(;,CD9/8$ MH2#RFIIBL/T.XK02Y^1FJ8ZN+A"R\"I3-M_%212L5EO*H($&)(=>A'$L[V0(P8XYP!F]2_>P,, MKF$6%'58A[HHZQ 9D.+W1M;%_MCMFC;$7).[="S%6G6IU0OP4JVM4B)'9,_9 M& (-UN9&[DB76(I5%@01$7PC/M-$,1-__L8*/O-D9^$LG-+WC1+OAR M:"SDY)@84,]R R#@(^H2%2#,,@,*@[C#9*JH,C*A" ")!Y6N<\JW9-NOV0R_3[Z6,*D$E.SHNPF&@ ,W36RT^U:Z5[T6[2! X( MK@XLKY4/O]!A MK?'6C?PGGM*<5#D"@!KCRQ+H))*;%X:+*KPACS@.FSYALBB/J79V8H7T&58R MO'S#E'>*C:_L%%5VX@NY/*YV]*; MY(,7!LT9 MU'[QX9L@1,KQ?3"ZG MEY/7KV?1/LA*6P-+O($!@1+Z*BH7EU8\X_5MSU;C?-8Z;6,PHF\PY)&T2>1: M;X_ +I31P&%?Q1..54KBU5!0]R'SS2'UOQB7]&F+CQWSD44 (E8R3[RQ/@RJ M.7P;__CP0LK=\PC,?MW"[->C,#O8DR85/72"'X+9HX2&8?8!ZKTPIDC$78'5 M0%A2USXH:@%3XNN]EGIL-)PP4N #-F:&:9PI9Y>32%5^O9]5MB++N:,,$^+C M75GFB#Y$]J>[NZ]=>>B+>%(MXNQ"+VN;4C6VSV82RB+"RVM".#%[T3:;$+4A MFUTB2IT"?OC0&CG$8$D0ML@1W+35 V (*N6/L@WOSIPJVU:;VB-D,\]E#F6 M)QX#8B=F@[(&4) P,.9R,\/'60#)MC/2XM9!OV6/+4R%1*"DS7T#A=['CT>F3976G*#O(;2R+7X?5PC+92GG@$2/6\D&IMT8_LH8\ A]SWNF$$J MD/X:W% /"S(F[G3!]7-H78P4.U3V$8,D:S#9^E8F1CSIA+V&\XQ[TV.:TI[- MW"1AO@I4+\YQHXZ:+GX[Y#31;K!PA!A0^"&?.%AE5Y\?CD6DSDPM^E[N$6-= M^K(C\>T2Q7[75"FTTCYH9(/*N31&O %J$:C/T^]-_X?>Z:HM7YI9Q'^O%&K, MN2N"NQTDOL:+^6]HG"%"8B>=G+Q]^[*9B]=5T]V CZ-VA_P(79@G%< 6U>N! MJ<;563C>W[%;;D]ES'W"I6RF/*(>,;S0[6HUL.PIC^FSJF6\RP"A&YN,K:I# MW:%)B!J ^F\U*C^6+<=A"1OR3/$*#'R1"E#I(?M][_F:EP<0(@21!5UAKTV7 M(VFZ'(U:'*(=Q0>/\UXB'#\9_Q:G31NA,Y2)#P,DH\ZJ@LG3=,+PA(6Y$ ,2 M)I#4WUT2]%-M31=FHM9HKUH8 1G7+03G:U SR4, MF'K*XICD19_GT]LP<#Z[/?'6@1=^I13!B-K!I=QY)^'H5<)"^!=' P(1N6I* M*U29*QWZ&BCB8:90P)GX&J8D9 /0D;<:X$VE[KU3K0?29" M]Y\?[D0N%TVK F"=-\%UG#9<1OMRV[G0DONUY./+5.FR:MU7;KOA"?Q5^OTT M"T0*[E%Q\XU'.+9Z MDH=HE+-6,J_6*3E/*%_A(4 [\9A&@6>B,17MXJJH?K'OON:JH-RV=F"&9,5L MA$J(WW-Q>;9O>C'."_WV$%&/@S'=/?[:&!.*B=FKT^G-) G?&I:9E_L 2;P@ MQ#T?NB+2B6/?BKZ:7IT$2I,HOFV @I;4ZK4*NG!E2 8;5:VIM__M\!#N?U,< MY8[18M?3=Z:S (SH4( AMZ VB"68"HQ)W0TBXM,/:/T3_#8'*T2(#NRC%@+W M"M(PD2/KDA38%VD+*MQ>*Z\[SVA#;$6G:*OH2V*C*%%7<+K?&REU[1!$416= M#;T1LS/QP"VNY:X9W:)#'XC# ;BRMV*^/SAXAM]DU, .2;>A=2LN*/?Z#39S MXX3..?M6O.)#18,T=G!0(^+QE9-N99+8Y5D31%DHC3 YJQY3U]>=] S @9A; MH]POQ/0GE!%PX*P M8_G>[7TVR^0'\>IFE00T:V3V7AWI#EKXX=/W5G;H$!&:1UH MD!Q:0-P?.N9KCX50'"O.0.V)(.& G, I1E.'!+"T\MG,GU598 UD8@K4M?4] M*DR_F0*+[WS?'JGYY4%S"A&*CJ#(6\\OI9#H=M[MY)^[Y^'T1+ G_ M.FQRH],/W!"):!ZN+TH>=;!U='$Y/;V83L1/OEA('@J4!RNJ/9SX&Y?^*'(+ M\9,Q&:?],6ET5WUFHW=SWG^FX\_/=.PF[KB+/BB2_^!^SQ[AOEP8H(44ZWMS M;PH;'2/XD.K'KLNJSY2]N!6H#] MI:Y>#J4UHT-R["I,!.C$\.94%#0[)SY>7#**BTUG_L+*F+A,BOB_9/HB/\!5TR78-7,1Z4T]ZFL1X2,ZW_WAT+M29@_R&PZ"-3"\>*B,)70Z5H;8O!,>)I[ZNR& MX2C>(RC-'=CV3,[16;+S8JFB@[>]Y:(9T666[IP.<'99YTFNEWVKH,J R#[ M\H!YQH/[@FL+"JJ]N>9NTGE4H<=MG[8OL$]9-+?-ADX6)]VEIJYA$*!YL)L^ MLQV13BRCJ&S67>Z;C=_N>Z2VU.D'[G.1()"[#U[M&RG9]2K=^[CSQ M>SKK].43G.,3MX3'-$D'Y4Q:.Z M6K*SS^XRAB\DDS\6VZLIWXD\L#H=N82<<^BN5:#2NE9[+)*T%]Y$5.%->O7A M_HV[NF@.3;!-41H7HG+_R'3HK'+PIMVX4W6WWF;CU]Y0@ZD7%YLMTA,Q>_!@ M;ISDH:IG?!WQ#^5OI*(0U&JK0CKC5@F),[Y'V9O'D-7X\R:NPW<)5TJ:IU,& MDMWQ6BA4%V1BB+P32EJ%Z1H)H7N@'=<&:>7O8(2R.?.EUY^X!.EO-5"C@CJ? M(1TU[8UAQ9U'=]51V:_X1C[??2PJ?VV]?=O>^K_S=]V[X?Z_#*!\6]'-A%PM M,75Z]AIN:_TM?/^C,B7??%^8JC(;?EPKB5A% _!]:4S5_* %VO\+\?Y?4$L# M!!0 ( '2$KU;^@6RD\@( 'H' 9 >&PO=V]R:W-H965TI19P"&/.5" +PYF J2*ZR'.J MGL? Y6;HA=[NX)XM,V,/_'BPHDN8@?FVFBK<^15*RG(0FDE!%"R&WBCLC]M6 MWRE\9[#1!VMB(YE+^6@WDW3H!980<$B,1:#X6\,U<&Z!D,;O+:97N;2&A^L= M^A<7.\8RIQJN)?_!4I,-O9Y'4EC0@IM[N?D*VW@7;@_1W-M%-Z:7W4!EWBM>CS;27V]H@D,/6P5#6H-7GQZ M$G:"JR-L+RJV%\?0XQEV9EIPL$5;4*;(FO("2 Y4%PJP8XRNHWP4M)[R.SPU M; EL':+&+:-SQIG![/4;8\JI2)QE"HJMJ>T^POE$87>U7C8G6!:3DLAE>1LU.-ZH$UU*L01F4[8PJ24;%$@@3A[P5)!+O M^!_41P$.-D7M:,"KW6YV>IWF91"2LPKB/1& 2%]P;S7;0;O9[88'<1RI>+NJ M>/M_*IXQC$ EV3/AL 9>5_2CN/]4]%?.&G=V4S4AN=FGZ. >D =I*&_<6@LR MJ2WN5G9<.'F5V_VZ+KO^P3S,02W=U-?$]7@Y&JO3ZF$9E?-TKUZ^2A@EWE&- M,2_0-#CO8D)5.>G+C9$K-UWGTN"L=LL,'T=05@'E"RG-;F,=5,]M_!=02P,$ M% @ =(2O5DDHK1V> @ UP4 !D !X;"]W;W)K&ULA51-;]LP#+WG5Q#>,+1 5CMQDA998B!IMZX8.A3]6 _##HI-QT)E M*9/DNMVO'R4G;H:FV<4B)?+Q/<#%^\# M?G"LS98-3LE"J0?G7&33('*$4&!J'0*CY1%/40@'1#1^KS&#MJ1+W+8WZ%^\ M=M*R8 9/E;CGF2VFP4D &>:L$O9:U5]QK6?H\%(EC/]"W<0.XP#2REA5KI.) M0,/2/0+@3 S!JV!@UM&GCF+7D^AMR\_Y>P$NFCR#N=:$?]>,]>'$K-O9XPS?PSI7*:BX$,)G! M:^5GW*1"F4HC_)PMC-7TR_S:=0U-E7AW%==&8[-B*4X#ZA.#^A&#Y,.[WBCZ MM$?#H-4PV(>>W%!;9A615CGP%PG,2]A%=B_<;K)[:W1FQNW3VZ1%^SB=XU6PEZJ4?*092)Z7INW:WG5JSIEE?PIN1 M1W>XY-* P)Q2HZ-C^G%U,T8:QZJ5;]V%LC0(O%G0Y$7M N@\5\IN'%>@G>7) M7U!+ P04 " !TA*]6+N&=I9(" "A!0 &0 'AL+W=O+T[SN[8.I*CJN^P%[FG#F'86:^$_)9%8@:7BM>JX53:-U<>YY* M"ZR8NA0-UG23"UDQ35NY]50CD6465'$O]/V)5[&R=I*Y/5O)9"Y:SS^90M'-\(0HZI-@R,7B]XAYP;(I+QL^=TAI0& M>+C>LW^PWLG+ABF\$_Q;F>EBX4P=R#!G+=>/8O<1>S^QX4L%5_8)NRXVBAQ( M6Z5%U8-)0576W9N]]M_A ##UWP"$/2"TNKM$5N5[IEDREV('TD03FUE8JQ9- MXLK:%&6M)=V6A-/)/9-U66\57'P62KV#%4JX$U5%'VQ=,(EP\<0V'-6[N:I63A::Y$^PXY)280*KMQI'+F3T(WU MF3L)(C<,9GMB.%8![Z!M*I1;.QP4I**M===!P^DP?VZ[MOL3W@TO,KLM23'' MG*#^Y17]<[(;"-U&B\8VX49H:FF[+&B&HC0!=)\+H?<;DV"8RLEO4$L#!!0 M ( '2$KU;,(E&PO=V]R:W-H965T%R[$R\JVG7VI<& M/P5N],X<;"8+*1_MXG,\=I@5A"E&QA(X#<]X@VEJ023CJ68Z34CKN#O?TC^6 MN5,N"Z[Q1J8/(C;)V!DZ$..2%ZFYEYM/6.?3L[Q(IKI\PJ:R#9@#4:&-S&IG M4I")O!KY2WT..P[#0PY^[>"7NJM I)$[D]J/, MC:*W@OQ,.#DQD&J/29R=#WQM MG>'OR4(;187Q9U^.%2+8C["7Y4JO>81CAVZ#1O6,3GAVXO79]1&!W49@]Q@] MG-/EBXL402YAPY7BN:D*F&3OTWJ4ME_KL1"MA[*:,8;),RJZG'"/]H:+?-5Z MJ&PU?"N,-CR/:;,QNWU!%0F-,%,B0KBA,K#G6_"T]44L$,,%N@VGYL#WROU^[WNG *7M )>M#K7++65_F?9"BKU[_>C@=#4"U%R9;O M[^&SP;OE^3!H7_:Z[;[/X++3#Z#;Z?;?O+$^C1C./<;:C#&XJ,*\3UU ^&&- M/Z4 T8!*.B^ G-W>D"&:E5V.@V1+')3M8-FMVFFDZJ'O)E7G9@TK$2N(<4E MN;+.@*Z1JKI;M3!R77:4A334G\II0C\$5-: WB^E--N%#=#\8L*_4$L#!!0 M ( '2$KU:7("*WC@( *L% 9 >&PO=V]R:W-H965TY;I5#2:48[/$E13543NYLC$=N9% MWN'@A:Y*;0^"=%J3%2Y0_ZR?I=D%'4I.*^2*"@X2BYEW%]W,A];>&?RBN%5' M,MA,ED*L[>9;/O-"2P@99MHB$+-L\!X9LT"&QI\]IM>%M(['\@']B\O=Y+(D M"N\%^TUS71MRE-M+66AIM-3X MZ?0!)=T06QGX3LF2,JIW/>P&?B/0AB:X@#N.D!R_I\DTF\_*&(8@"1.T>+^OCVHMVFFM? MB(&I>58.)E?0"J;Z UM]=P6#.\X;PB"G&YHCSV%'D>7P\6P21_'M81T\OM:F M[3 WJ 7"Q0Z)5)<0^:']!B]4K3\5$A$HUVA(:9!$(XS\> +G,/0GUW#^AK$1 MS-R8>YG1>&@,HG&K1YE1A5!+FB%\@-B/0[,D_B@9++3(UIUFY">QTUQ'<.J" M@J,&JE"NW)A0D(F&Z[:7NM-N$MVU#?AFWHXQ4[,5Y0H8%L8U]#^;ERC;T=!N MM*A=.RZ%-LWMQ-),4Y36P.@+(?1A8P-T\SG]"U!+ P04 " !TA*]64=$M MKR@# 6"0 &0 'AL+W=O]Y M'I_/=Y[ON'B4.8 BSV51R865*U6?V[9,)[)*RRDKFS=R-2.9\HPI6P8T@L). MYC5=PQVH^_I&X,CN4#)60B49KXB U<):NN<7KJ<-FA4_&>QDKT_T5AXX?]2# M[]G"6E"KX]2&_?X>_6NS>=S, Y5PR8M?+%/Y MPII9)(,5W13JEN^^0;NA4..EO)#-E^S,VBBR2+J1BI>M,2HH665:^MPZHF<0 M.$<,O-:@<81MB!J55U319"[XC@B]&M%TI]EJ8XWB6*5/Y4X)_,O03B77(-8@ MR'(M -#9BM J([>P!2$!VY363-&"_:&-#T^O0%%62/*#"D&U/\_FMD(9&LQ. M6\H+0^D=H?3)-:]4+LF7*H/L?WL;Y7=[\/9[N/!& :^IF!#?_40\Q_/)_=T5 M.3TY(R?$)C*G F3;C##YG;?\ABE\K[>6(]X:\HR!]X?A]0T\ES5-86'A%9,@ MMF E'S^XD?-Y1'S0B0_&T)-+*G.R3)\V3$!&5H*79B39,;4&+VKP]/7>)H'C MN7-[.Z B[%2$HRJ6$A, \A>,/K "J5\>C*$.7U''WBQTG&'RJ"./1LGO%$\? M,9ED^O@R\GZR;BY3#2+%&,+<-\1O M8.(>OS.)XW"8?=:QS][-+E@*6@/Z0 "ZXG!?AN08W%E/CNM,CH1"W*F)WZN& MEGQ3J2'B^%4@1*'O.K/XR$&XSB'S.6_0FWLK7F:Y-FN,14<+W0\/-YY&TR ^ MHJJ7C]WQ6\K+\J!!&(WCH=HB]L7$H1M, _^(&.\@QGO#12]$HM3O^8 MW- /'?]EP-J]4E7J;*H+LD10?4$L#!!0 ( M '2$KU8_G>S W@( #D( 9 >&PO=V]R:W-H965TF]:$2*NKV,.W!)#>)5<=FMH%NOW[^ M@(R/$$W37DALWW/N.8Y]+\,M%R^R!%#HM:),CKQ2J=6][\NTA K+6[X"IE=R M+BJL]% 4OEP)P)D%5=0/@R#V*TR8EPSMW%PD0[Y6E#"8"R37587%SPE0OAUY M'6\_\42*4ID)/QFN< $+4,^KN= COV;)2 5,$LZ0@'SDC3OWTX&)MP%?"&SE MP3LR3I:W# 4#S- /"'2 \!70O *(=(+)&G3)K:X853H:";Y$PT9K-O-B]L6CM MAC#S%1=*Z%6B<2I9N*^'>(X6I& D)REF"HW3E*^9(JQ 3%#5V^OA[[2&@R3G^[R35R^\$*^"#URIDJ)/K(,LF.\K[77!L*]@4G8 M2OB(Q2V*.N]1&(11@Y[IW\/#%CE1O9^1Y>M=X&O:N&_CI51"']CO3?OE^*)F M/G.)[^4*IS#R]"V5(#;@)>_>=.+@0Y/9_T1V9+U;6^^VL2O*<&(?K M'J2ZZ]R%<3\\D70>=T%27$N*6R5-.=N 4,VJXI9L3D];Q)&>?JVGWZZGQ*P M1!C*,1%H@^D:=,E.N2X0OR S"[J-"&P*L6S2W#]3=-.+!_%=T#F1?AYX0?J@ MEC[XET,(++MP @=GYROJ!;U^_U3I>=RI4O^@"E<@"MN<)++UP-6S>K;N?V-; M]D_F)[HONC;VA\8U55VM]&62B$*N*8/;OCZ*PC4J-U!\96O]DBO=.>QKJ7L[ M"!.@UW/.U7Y@$M3_%I+?4$L#!!0 ( '2$KU9$6XX5400 & D 9 M>&PO=V]R:W-H965TDN>57HA' M&A^$_*XVE&KT(^69FG@;K;?WOJ^2#4V)NA5;FIDS*R%3HLVN7/MJ*RE9%D$I M]Z,@&/HI89DW'1?'9G(Z%CO-649G$JE=FA+Y]P/EXC#Q0N_UP&>VWNC\@#\= M;\F:SJG^LIU)L^?7E"5+:::8R)"DJXGW,;R/HR*@:/&5T8,ZVD;Y5!9"?,]W MGI<3+\A'1#E-=(X@YF]/'RGG.F*[+C^+ Z_TVI"@YR7"*Z*7W2HV@8>2G9*B[0*-B-(65;^DQ]5 M(HX"POZ)@*@*B,X-Z%4!O7,#^E5 _]R 01503-TOYUXD#A--IF,I#DCFK0TM MWRBR7T2;?+$LOU#F6IJSS,3IZ;R\0)!8H3E;9VS%$I)I]#%)Q"[3+%NCF> L M852A=YAJPKA"X7OT*_HRQ^C=S^_'OC:CR%E^4O7X4/88G>CQA=LGPB3Z"OA.WJ# MGK/M3JL;](GN*4BD]KU0H2$84A8# 2SI!G4T@RNZA4#2(D@ M81@2%@/!+(F&M41#6*]PXMH'B]KDN(!S6@Y(6 P$L^08U7*,_K>9H7_0D6I/ M+"-9P@@W[966._-(7 0=B>ER0>=PNMYBD# ,"8N!8):F=[6F=U=UP3M(B2!A M&!(6 \$LB3[4$GV =4$GKH,+7L Y+07M74*CR44) T#$J+H6BV4,UR/70N-;M;FYO7P=LN 3E$ M 5V>0]%L49H%>NA>H9]C;Z"/>>[Q=+[=(&D8E!9#T6QEFV)$V+^N+X*6)4!I M&)060]%LH9K21.A<5E_@BQN_^1+ MW7'GI(/6$*!H=M*;*D+H+B.<8U^PCW602_Y'4!H&I<50-/N=9U./B(+KOO4$ MK4N TC H+8:BV4(U=8G(N9SN[GL5[^V7G^Z..R<=M,8 12N3[A]]G)%_>_-" MY)IE"G&Z,OC@=F3N$EE^SE+N:+$MOM=8"*U%6FQN*%E2F3=_!.0 M^J.BZ;]02P,$% @ =(2O5B_7$+7^ @ M D !D !X;"]W;W)K&ULK59M;]HP$/XK5C9-G;0U;R2T#")1LFK]T D5=?LP M[8-)#F(UL5/;0/?O9SLAY25$;54^@.W<\]P]=^%\PPWC#R(#D.BIR*D869F4 MY<"V19)!@<4Y*X&J)PO&"RS5EB]M47+ J0$5N>TY3F@7F% K&IJS*8^&;"5S M0F'*D5@5!>;_KB!GFY'E6MN#.[+,I#ZPHV&)ES #>5].N=K9#4M*"J"",(HX M+$;6V!W$?6UO#'X1V(B=-=)*YHP]Z,U-.K(<'1#DD$C-@-7/&B:0YYI(A?%8 M#? . ;T3 +\&^"\%]&I SV2F MDF+R$&.)HR%G&\2UM6+3"Y-,@U;R"=5EGTFNGA*%D]&L*C=B"S0C2TH6),%4 MHG&2L!65A"[1E.4D(2#060P2DUR@GYASK,OU&7U%][,8G7W\/+2EBD9SVDGM M^:KR[)WP[*-;1F4FT'>:0KJ/MY6*1HJWE7+E=1+>8GZ.?/<+\AS/;XEG\G*X MUP*/N^$Q)*?@>VK\IC"^X0M.\+55X,]X+B17?Y6_;>FN^/QV/MT^!J+$"8PL MU1\$\#58T:Y+%[T2VE\=>D\=>%WMTIQ@Q3S*$::H:PEHUNE*U M+8G@2;5. 6V9K!A#PZC[YCJZ",,P&-KKW10=6[FN[^P;Q9W!O5%ZT$@/.J6/ MTS5P281^AQ(FI&C36E'T=E3T+H/ /= :'&GU//_RXD!L9SAO%!LV8L-.L1,L M,@2/*[+&N2IOJ];P2.M!N2:=/E[[VH='27MVMZ>QWVCL=VJ\CF\FB%"QXI B M7.C^T":S?URLP%&? ZV=OEZK]9W(JK38._=9 7QIY@*!3$.L[H/FM!D]QN;& M/3B_<@>3:H)XIJGF&=7MERJ3*(>%HG3.^^K=Y=6,4&TD*\VM.6=2W<%FF:FQ M"K@V4,\7C,GM1CMH!K7H/U!+ P04 " !TA*]6+U5BE"(# "A# &0 M 'AL+W=OM[7NBF MF# GZMNQ&Q'U>:8H87 CD,S2%(N74Z!\,7!:SG+@EDRFR@RX47^&)W 'ZGYV M(W3/+5D2D@*3A#,D8#QP3EK'PY9O -;B-X&%K+21D3+B_,ET+I.!XQF/@$*L M# 76MSD,@5+#I/WX6Y ZY9P&6&TOV<^M>"UFA"4,.7T@B9H.G)Z#$ACCC*I; MOKB 0E#'\,6<2ON/%KEMN^V@.).*IP58>Y 2EM_QU2Z6?OI+/T_]1L)K+ Y1T/J.?,\/:OP9-L//("[A?H,[01FVP/)UWN$[ M)XPH.+C26S!!ZS%\O-+VZ%)!*O_4!2\G#^K)SW7[X%SZ1' IZS3G1*$E,LEE'O4\??7=>55,XW1; MBNF48CH;BL%QG*49Q4JO,DZY4.0?-MFG3E_.W:[H.VB'8=A]([#1A2T%AJ7 M<$.!#%2=EG!-2V"N-U+"M14-NE6K%1^[I8_=1A]_,6U_H7]7)-9O"T"/UY". M0-2>HT:J3<_1CLA65/=*U;W/S">]7<9A1V0K<3@JXW"TJWQRM+9'Z_))XW1; MBFEYKR]7[Q,S2D'^84II=F);D94*HK6;K%+PA!^DE>;IMI7CO\KQ&^4\V,K/ M+,\85>G+9'7PWE'\9DM*4=&PO=V]R:W-H965TXWU3;%MQ>*AX&IXEO*?JBD2]MR0,PJBCGMF_P\,SY43M "/'-SC!=RME M5C'."149^7N::1+FL+8,\NJ0>W M2]Z\Z@V#]UTC^$]DSP;2;P?2/\>>3 JID/VB;DMA;^1&0U?#-?P%JXU1!DU1N!=;OJO6VPC-Q^_;"/S6"5.O' M'YI:SUH0RNKLUS4+5"U ;*TBW92J)967?,C:B"L@'F?BTE'@R; MH)7IY#=02P,$% @ =(2O5@J5X1)' @ V@8 !D !X;"]W;W)K&ULK95=;YLP%(;_BL6FJ96VFJ]\+ .D-FC:+C9%C;I= M.W 2K!K,;)-T^_6S#4%I2J)LZDVPX3RO_;[$AVC'Q:,L !1Z*EDE8Z=0JIYA M++,"2B)O> V5?K+FHB1*3\4&RUH R2U4,NR[[AB7A%9.$ME["Y%$O%&,5K 0 M2#9E2<3O.V!\%SN>L[]Q3S>%,C=P$M5D TM0#_5"Z!GN57):0B4IKY" =>S< M>K,T-/6VX >%G3P8(^-DQ?FCF7S-8\QJ].T^F7 M-.#A>*_^V7K77E9$PIRSGS171>Q,'93#FC1,W?/=%^C\C(Q>QIFTOVC7UH:! M@[)&*EYVL-Y!2:OV2IZZ' X +SP!^!W@7PH$'1!<"H0=8*/&K16;0TH422+! M=TB8:JUF!C9,2VO[M#*O?:F$?DHUIY(%45 I-.=22725@B*42?2="$',"[E& M']##,D57;Z\CK/1ZAL)9IWW7:OLGM+\1<8,"[SWR73\8P.?G\12R'O<'\/3R MU8]PK$/JD_+[I'RK-[H@J:$L6CH8ILWIG6]JTJ&T23 +OXR3"V\,\!LI\+W"GS\O2 MLWOY3Z=A[S0\Z_0VRYJR8=IOCDC)A:)_B&EM0Z[#%W8FT]&1Y;.K_>M?X.6" M1_FUEO%!(S%=7Y^A#:TD8K#6H'LST8=#M)VTG2A>V]ZRXDIW*CLL],<'A"G0 MS]>\"7"W=5;(B;56JKRV;9FL(:=RP$LH\,Z2BYPJG(J5+4L!-#6B/+-=Q_'MG++"BD)S M;2:BD&]4Q@J8"2(W>4[%RRUD?#>QAM;KA0>V6BM]P8["DJY@#NJQG FZ8RX)*F/+L#TO5>F)=6B2%)=UDZH'O?D"= MSUC[)3R3YIOLJK5CWR+)1BJ>UV+<0+7 M^ZA@5 M&ADR5BN$04T6C4/ =$7HUNNF!@6G4F#XK]&.?*X%W&>I4])T5M$B MW*P$ #Y.16;TA2XR(&RD#G1; M!7(/!/J5J 'QAA?$=5RW0S[ME]]3T]\Z\)T2K/X1&9["+T&H=?G7B-D MQ8K0!B)^0$!*6*$XP9I&,&Y)F;X@-T(3[^);Q?%-'%WFMM'0\8+ \4-[VT;7 MNY]CT9W(; _=J$$WZD5W9S!)1?!<=A*IY$.GA<09.+X[?(ND-\ZQ2$YDMH=D MW" 9]R*YIVHCF'HAZ0$D_?(YE /B7EZ00_5EVJL_EM2)S/9(^0TI_P/G#EJG MKCQL6.2 M(+NR#=Y%]D=^<#5^&PO=V]R:W-H965T1"NVT2JV&BK8^5'LPR858C>/,=J#[][.=- 4* M42OEH2_$'_<J)9+L96*F5Q;MLB3H%B<<8*R-7.DG&* MI9KRE2T*#C@Q()K9GN.$-L4DMZ*169OQ:,1*F9$<9AR)DE+,_TT@8YNQY5K/ M"W=DE4J]8$>C J]@#O)7,>-J9CR8.Q13ZZ3L>7HC""#6&H*K!YKF$*6:2:5Q]^:U&K.U,#M\3/[=U.\*F:! M!4Q9=D\2F8ZM@8426.(RDW=L\P/J@@+-%[-,F%^TJ6,="\6ED(S68)4!)7GU MQ$^U$%L Q7,8X-4 ;Q_0.P+P:X!O"JTR,V5=8HFC$6<;Q'6T8M,#HXU!JVI( MKJ]Q+KG:)0HGHRO,5@DW67O/64^\5L);S,^0[WY% MGN/Y!_*9OAWNM:3C-R+ZAB\XPG>12Y*0K-2.1'.(2TXD 57N4YR5JF*TY(QJ M68M28N->MD2-\EKR2NN'&T6,KB50\>>0RE46_N$L] M_+@H8?@AG#SL4K".R'8$D>VMWH4"7YF63J"8E;FL&H)FM6D;+TRSM+<^T>VDZ8E>:*I>5/W= MKXBR?09+1>F<]95E>-7>51/)"M,A+9A4_989IJHE!JX#U/Z2,?D\T0W/O Q0J@1_P7PYY7VDB%LJ#T1=U\BL:6HSR"!$*A*(B\[& &2:*8 MI!_?"U*KM*F U?:1_:,.7@:S(!QF-/D21V(]M@86BF!)MHGX3/=_0Q&0K_A" MFG#]C_;YV/[00N&6"YH68.E!&F?YE;P60E0 V+\ P 4 GP'"3$:,[A%3HR6;:FCU-5KJ%6=JHCP+)I_&$B!?7$-@R^%(!?%1@BFL9 M'PGK(,_]@+"#/8-#L^9P;(JG'CZ'L!8>-(>[-6)XY73P-)]_:3JHM-Y-Y9L7 MH1E-Y7+$B7ZA']0L6(%<(@1:'%!UW!,YZ.Z'/6$1^OJ/I$2?!*3\FVEZY/8] MLWVU+-[S#0EA;,EUCP/;@37Y[1>WY_QE2DV;9/,VR8*6R$Z2V"V3V*UCGQ2O M+$>R,'!!LBC.5A_0 E9QELFF*2LY85<3JMJRF_2'?K>'G9&]JPK^?AQV_9[? M/1TV;S8LJ WC1I'\4B2_7B1=0N3T)3M@LB0B> 46QAS0AL4A7*%=;F=0"7;8 MZ7E.Y>>>J?@>X7H=SS\3L=&HH#;*&S7LE1KVKM.0@=J;2)U0*!=I)GR]9QDV2US)0(9,XK?I5- 2V4D&!F4&!C^U MINP;9*C6PK49NH',F*$VG0I:(CO)T+#,T/"&T@CZ:LK&\'U=')CJXOMQQKIH MH#.5V>"'="?!N\[;9M]IK^A=5J6P_,X$,$%/-,S/7%=/@A\RG6E4^ MC-QF4^6HD>EK95J05%-UYVH_SP6HM7;M7K55MJ MME.E\9O2^*=F97T"<).) M-:MWX6KYVV0+VF++Y;%R0[;-1/XA6/:6)ST/^GSCK'_JWL]< M0_];4Y:?U.0W@F[T4<2""D%3W5P# MB8"I ?+YDE)QO%$&RO.RR?]02P,$% @ =(2O5F6%8F" " DV, !D M !X;"]W;W)K&ULM=U=<]JX @;@OZ)AS^RT,ST! MRYB/;L),&TNRSVRVF6:Z>[&S%PJ(Q%-CL[9(VOWUQU_%"(P".V]ZT80$/3+P MQE'\&KA\3K.O^:-2FGQ;Q4E^U7O4>OV^W\_GCVHE\XMTK9+B.\LT6TE=7,P> M^ODZ4W)1#5K%?3H8C/HK&26]V67UM=ML=IEN=!PEZC8C^6:UDMGWCRI.GZ]Z M3N_'%SY'#X^Z_$)_=KF6#^I.Z2_KVZRXU-\JBVBEDCQ*$Y*IY57O@_,^=$?E M@.H:OT?J.=_YG)0WY3Y-OY87PL55;U!ND8K57)>$+#X\J6L5QZ54;,??#=K; MSED.W/W\A\ZK&U_KWJ1'%FHI-['^G#X'JKE!7NG-TSBO M_B?/]76]8L;Y)M?IJAE<7%Y%2?U1?FONB)T!SO#( -H,H/L#O",#W&: NS_ M/3)@V P8GKI)7C/ .W631LV T:D#QLV \:FW8=(,F)QZ&Z;-@&D5A_KQJQY\ M7VHYN\S29Y*5URZT\I,J0=7HXC&/DC+L=SHKOAL5X_3L3J?SKX]IO%!9_O-/ M$^J,?R'L[TVDOY,WOM(RBG/RF\PR66;R+?DO^7+GDS?_>7O9U\7LI=&?-S/Q M>B9Z9":'W*2)?LP)2Q9JT3%>V,>[EO']XE9O;SK]<=,_4BMX([,+,J#O"!U0 MMV-[KNW#/\WU!:%>-9QV#/=?FOT[&8R.CF8G;+M33^YT/1;VX1_6Q7!W<'1V M<<+LKG/TG@M>ONG4/3IY>,+]/J@F=Z:6&+C;GP"W\KQC/P&;^SQ:1,6>_AVY MD[$BZ9)4/Q7DSU^+JY)0JU7^5\=V?JQ=M]LM?TN]S]=RKJYZQ:^A7&5/JC?[ M^2=G-/BE*VQ(S$=B#(EQ)":06(#$0A!F!'JX#?30IL^NT]6J6$;D58:C/-_( M9*ZZ\FMESLTO$O.1&$-B'(D))!8@L;#&AA56KI>?9I1Z@\%E_ZDCF-XVF-X+ MP4R>BF5&N<8M]K'YHRPVY%WSL2N?5NW9(LLH*7Z?1\D#F&&W?LB!,UHY&VZS=O4 MFC?V;1UEU>Z/+*3N#)H5.#=H2,Q'8@R)HU:(YPO0EB71.WGR^^Y*_)7_>J-6]RCH/-=GA M$?7= Y0Y1F9K3ML!QKHS!K*MM/ZVHM;%U)0%LKJ.9#-0;5.%034"V :B%* M,Z/O1/0*0.H%J(T,Z%M >;8&[ 3#JC9A;.C:=^>\E2AZC0I0@=N MYUE6T,UA4(U#-0'5 J@6HC0SMFTOYMB+L7K=FU=GNW2>6_C1#IR=VO%A9S_V MIMYT;U?C=US1<]RAX^X5"M#-XU!-0+4 JH4HSH1U46%'SHXGM#F#:@RJ<:@FH%H U4*4 M9L:X;1+E67=)_'8N7,##=5\J,:@&H=JPNWHXT;EJ\/L/\," M.FV(TLRLMI6<:Z_DS&-INR^;9UU>V-6S(POMZ* :@VHU.CH7VM%!-1^J,:C&H9J :@%4"U&:&>V=%W:T=W0'RXOB[T$5/1U96T![ M.JCF0S4&U3A4$XVV>PAC-)FX[F"TO[: ]G0HS0QJV].Y]IXNO/UD7T1 VSFH MYD,U!M4X5!-0+8!J(4HS ]RV<^YKM7,NM)V#:CY48U"-0S4!U0*H%J(T,]IM M.^?:V[F#1<3QYQC9I;.S#.WHH!J#:ARJ"?>PHYO2B3=V]E<0T)(.I=4I[>^\ MH/]*90_5NT'D9%[V;_5K^V^_NGW'B0_5^RSTVZO7;U=Q([.'*,E)K);%T,'% MN/AQRNIW@*@OZ'1=O3W ?:IUNJH^?51RH;+R"L7WEVFJ?UPH)]B^#\?L_U!+ M P04 " !TA*]6\P?[J^@$ #S"P &0 'AL+W=OI=2\&TTDI5GS/]D.YT%@-&I1$YEP8J0K2 MO+SISH8O;\=NO]_P4?+&'#V38Q(I]<4M[I*;;N "XHQCZQ $_M9\RUGF@!#& M7SO,;N/2&1X_[]%_]-S!)1*&;U7V228VO>E>=RGAI:@R^UYM?N8='Q]@K#+C M?VE3[QU?=2FNC%7YSA@1Y+*H_\7771Z.#*Z#1PS"G4'XC<'P\A&#TJLL&UJ( MK7"K\SE;(3-#;X76PB7[@GZ@#_=S.C^[F PLG#N(0;QS]+IV%#[BZ%>A^Q1< M]R@,PE&+^>V_,!\-V\P'H-SP#AO>H<<;/X(WY\C27)HX4Z;23+_/(F,U1/5' M&[4::]2.Y1KMI2E%S#===))AO>;N]-F3X57PJHWH_P3V@/:HH3TZA3Y=5#I. MH7H2JY5F=*.%YDVL9>F:JHWZ:3R;,MVJO!3%E@#&FA.2A54DR'!<:6DE)%4> MO&KV7COGSYYB0*N MUFRLI[&LB@2-46#T)!1MZ3.FQUIF$/(L64NCM*&?,A6)#.8+VKMO=NU==0## MFC:IC%,Z9N=#3PC4,(,R. =18RIV;PZ^XJ-V2CA"8!"7:=P==]N\^=S0E!AK MM-+*F(ZOSTI8IE++(I:E@,]<56"JEE25SNW9<-@/,12RS W$)J-5U!249MYD M[Z!/OWE&;4&0T _#=V7LF%2X;W 9JSP'( 92_,6M'^0&R7#FIHK^Q'AVL:V% MEJHR#M'*8L6@ )R(\4P&T\0L);(I#+*)VBF-^H*] VU11*=11,V@\(/JVX"% M)1>,Q2$#(*VJ55U!S'H'N*4$Z>S5I>TY;RQ0XQCX6(%CP;1EH6FI5>X,.VZ_ MH^KJ+(J8:^>U2W^*H30Q6*<"@HA*B8%@[=7'0.R78%N/<%2, (F73O$83"L7Q"F6.*^)6)+)>-CTJ=W!6& @NUN_O8>E,_K./%5-"I+'BI:'.NET^AE M7ZTV=9Z-^\%>ECU7W%T[28MS/V:<) F=7?;'ASV^OP4,@Z 7! $I+5>R &C= M8@GFM ??:_S=W?R@::([/WF0T%W:<5LQ%G1<&@X!HO==%7%SB'7E] .]D-[5 M.'CJ^6\0$:C%N! 9W]K#\5-TFRHZF#9OUEP3G-?7!$_-N&K"#Z3L^;F;DZ&J M@(@Y:1O_)P?J?QS_E\WXOSPYKH];OVZBLC[MVR;_2:CO/?1JL"L/YFZ6Z^EH M. ZNKB>#=0N?<<-G?)*//\4;=11LVWB'N-_\+B\NKY\,0J_(3(XNI*Y MZS#:;^6$D?$2ED'_.8!T?<6L%U:5_I86*8L[GW],<2MG[3;@^U*A7KN%N_@U M]_SIWU!+ P04 " !TA*]6]H,IK*L" !U" &0 'AL+W=OW0-EF9GG6\XU'LBRDON$D<8V7\ 3R1_W 5<\97#)20B4(JQ"'?&;= M>-?S2->W!3\);,2HC33)@K&5[GS-9I:K P&%5&H'K"X-S(%2;:1B_.X]K6%( M+1RWG]WO6W;%LL "YHS^(IDL9E9DH0QRO*;RD6V^0,\3:K^44='^HDU7.YE8 M*%T+RK!*4I.JN>-O/PTC@'1/XOZPQ$G,V09Q7:W< M=*.=FU:M:$BEW^*3Y.HI43J9W $G#=93B;X1O""4R!TZNP.)"17GZ *]1PX2 M!>8@8D>J ;7,27OSV\[3"?$_F>T!!P-P<,H]N:FJ M-:8H(PW)H,K0C@#-3,0G;QTXR#&\M"/QK*]G).AYS3U\UWPZA:3\?646?B>:/1/7MZ&-%<-3$G MO!P27OXE(?"4"$ U)ZEQ CM]-!HUL,/@(-O+(M_VS*S( M$.O*.XCULBBT@\-RVDV7I!*(0JYDKGVI_AN\.^2ZCF1U>TXLF%2G M3MLLU',R>>./GJ&+XWD#U!+ P04 " !TA*]68\9$J1D" "8 M! &0 'AL+W=ONW?G.Z6M M-B^V D"RKZ6R650A-C>4VJ*"FMN1;D"YF[4V-4=GF@VUC0%>!E M*8OC*:VY M4%&>AK.%R5.]12D4+ RQV[KFYG4&4K=9-(X.!T]B4Z$_H'G:\ TL 9^;A7$6 M'5A*48.R0BMB8)U%M^.;V<3[!X>? EI[M"<^DY76+]YX*+,H]H) 0H&>@;ME M!W<@I2=R,G[WG-$0T@./]P?V;R%WE\N*6[C3\IP]] M/E>>K]#2AB]I.]^)BUAL+>JZ!SN[%JI;^;ZOPQ& L3< K >PH+L+%%3..?(\ M-;HEQGL[-K\)J0:T$R>4_RE+-.Y6.!SF5[.R<7[RS.\R5"")/!>_4<)3J7;L22G6?SPW-B&%Y!%;CHLF!U$ M^8=WXVG\Y8S&R:!QF^ET75RV%;NZ0#C'=S]6FL\&#[ \!CE?P!02P,$% @ =(2O5A8P MN5N) @ +P< !D !X;"]W;W)K&ULK55=;YLP M%/TK%INF5MH*@82N'4%JDU;;0Z>J4;>':0\.W 14?U#;D.[?[]H0EG8TZJ;F M ?QQS[GG7(?K9"/5G2X #'G@3.BI5QA3G?J^S@K@5!_)"@3NK*3BU.!4K7U= M*:"Y W'FAT$0^YR6PDL3MW:MTD36AI4"KA71->=4_3H')C=3;^1M%V[*=6'L M@I\F%5W# LQM=:UPYO_L MY$L^]0(K"!ADQC)0?#4P \8L$/Y+"B-3,W:KBO01ART>!3DX,Y&%HR3;Y2I:@M\B'Y0&X7V'SR'K MX>$>.5%?P,CQ1<_PS:1H0!G(228YQS\F'EEV1QK*:ABJ5LL6.S;[B37I29SX MS:Z!@9!)'_)(Y+@7.7Z)R'+)@,Q:F0LG\\<5\"6HGT-*]U+:[G*J*YK!U,/V MH4$UX*7OWHSBX-/0H;P2V2/WD][]Y%6/:/)7_8\#^WMR3'N3_J>EN+<4O\"2 M:Z5RU?G1!<5$0X9:KO&.H2@>!2?C)X;VIOQ70_Y.3^*@UJY5:SR!6IBV/?6K M_6UPYIJ@_R>\O4KPBU^70A,&*X0&1\=8>=6VYW9B9.4ZW%(:[)=N6."-!LH& MX/Y*2K.=V 3]'9G^!E!+ P04 " !TA*]68R:ONCD# R$P #0 'AL M+W-T>6QEU MY-B9X["67S_?.$T_\(6.AZU,2U5B^_B<>VQ?RZ:#TBP%NYDS9H)%+F0Y)'-C MB@]A6$[G+*?EF2J8M$BF=$Z-K>I96!::T;0$4B["7J<3ASGEDHP&LLJOQ(XN;%*V9#=N]/+W?:3 M&C@EH5?T? _1LPX\J+2#L0#Q?@&>4L>D+[:E5]V/K5;+/<;(?3]YFXW3$P]] M376TL%G7T2!3O8+H+[.VFZ[P"K&ACD0K0&>\0UC 8%-89I>64K M=>>Z\1$4-.7;96$=SC1==GOG9$VH7S;(1.F4Z39,EZR:1@/!,K"C^6P.;Z.* M$$!C5&X+*:F4^5'8ZLZY#?[%JSC"_J^B)K#6#J75R=%H58?A1\)G/F M!K]WP-& KGC!7&G^8*-!JDQM ],DN&?:\.EFRT]-BUNV,*MT6F2XY]Y_S\]X MGC')-!6;IFWN[^$XNOA;ENL]NFOXN5G]L]G[XEEM#MG#GM;FT#YTD_%K,/D* M=E%S53ETD\E!F@R; WSCEK!U1VA; [B+#JW+7V!XW;B]"-I8 M7*9LP=)Q4]6S25T,;,%&;1X@[")7]>-',([#_ A@6!S, <9Q+"S.OS2>/CH> MAV'>^EZDCW+Z*,>Q?,BX_F!Q_)S$/OZ1)DD4Q3$VH^.QU\$8F[*NQS M $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/ M:(7->=I3W;+T]!;X"O M.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_ M'KK56 [\@#62&2V$K7<4/#O?ZN=T5R9%KON$%-P^3 MJ/Y=0$1*+GC)'R&?1,.(Z+V\_RH5?Y3"L"+-E"R*210W#3] &9Z]J$X=Y"W; MZ+K&L,UW9D$FT7AH+[CE2IOZC/KZS#(>P9[H^^%T;#KQ4OU/-\KMEFW[0$1&LA$DTDT=0 M[GGL#:[SYMF,A?)Z2EURVZ"N\QHO(,K-:KY8I8LYL;_2F^7U?'IK"Y^FR^EJ MMB >)$4@:8^0/ZD'F2"022^0Z:T]?%NL/,@1 CGJ$;+5D^<(Y'F?D(D'.48@ MQWU"CCS(]PCD^SXASSW(#PCDA["0-VK'!'^L&P@3.?G$--=$;LE:@08/\@*! MO @+^0W4#A29[A2 .[4&_0YV']=@C_YF/L1V\V%8S+0J2Z8>7.>E?">X_1NS ML-,LDY4PW,=$I1/8.M=6^&+G;DJF6EO;^F"8:.+ IEG;^]K^FDG=9L*\$@<6 MRV<7,I4U8[T\^)OJ2K*]DIF'V,3'[)'VF-*UH M(\'\D[QB2O/F29)=*P@34!)80-TJ?YJB/B8FH"3TR[)_Y6 OIR8FH"2P@+IC MCJXQQ_R3!/8/2MD:\Q'FGU'PY.>OK.R?F_L(<]"H^8AT^G*4PY8+R%?V%MK6 M9ZS(UHJX0_.":W3N4M%M510S6W&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/- MV4V.@D 0AN&K& Y@6U7X-U%7LW$[\0)$6S&"$+HGH[PS,H8VP_GPK;T=1&&3>O/MS/[IJN+>%MV M!]<6VU-Q\$Y'HXGK7F=DJ\7KS,'FVOK_3&SV^^/6?S;;[]J?XQ^#W4_3G4+I M?0J"WHMY*H+>BWDJ@M_9> MM@GT5M1;"?16U%L)]%;46PGT5M1;"?16U%L)]%;46PGT5M1;"?0VU-L(]#;4 MVPCT-M3;"/2VWL<2 KT-]38"O0WU-@*]#?4V KT-]38"O0WU-@*]#?4V KUS MU#LGT#M'O?-WZAWBM?+AV?-8X_W?276\7>N?M[\O'YN]AW#'V<$OC=4O4$L# M!!0 ( '2$KU:(C*DWI0$ "\9 3 6T-O;G1E;G1?5'EP97-=+GAM M;,V9S6Z#,!"$7P5QC8)C.TU_E.32]MKFT!=P80DH@"W;29.WKR$_4JL4-4JE MS@4+O#LS>*7O -.WG2$7;>NJ<;.X\-X\,.;2@FKE$FVH"3NYMK7RX=8NF5'I M2BV)B=%HPE+=>&K\T+<:\7SZ1+E:5SYZWH;'KM3-++94N3AZW!>V7K-8&5.5 MJ?)AGVV:[)O+\."0A,ZNQA6E<8-0$+.S#NW.SP:'OM<-65MF%"V4]2^J#E5L M6S'G=Q6YI%_B3$:=YV5*F4[7=6A)G+&D,E<0^;I*]J*#?FH?C_=!VUM M5W_]";]=DUJ5S=&?=?])YI]02P$"% ,4 " !TA*]6!T%-8H$ "Q M$ @ $ 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( M '2$KU:+*K5O[P "L" 1 " :\ !D;V-0&UL4$L! A0#% @ =(2O5JO# M8V1_!@ ^"0 !@ ("!#@@ 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0#% @ =(2O5ITS&PO=V]R:W-H965T&UL4$L! M A0#% @ =(2O5BJQ*0;B!@ %2, !@ ("!=R0 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ =(2O5B&2 MD5G% P 8P@ !D ("!5#4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ =(2O5M2E 6:P @ 0@8 !D M ("!7TP 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ =(2O5M7+:7FR!P M!, !D ("! M'U4 'AL+W=O&PO=V]R:W-H965T@0 *0) 9 M " @79B !X;"]W;W)K&UL4$L! A0#% M @ =(2O5M4^ NYI"@ )1L !D ("!)V< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ =(2O5OZ!;*3R M @ >@< !D ("!:(4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ =(2O5LPB5SC& @ ;@8 !D M ("!+XX 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ =(2O5C^=[,#> @ .0@ !D ("!4)< M 'AL+W=O&PO=V]R:W-H965TV> !X;"]W;W)K&UL4$L! A0#% @ M=(2O5B]58I0B P H0P !D ("!(J( 'AL+W=O$21P( -H& 9 " @1&H !X;"]W M;W)K&UL4$L! A0#% @ =(2O5ND&PO=V]R:W-H965TP !X;"]W;W)K&UL4$L! A0#% @ =(2O5F6%8F" " DV, !D M ("!'[4 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ =(2O5F/&1*D9 @ F 0 !D ("!U\4 'AL M+W=O&PO=V]R:W-H965T?* !X;"]S='EL97,N>&UL4$L! A0#% @ =(2O5I>*NQS $P( M L ( !2\X %]R96QS+RYR96QS4$L! A0#% @ =(2O M5HOF.[VP P R!L \ ( !-,\ 'AL+W=O7!E&UL4$L%!@ Q #$ 3@T ++6 $! end XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 71 190 1 false 21 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://cardiodiagnosticsinc.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) Sheet http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) Sheet http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 7 false false R8.htm 00000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical) Sheet http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical) Statements 8 false false R9.htm 00000009 - Disclosure - Organization and Basis of Presentation Sheet http://cardiodiagnosticsinc.com/role/OrganizationAndBasisOfPresentation Organization and Basis of Presentation Notes 9 false false R10.htm 00000010 - Disclosure - Merger Agreement and Reverse Recapitalization Sheet http://cardiodiagnosticsinc.com/role/MergerAgreementAndReverseRecapitalization Merger Agreement and Reverse Recapitalization Notes 10 false false R11.htm 00000011 - Disclosure - Summary of Significant Accounting Policies Sheet http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 00000012 - Disclosure - Intangible Assets Sheet http://cardiodiagnosticsinc.com/role/IntangibleAssets Intangible Assets Notes 12 false false R13.htm 00000013 - Disclosure - Patent Costs Sheet http://cardiodiagnosticsinc.com/role/PatentCosts Patent Costs Notes 13 false false R14.htm 00000014 - Disclosure - Finance Agreement Payable Sheet http://cardiodiagnosticsinc.com/role/FinanceAgreementPayable Finance Agreement Payable Notes 14 false false R15.htm 00000015 - Disclosure - Earnings (Loss) Per Common Share Sheet http://cardiodiagnosticsinc.com/role/EarningsLossPerCommonShare Earnings (Loss) Per Common Share Notes 15 false false R16.htm 00000016 - Disclosure - Stockholders??? Equity Sheet http://cardiodiagnosticsinc.com/role/StockholdersEquity Stockholders??? Equity Notes 16 false false R17.htm 00000017 - Disclosure - Convertible Notes Payable Notes http://cardiodiagnosticsinc.com/role/ConvertibleNotesPayable Convertible Notes Payable Notes 17 false false R18.htm 00000018 - Disclosure - Derivative Liability Sheet http://cardiodiagnosticsinc.com/role/DerivativeLiability Derivative Liability Notes 18 false false R19.htm 00000019 - Disclosure - Commitments and Contingencies Sheet http://cardiodiagnosticsinc.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 19 false false R20.htm 00000020 - Disclosure - Subsequent Events Sheet http://cardiodiagnosticsinc.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - Intangible Assets (Tables) Sheet http://cardiodiagnosticsinc.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://cardiodiagnosticsinc.com/role/IntangibleAssets 23 false false R24.htm 00000024 - Disclosure - Earnings (Loss) Per Common Share (Tables) Sheet http://cardiodiagnosticsinc.com/role/EarningsLossPerCommonShareTables Earnings (Loss) Per Common Share (Tables) Tables http://cardiodiagnosticsinc.com/role/EarningsLossPerCommonShare 24 false false R25.htm 00000025 - Disclosure - Stockholders??? Equity (Tables) Sheet http://cardiodiagnosticsinc.com/role/StockholdersEquityTables Stockholders??? Equity (Tables) Tables http://cardiodiagnosticsinc.com/role/StockholdersEquity 25 false false R26.htm 00000026 - Disclosure - Derivative Liability (Tables) Sheet http://cardiodiagnosticsinc.com/role/DerivativeLiabilityTables Derivative Liability (Tables) Tables http://cardiodiagnosticsinc.com/role/DerivativeLiability 26 false false R27.htm 00000027 - Disclosure - Merger Agreement and Reverse Recapitalization (Details Narrative) Sheet http://cardiodiagnosticsinc.com/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative Merger Agreement and Reverse Recapitalization (Details Narrative) Details http://cardiodiagnosticsinc.com/role/MergerAgreementAndReverseRecapitalization 27 false false R28.htm 00000028 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesTables 28 false false R29.htm 00000029 - Disclosure - Summary of Significant Accounting Policies (Details 1) Sheet http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails1 Summary of Significant Accounting Policies (Details 1) Details http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesTables 29 false false R30.htm 00000030 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesTables 30 false false R31.htm 00000031 - Disclosure - Intangible Assets (Details) Sheet http://cardiodiagnosticsinc.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://cardiodiagnosticsinc.com/role/IntangibleAssetsTables 31 false false R32.htm 00000032 - Disclosure - Intangible Assets (Details Narrative) Sheet http://cardiodiagnosticsinc.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://cardiodiagnosticsinc.com/role/IntangibleAssetsTables 32 false false R33.htm 00000033 - Disclosure - Patent Costs (Details Narrative) Sheet http://cardiodiagnosticsinc.com/role/PatentCostsDetailsNarrative Patent Costs (Details Narrative) Details http://cardiodiagnosticsinc.com/role/PatentCosts 33 false false R34.htm 00000034 - Disclosure - Finance Agreement Payable (Details Narrative) Sheet http://cardiodiagnosticsinc.com/role/FinanceAgreementPayableDetailsNarrative Finance Agreement Payable (Details Narrative) Details http://cardiodiagnosticsinc.com/role/FinanceAgreementPayable 34 false false R35.htm 00000035 - Disclosure - Earnings (Loss) Per Common Share (Details) Sheet http://cardiodiagnosticsinc.com/role/EarningsLossPerCommonShareDetails Earnings (Loss) Per Common Share (Details) Details http://cardiodiagnosticsinc.com/role/EarningsLossPerCommonShareTables 35 false false R36.htm 00000036 - Disclosure - Stockholders' Equity (Details) Sheet http://cardiodiagnosticsinc.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details 36 false false R37.htm 00000037 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://cardiodiagnosticsinc.com/role/StockholdersEquityTables 37 false false R38.htm 00000038 - Disclosure - Convertible Notes Payable (Details Narrative) Notes http://cardiodiagnosticsinc.com/role/ConvertibleNotesPayableDetailsNarrative Convertible Notes Payable (Details Narrative) Details http://cardiodiagnosticsinc.com/role/ConvertibleNotesPayable 38 false false R39.htm 00000039 - Disclosure - Derivative Liability (Details) Sheet http://cardiodiagnosticsinc.com/role/DerivativeLiabilityDetails Derivative Liability (Details) Details http://cardiodiagnosticsinc.com/role/DerivativeLiabilityTables 39 false false R40.htm 00000040 - Disclosure - Derivative Liability (Details Narrative) Sheet http://cardiodiagnosticsinc.com/role/DerivativeLiabilityDetailsNarrative Derivative Liability (Details Narrative) Details http://cardiodiagnosticsinc.com/role/DerivativeLiabilityTables 40 false false R41.htm 00000041 - Disclosure - Subsequent Events (Details Narrative) Sheet http://cardiodiagnosticsinc.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://cardiodiagnosticsinc.com/role/SubsequentEvents 41 false false All Reports Book All Reports cdio_10q.htm cdio-20230331.xsd cdio-20230331_cal.xml cdio-20230331_def.xml cdio-20230331_lab.xml cdio-20230331_pre.xml ex31x1.htm ex31x2.htm ex32x2.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 58 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cdio_10q.htm": { "axisCustom": 0, "axisStandard": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 262, "http://xbrl.sec.gov/dei/2022": 34 }, "contextCount": 71, "dts": { "calculationLink": { "local": [ "cdio-20230331_cal.xml" ] }, "definitionLink": { "local": [ "cdio-20230331_def.xml" ] }, "inline": { "local": [ "cdio_10q.htm" ] }, "labelLink": { "local": [ "cdio-20230331_lab.xml" ] }, "presentationLink": { "local": [ "cdio-20230331_pre.xml" ] }, "schema": { "local": [ "cdio-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 307, "entityCount": 1, "hidden": { "http://cardiodiagnosticsinc.com/20230331": 9, "http://fasb.org/us-gaap/2022": 14, "http://xbrl.sec.gov/dei/2022": 5, "total": 28 }, "keyCustom": 34, "keyStandard": 156, "memberCustom": 9, "memberStandard": 12, "nsprefix": "CDIO", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://cardiodiagnosticsinc.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "CDIO:MergerAgreementAndReverseRecapitalizationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Merger Agreement and Reverse Recapitalization", "menuCat": "Notes", "order": "10", "role": "http://cardiodiagnosticsinc.com/role/MergerAgreementAndReverseRecapitalization", "shortName": "Merger Agreement and Reverse Recapitalization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "CDIO:MergerAgreementAndReverseRecapitalizationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "11", "role": "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Intangible Assets", "menuCat": "Notes", "order": "12", "role": "http://cardiodiagnosticsinc.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "CDIO:PatentCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Patent Costs", "menuCat": "Notes", "order": "13", "role": "http://cardiodiagnosticsinc.com/role/PatentCosts", "shortName": "Patent Costs", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "CDIO:PatentCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "CDIO:FinanceAgreementPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Finance Agreement Payable", "menuCat": "Notes", "order": "14", "role": "http://cardiodiagnosticsinc.com/role/FinanceAgreementPayable", "shortName": "Finance Agreement Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "CDIO:FinanceAgreementPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Earnings (Loss) Per Common Share", "menuCat": "Notes", "order": "15", "role": "http://cardiodiagnosticsinc.com/role/EarningsLossPerCommonShare", "shortName": "Earnings (Loss) Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Stockholders\u2019 Equity", "menuCat": "Notes", "order": "16", "role": "http://cardiodiagnosticsinc.com/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Convertible Notes Payable", "menuCat": "Notes", "order": "17", "role": "http://cardiodiagnosticsinc.com/role/ConvertibleNotesPayable", "shortName": "Convertible Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Derivative Liability", "menuCat": "Notes", "order": "18", "role": "http://cardiodiagnosticsinc.com/role/DerivativeLiability", "shortName": "Derivative Liability", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "19", "role": "http://cardiodiagnosticsinc.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "20", "role": "http://cardiodiagnosticsinc.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "21", "role": "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "CDIO:FairValueOptionQuantitativeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "22", "role": "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "CDIO:FairValueOptionQuantitativeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Intangible Assets (Tables)", "menuCat": "Tables", "order": "23", "role": "http://cardiodiagnosticsinc.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Earnings (Loss) Per Common Share (Tables)", "menuCat": "Tables", "order": "24", "role": "http://cardiodiagnosticsinc.com/role/EarningsLossPerCommonShareTables", "shortName": "Earnings (Loss) Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "CDIO:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Stockholders\u2019 Equity (Tables)", "menuCat": "Tables", "order": "25", "role": "http://cardiodiagnosticsinc.com/role/StockholdersEquityTables", "shortName": "Stockholders\u2019 Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "CDIO:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Derivative Liability (Tables)", "menuCat": "Tables", "order": "26", "role": "http://cardiodiagnosticsinc.com/role/DerivativeLiabilityTables", "shortName": "Derivative Liability (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "p", "CDIO:MergerAgreementAndReverseRecapitalizationTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAcquiredFromAcquisition", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Merger Agreement and Reverse Recapitalization (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://cardiodiagnosticsinc.com/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative", "shortName": "Merger Agreement and Reverse Recapitalization (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "CDIO:MergerAgreementAndReverseRecapitalizationTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAcquiredFromAcquisition", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "CDIO:FairValueOptionQuantitativeTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Summary of Significant Accounting Policies (Details)", "menuCat": "Details", "order": "28", "role": "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "CDIO:FairValueOptionQuantitativeTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "CDIO:DerivativeLiabilitiesIssued", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "CDIO:FairValueOptionQuantitativeTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Summary of Significant Accounting Policies (Details 1)", "menuCat": "Details", "order": "29", "role": "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails1", "shortName": "Summary of Significant Accounting Policies (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2023-03-31_us-gaap_FairValueInputsLevel3Member", "decimals": "0", "lang": null, "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Intangible Assets (Details)", "menuCat": "Details", "order": "31", "role": "http://cardiodiagnosticsinc.com/role/IntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Intangible Assets (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://cardiodiagnosticsinc.com/role/IntangibleAssetsDetailsNarrative", "shortName": "Intangible Assets (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherIntangibleAssetsNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Patent Costs (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://cardiodiagnosticsinc.com/role/PatentCostsDetailsNarrative", "shortName": "Patent Costs (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "CDIO:PatentCostsTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:AccumulatedAmortizationOfOtherDeferredCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "CDIO:FinanceAgreementPayableTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2022-10-302022-10-31", "decimals": "0", "first": true, "lang": null, "name": "CDIO:FinancingAgreementEnteredIntoForPrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Finance Agreement Payable (Details Narrative)", "menuCat": "Details", "order": "34", "role": "http://cardiodiagnosticsinc.com/role/FinanceAgreementPayableDetailsNarrative", "shortName": "Finance Agreement Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "CDIO:FinanceAgreementPayableTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2022-10-302022-10-31", "decimals": "0", "first": true, "lang": null, "name": "CDIO:FinancingAgreementEnteredIntoForPrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Earnings (Loss) Per Common Share (Details)", "menuCat": "Details", "order": "35", "role": "http://cardiodiagnosticsinc.com/role/EarningsLossPerCommonShareDetails", "shortName": "Earnings (Loss) Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "CDIO:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Stockholders' Equity (Details)", "menuCat": "Details", "order": "36", "role": "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "CDIO:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-012023-03-31_us-gaap_WarrantMember", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2019-10-01", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "menuCat": "Details", "order": "37", "role": "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2019-10-01", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-03-012023-03-08", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantPurchaseCommitmentDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Convertible Notes Payable (Details Narrative)", "menuCat": "Details", "order": "38", "role": "http://cardiodiagnosticsinc.com/role/ConvertibleNotesPayableDetailsNarrative", "shortName": "Convertible Notes Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-03-012023-03-08", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantPurchaseCommitmentDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-03-302023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Derivative Liability (Details)", "menuCat": "Details", "order": "39", "role": "http://cardiodiagnosticsinc.com/role/DerivativeLiabilityDetails", "shortName": "Derivative Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueOptionQuantitativeDisclosuresTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-03-302023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Derivative Liability (Details Narrative)", "menuCat": "Details", "order": "40", "role": "http://cardiodiagnosticsinc.com/role/DerivativeLiabilityDetailsNarrative", "shortName": "Derivative Liability (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Subsequent Events (Details Narrative)", "menuCat": "Details", "order": "41", "role": "http://cardiodiagnosticsinc.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2023-03-31_us-gaap_ConvertibleCommonStockMember", "decimals": "0", "lang": null, "name": "us-gaap:CommonStockValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EarningsPerShareBasic", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "5", "role": "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EarningsPerShareBasic", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "menuCat": "Statements", "order": "7", "role": "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "CDIO:OriginalIssueDiscount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "8", "role": "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "CDIO:OriginalIssueDiscount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Organization and Basis of Presentation", "menuCat": "Notes", "order": "9", "role": "http://cardiodiagnosticsinc.com/role/OrganizationAndBasisOfPresentation", "shortName": "Organization and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cdio_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 21, "tag": { "CDIO_AdjustmentToLiabilitiesAssumedInAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Adjustment to liabilities assumed in acquisition" } } }, "localname": "AdjustmentToLiabilitiesAssumedInAcquisition", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CDIO_AdjustmentToLiabilitiesAssumedInMergerWithMana": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Adjustment to liabilities assumed in merger with Mana" } } }, "localname": "AdjustmentToLiabilitiesAssumedInMergerWithMana", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "CDIO_AssumedLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Assumed liabilities" } } }, "localname": "AssumedLiabilities", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "CDIO_BasicAndFullyDilutedIncomeLossPerCommonShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and fully diluted income (loss) per common share:" } } }, "localname": "BasicAndFullyDilutedIncomeLossPerCommonShareAbstract", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "CDIO_CashPaidDuringYearForAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash paid during the year for:" } } }, "localname": "CashPaidDuringYearForAbstract", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "CDIO_CashUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "cash used in operating activities" } } }, "localname": "CashUsedInOperatingActivitiesAbstract", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "CDIO_ChangeInFairValueOfDerivativeLiability": { "auth_ref": [], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Change in fair value of derivative liability", "negatedLabel": "Chain in fair value of derivative liability" } } }, "localname": "ChangeInFairValueOfDerivativeLiability", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "CDIO_ChangeInFairValueRecognizedInOperations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Change in fair value recognized in operations" } } }, "localname": "ChangeInFairValueRecognizedInOperations", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "CDIO_CommonSharesReversed": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common shares reversed" } } }, "localname": "CommonSharesReversed", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "CDIO_CommonStockParValue0.00001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, par value $0.00001 per share" } } }, "localname": "CommonStockParValue0.00001PerShareMember", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "domainItemType" }, "CDIO_ConsultantForServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Consultant for services" } } }, "localname": "ConsultantForServices", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "CDIO_ConvertibleInstrumentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Instruments" } } }, "localname": "ConvertibleInstrumentsPolicyTextBlock", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "CDIO_DebtDiscountRelatedToDerivativeLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Debt discount related to derivative liability" } } }, "localname": "DebtDiscountRelatedToDerivativeLiability", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CDIO_DerivativeLiabilitiesConverted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Converted" } } }, "localname": "DerivativeLiabilitiesConverted", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "CDIO_DerivativeLiabilitiesIssued": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issued" } } }, "localname": "DerivativeLiabilitiesIssued", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "CDIO_DisclosureDerivativeLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liability" } } }, "localname": "DisclosureDerivativeLiabilityAbstract", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "xbrltype": "stringItemType" }, "CDIO_DisclosureFinanceAgreementPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Agreement Payable" } } }, "localname": "DisclosureFinanceAgreementPayableAbstract", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "xbrltype": "stringItemType" }, "CDIO_DisclosureMergerAgreementAndReverseRecapitalizationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Merger Agreement And Reverse Recapitalization" } } }, "localname": "DisclosureMergerAgreementAndReverseRecapitalizationAbstract", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "xbrltype": "stringItemType" }, "CDIO_DisclosurePatentCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Patent Costs" } } }, "localname": "DisclosurePatentCostsAbstract", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "xbrltype": "stringItemType" }, "CDIO_FairValueOptionQuantitativeTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of fair value measurements" } } }, "localname": "FairValueOptionQuantitativeTextBlock", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "CDIO_FinanceAgreementPayable": { "auth_ref": [], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Finance agreement payable", "verboseLabel": "Finance agreement payable" } } }, "localname": "FinanceAgreementPayable", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets", "http://cardiodiagnosticsinc.com/role/FinanceAgreementPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "CDIO_FinanceAgreementPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FinanceAgreementPayableTextBlock", "verboseLabel": "Finance Agreement Payable" } } }, "localname": "FinanceAgreementPayableTextBlock", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/FinanceAgreementPayable" ], "xbrltype": "textBlockItemType" }, "CDIO_FinancingAgreementEnteredIntoForPrepaidInsurance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Financing agreement entered into for prepaid insurance" } } }, "localname": "FinancingAgreementEnteredIntoForPrepaidInsurance", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/FinanceAgreementPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "CDIO_InterestExpensesRelatedParty": { "auth_ref": [], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "InterestExpensesRelatedParty", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpensesRelatedParty", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "CDIO_KnowHowLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Know How License [Member]" } } }, "localname": "KnowHowLicenseMember", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "CDIO_LegacyCardioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Legacy Cardio [Member]" } } }, "localname": "LegacyCardioMember", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "CDIO_LegacyCardioStockholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Legacy Cardio Stockholders [Member]" } } }, "localname": "LegacyCardioStockholdersMember", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "CDIO_ManasFormerOfficersAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Manas Former Officers And Directors [Member]" } } }, "localname": "ManasFormerOfficersAndDirectorsMember", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "CDIO_MergerAgreementAndReverseRecapitalizationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Merger Agreement and Reverse Recapitalization" } } }, "localname": "MergerAgreementAndReverseRecapitalizationTextBlock", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/MergerAgreementAndReverseRecapitalization" ], "xbrltype": "textBlockItemType" }, "CDIO_NumberOfSharesTransferred": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of shares transferred" } } }, "localname": "NumberOfSharesTransferred", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "CDIO_OriginalIssueDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Original issue discount" } } }, "localname": "OriginalIssueDiscount", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "CDIO_PatentCostsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PatentCostsTextBlock", "verboseLabel": "Patent Costs" } } }, "localname": "PatentCostsTextBlock", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/PatentCosts" ], "xbrltype": "textBlockItemType" }, "CDIO_PaymentsOfPlacementAgentFee": { "auth_ref": [], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "PaymentsOfPlacementAgentFee", "negatedLabel": "Payments of placement agent fee" } } }, "localname": "PaymentsOfPlacementAgentFee", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CDIO_PlacementAgentFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Placement agent fee" } } }, "localname": "PlacementAgentFee", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "CDIO_Plan2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Plan 2022 [Member]" } } }, "localname": "Plan2022Member", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "CDIO_PreFinancingCapitalization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Pre financing capitalization" } } }, "localname": "PreFinancingCapitalization", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "CDIO_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock" } } }, "localname": "RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "domainItemType" }, "CDIO_RedemptionPricePerShre": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redemption price per shre" } } }, "localname": "RedemptionPricePerShre", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "CDIO_RestrictedStockAwardsVested": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Restricted stock awards vested" } } }, "localname": "RestrictedStockAwardsVested", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "CDIO_RestrictedStockAwardsVestedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted stock awards vested, shares" } } }, "localname": "RestrictedStockAwardsVestedShares", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "CDIO_RevenueRecognitionsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionsPolicyTextBlock", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "CDIO_ReverseRecapitalizationShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reverse recapitalization shares" } } }, "localname": "ReverseRecapitalizationShares", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "CDIO_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of warrant activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTableTextBlock", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "CDIO_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/DerivativeLiabilityDetails" ], "xbrltype": "perShareItemType" }, "CDIO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantActivity": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant activity" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantActivity", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "CDIO_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageWarrantActivity": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price warrant activity" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageWarrantActivity", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "CDIO_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options [Member]" } } }, "localname": "StockOptionsMember", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/EarningsLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "CDIO_StockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Warrants [Member]" } } }, "localname": "StockWarrantsMember", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/EarningsLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "CDIO_WarrantsConvertedToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrants converted to common stock" } } }, "localname": "WarrantsConvertedToCommonStock", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "CDIO_WarrantsConvertedToCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants converted to common stock, shares" } } }, "localname": "WarrantsConvertedToCommonStockShares", "nsuri": "http://cardiodiagnosticsinc.com/20230331", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r359", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r380", "r418" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r9" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedAmortizationOfOtherDeferredCosts": { "auth_ref": [ "r370" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amortization of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs, deferred acquisition costs of insurance companies, or deferred leasing costs for real estate operations.", "label": "Accumulated amortization" } } }, "localname": "AccumulatedAmortizationOfOtherDeferredCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/PatentCostsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average useful life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r4", "r347" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r274", "r275", "r276", "r376", "r377", "r378", "r412" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r29", "r48" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r20", "r29", "r80", "r217" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Non-cash interest expense" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Anti-dilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/EarningsLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/EarningsLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/EarningsLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/EarningsLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r86", "r95", "r109", "r133", "r174", "r177", "r181", "r186", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r292", "r296", "r303", "r347", "r383", "r384", "r419" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r106", "r114", "r133", "r186", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r292", "r296", "r303", "r347", "r383", "r384", "r419" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r245", "r246", "r247", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r269", "r270", "r271", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetails", "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r67" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Acquisition related expense", "negatedLabel": "Acquisition related expense" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r330", "r331", "r347", "r369" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r22" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired from Acquisition" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r31", "r107", "r334" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r26", "r31", "r37" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "CASH - END OF PERIOD", "periodStartLabel": "CASH - BEGINNING OF PERIOD" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r26", "r79" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "NET INCREASE (DECREASE) IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "FDIC insured amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r110", "r111", "r112", "r133", "r151", "r152", "r155", "r157", "r164", "r165", "r186", "r197", "r199", "r200", "r201", "r204", "r205", "r221", "r222", "r224", "r228", "r234", "r303", "r333", "r368", "r374", "r379" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover", "http://cardiodiagnosticsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrant exercise price", "periodEndLabel": "Weighted average exercise price outstanding, ending", "periodStartLabel": "Weighted average exercise price outstanding, beginning" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetails", "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Warrants outstanding, ending", "periodStartLabel": "Warrants outstanding, beginning" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r53", "r195", "r196", "r332", "r382" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common stock issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r376", "r377", "r412" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r3", "r55" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r3", "r347" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.00001 par value; authorized - 300,000,000 shares; 9,615,835 and 9,514,743 shares issued and outstanding\u00a0\u00a0\u00a0as of March 31, 2023 and December 31, 2022, respectively", "verboseLabel": "Converted common stock value" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets", "http://cardiodiagnosticsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r68", "r336" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r34", "r35", "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of shares, Value" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r34", "r35", "r36" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of stock shares" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r34", "r35", "r36" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of shares, shares" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleCommonStockMember": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Common stock securities that may be converted to another form of security.", "label": "Convertible Common Stock [Member]" } } }, "localname": "ConvertibleCommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r1", "r87", "r96", "r102" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible notes payable" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r11" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes payable, net" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r54", "r131", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r215", "r218", "r219", "r220" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Convertible Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/ConvertibleNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r81", "r84", "r206", "r311", "r340", "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r12", "r81", "r216" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/FinanceAgreementPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Redemption percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r80", "r81", "r82", "r83", "r84", "r385" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt discount net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r370" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r29", "r50" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Amortization", "verboseLabel": "Amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations", "http://cardiodiagnosticsinc.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r70" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative liabilities ending", "periodEndLabel": "Derivative liabilities ending", "periodStartLabel": "Derivative liabilities beginning" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails", "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.", "label": "Derivative Financial Instruments, Liabilities [Member]" } } }, "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r115" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesAndFairValueTextBlock": { "auth_ref": [ "r71", "r77" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities.", "label": "Derivatives and Fair Value [Text Block]", "verboseLabel": "Derivative Liability" } } }, "localname": "DerivativesAndFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/DerivativeLiability" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r124", "r140", "r141", "r142", "r143", "r144", "r148", "r151", "r155", "r156", "r157", "r161", "r300", "r301", "r321", "r323", "r337" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings per share, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r124", "r140", "r141", "r142", "r143", "r144", "r151", "r155", "r156", "r157", "r161", "r300", "r301", "r321", "r323", "r337" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings per share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r158", "r159", "r160", "r162" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings (Loss) Per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/EarningsLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r55", "r104", "r119", "r120", "r121", "r135", "r136", "r137", "r139", "r145", "r147", "r163", "r187", "r236", "r274", "r275", "r276", "r287", "r288", "r299", "r304", "r305", "r306", "r307", "r308", "r309", "r312", "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r72", "r73" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of fair value hierarchy level" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r214", "r237", "r238", "r239", "r240", "r241", "r242", "r302", "r315", "r316", "r317", "r340", "r341", "r342", "r343", "r344" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r75", "r76" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r214", "r237", "r242", "r302", "r315", "r342", "r343", "r344" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r214", "r237", "r242", "r302", "r316", "r340", "r341", "r342", "r343", "r344" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r214", "r237", "r238", "r239", "r240", "r241", "r242", "r302", "r317", "r340", "r341", "r342", "r343", "r344" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r214", "r237", "r238", "r239", "r240", "r241", "r242", "r315", "r316", "r317", "r340", "r341", "r342", "r343", "r344" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock": { "auth_ref": [ "r78", "r415", "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about asset and liability measured at fair value under fair value option.", "label": "Schedule of option liability" } } }, "localname": "FairValueOptionQuantitativeDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/DerivativeLiabilityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r108", "r192" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible assets accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r190", "r191", "r192", "r193", "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r47", "r320" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible assets gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r44", "r46" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r47", "r319" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible assets, net", "verboseLabel": "Intangible assets net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets", "http://cardiodiagnosticsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r19" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r49", "r51" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r16", "r85", "r90", "r101", "r174", "r176", "r180", "r182", "r322", "r339" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss from operations before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r134", "r146", "r147", "r173", "r282", "r289", "r290", "r324" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r118", "r280", "r281", "r283", "r284", "r285", "r286" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r28" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r28" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeposits": { "auth_ref": [ "r32", "r93" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.", "label": "Deposits" } } }, "localname": "IncreaseDecreaseInDeposits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "auth_ref": [ "r28" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Expenses, Other", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r82", "r92", "r122", "r172", "r310" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/DerivativeLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOperating": { "auth_ref": [ "r18" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.", "label": "Interest income" } } }, "localname": "InterestIncomeOperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r125", "r128", "r129" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r10", "r133", "r186", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r293", "r296", "r297", "r303", "r338", "r383", "r419", "r420" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r8", "r88", "r98", "r347", "r375", "r381", "r414" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtMaturityDate": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Maturity date of long-term debt, in YYYY-MM-DD format.", "label": "Maturity date" } } }, "localname": "LongTermDebtMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/FinanceAgreementPayableDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r127" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r127" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r26", "r27", "r30" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r17", "r30", "r91", "r100", "r105", "r116", "r117", "r121", "r133", "r138", "r140", "r141", "r142", "r143", "r146", "r147", "r153", "r174", "r176", "r180", "r182", "r186", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r301", "r303", "r339", "r383" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r140", "r141", "r142", "r143", "r148", "r149", "r154", "r157", "r174", "r176", "r180", "r182", "r339" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "negatedLabel": "Net loss" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r69" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/OrganizationAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expenses)" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIntangibleAssetsNet": { "auth_ref": [], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.", "label": "Patent costs, net", "verboseLabel": "Patent costs" } } }, "localname": "OtherIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets", "http://cardiodiagnosticsinc.com/role/PatentCostsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r21" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Total other income (expenses)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireFinanceReceivables": { "auth_ref": [ "r24" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of amounts due from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith.", "label": "Payments to Acquire Finance Receivables", "negatedLabel": "Payments of finance agreement" } } }, "localname": "PaymentsToAcquireFinanceReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r23" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Patent costs incurred" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r2", "r221" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r2", "r221" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r2", "r347" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $.00001 par value; authorized - 100,000,000 shares; \u00a00 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r371" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r113", "r188", "r189", "r335" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/FinanceAgreementPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r25" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from convertible notes payable, net of original issue discount of $500,000" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r373" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r105", "r116", "r117", "r126", "r133", "r138", "r146", "r147", "r174", "r176", "r180", "r182", "r186", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r291", "r294", "r295", "r301", "r303", "r322", "r339", "r345", "r346", "r372", "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecapitalizationCosts": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of recapitalization costs for professional fees associated with restructuring debt and equity mixture that do not qualify for capitalization.", "label": "Recapitalization cost" } } }, "localname": "RecapitalizationCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r66", "r103", "r421" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "verboseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations", "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r5", "r57", "r97", "r328", "r329", "r347" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r104", "r135", "r136", "r137", "r139", "r145", "r147", "r187", "r274", "r275", "r276", "r287", "r288", "r299", "r325", "r327" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionServicesLicensingFees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue recognition for licensing fees, which is consideration paid to the entity (licensor) by another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, or trademark.", "label": "Revenue Recognition, Services, Licensing Fees [Policy Text Block]", "verboseLabel": "Patent Costs" } } }, "localname": "RevenueRecognitionServicesLicensingFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r123", "r133", "r170", "r171", "r175", "r178", "r179", "r183", "r184", "r185", "r186", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r303", "r322", "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.", "label": "Number of shares received" } } }, "localname": "SaleOfStockConsiderationReceivedPerTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/EarningsLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of anti dilutive earning per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/EarningsLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r59", "r60", "r61", "r62", "r63" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r44", "r46", "r319" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r44", "r46" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r243", "r244", "r245", "r246", "r247", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r269", "r270", "r271", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Sales and marketing", "verboseLabel": "Advertising costs" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperations", "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r28" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Date the equity-based award expires, in YYYY-MM-DD format.", "label": "Expiration date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/DerivativeLiabilityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Annual dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/DerivativeLiabilityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/DerivativeLiabilityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/DerivativeLiabilityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "negatedLabel": "Warrants exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Options issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r245", "r246", "r247", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r269", "r270", "r271", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetails", "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted average exercise price exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r248", "r267", "r268", "r269", "r270", "r273", "r277", "r278" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/DerivativeLiabilityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r38", "r130" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantPurchaseCommitmentDescription": { "auth_ref": [ "r13", "r89", "r99" ], "lang": { "en-us": { "role": { "documentation": "Excluding long-term commitments, description of arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers, which may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing (such as penalties) of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.", "label": "Purchase aggrement description" } } }, "localname": "SignificantPurchaseCommitmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r110", "r111", "r112", "r133", "r151", "r152", "r155", "r157", "r164", "r165", "r186", "r197", "r199", "r200", "r201", "r204", "r205", "r221", "r222", "r224", "r228", "r234", "r303", "r333", "r368", "r374", "r379" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/Cover", "http://cardiodiagnosticsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r15", "r55", "r104", "r119", "r120", "r121", "r135", "r136", "r137", "r139", "r145", "r147", "r163", "r187", "r236", "r274", "r275", "r276", "r287", "r288", "r299", "r304", "r305", "r306", "r307", "r308", "r309", "r312", "r325", "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://cardiodiagnosticsinc.com/role/Cover", "http://cardiodiagnosticsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r135", "r136", "r137", "r163", "r318" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://cardiodiagnosticsinc.com/role/Cover", "http://cardiodiagnosticsinc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r2", "r3", "r55", "r56", "r57" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Conversion shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r2", "r3", "r55", "r57" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.", "label": "Stock redeemed" } } }, "localname": "StockRedeemedOrCalledDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "auth_ref": [ "r55" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.", "label": "Redemption amount" } } }, "localname": "StockRedeemedOrCalledDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/MergerAgreementAndReverseRecapitalizationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r3", "r6", "r7", "r43", "r347", "r375", "r381", "r414" ], "calculation": { "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets", "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r58", "r132", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r236", "r298" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r313", "r314" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r40", "r41", "r42", "r166", "r167", "r168", "r169" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates in the Preparation of Financial Statements" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r150", "r157" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average number of shares outstanding, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r148", "r157" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average number of shares outstanding, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://cardiodiagnosticsinc.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3095-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r348": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r349": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r351": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r352": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r353": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r354": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r355": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r356": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r357": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r358": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r359": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r361": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r362": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r363": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r364": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r365": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r366": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r367": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r382": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14210-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14217-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126966630&loc=d3e41228-113958", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "https://asc.fasb.org/topic&trid=2155941", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 59 0001079973-23-000711-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-23-000711-xbrl.zip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�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end